













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
The relationship between cognition and white matter








I declare that this thesis was composed by myself, that the work contained herein
is my own except where explicitly stated otherwise in the text or where work
forming part of a jointly authored publication has been included. This work has
not been submitted for any other degree or professional qualification.
The work presented in Chapter 3 is adapted from a previous publication in PLoS
One (2017) titled ‘The clinico-radiological paradox of cognitive function and MRI
burden of white matter lesions in people with multiple sclerosis: A systematic
review and meta-analysis’ authored by myself, Robin Sellar, Mark Bastin, Denis
Mollison, Siddharthan Chandran, Joanna Wardlaw and Peter Connick. All
authors contributed to study conception and design. I was responsible for data







Multiple sclerosis (MS) is a highly variable disease of the central nervous system
with inflammatory and neurodegenerative components, associated with both
physical and cognitive disability. Abnormalities are visible on routine magnetic
resonance imaging (MRI) of the brain, with ‘white matter hyperintensities’
(WMHs) representing sites of previous inflammation. Techniques for measuring
WMHs have not been standardised, although manual outlining is conventionally
taken to be the reference standard, despite its subjective element.
WMHs have been found to only partly explain the degree of cognitive impairment,
forming part of the ‘clinico-radiological paradox’. Research interest has largely
moved to advanced imaging techniques, one such technique being diffusion tensor
imaging (DTI). Through sensitivity to water molecule movement, DTI reflects the
integrity of white matter tracts and thus its measures may be relevant to both
the inflammatory and degenerative disease components.
Aims
The work described in this thesis aims to improve our understanding of the true
relationship between measures of white matter damage and cognitive impairment
in people with MS, to determine the optimum measurement technique(s) for
quantifying WMHs, including developing and testing a novel visual rating scale,
and to assess whether information provided by DTI can strengthen the association
of imaging and clinical findings.
Methods
A systematic review of the literature and meta-analysis relating WMHs to
cognition was conducted, focussing on image analysis technique. Three separate
methods for quantifying WMHs were then investigated. The reproducibility
v
of manual outlining was assessed using scans available from 43 people with
secondary progressive MS (SPMS). An automated software method was optimised
for the same cohort, based on the results of the manual outlining. A novel
semi-quantitative visual rating scale was developed, with validation using the
same scans within a larger, more varied cohort. All available information
regarding the participants studied was then used to construct a linear regression
model predicting cognitive outcomes and determining the utility of the various
imaging markers derived from conventional imaging techniques. A non-linear
relationship for WMHs was also considered. White matter DTI metrics in the
same smaller cohort of 43 people were then investigated, primarily considering
tissue outwith WMHs, as well as that within major tracts and the novel diffusion
marker ‘peak width of skeletonised mean diffusivity’. The additional explanatory
power of DTI metrics within the linear models developed previously was then
determined.
Results
High variability was found in the literature regarding imaging marker
measurement and reporting of technique reproducibility. Manual outlining was
found to be associated with considerable measurement error, dependent on
observer and cohort factors. It was possible to optimise the automated software
for a particular cohort, either for volumetric or spatial outputs. Visual rating of
MS imaging features was found to be feasible and measures of WMH burden were
closely related to fully quantitative measures. The overall association of WMHs
to cognitive function was similar to that found in the published literature, with
no additional association following addition of DTI metrics. A trend towards
a greater effect of WMH volume at higher levels was found, consistent with a
non-linear relationship between imaging metrics and cognitive phenotype.
Conclusions
Substantial heterogeneity in the reporting of the reproducibility of WMH
measurement supports a move towards benchmarking against reference datasets.
Poor reliability of the current reference standard, manual segmentation, should
be recognised as a key limitation for the field. Rich information can be captured
quickly using visual rating of imaging features. The close correlation of visual
ratings of WMHs with quantitative measures may represent a practical alternative
in the appropriate circumstances. Combining visual rating features provided
additional explanatory power, supporting a multidimensional substrate for the
vi
cognitive phenotype. Finally, both automated and visual rating analyses support





Multiple sclerosis (MS) is a highly variable, progressive, disabling disease
affecting the brain and spinal cord. Many people with MS experience problems
with cognitive function, such as poor memory and slowed processing of new
information. Characteristic signs related to inflammation show up on magnetic
resonance imaging (MRI) scans of the brain and these tend to worsen with time.
Previous research has shown that the changes on scans are partly associated
with cognitive performance but are not enough to accurately predict who will
have these problems. The aim of the work described here is to improve our
understanding of how the changes visible on brain scans are associated with
cognition.
A review was carried out of all the research into the relationship between the
most common changes seen on brain scans, ‘white matter hyperintensities’ or
WMHs, and cognitive function in people with MS. This found that the techniques
for measuring both these were very variable, leading to a recommendation that
researchers work together to establish common standards. In addition the
relationship between imaging and cognitive features may depend on how advanced
the disease is.
Three different approaches to measuring the severity of the WMHs were then
investigated. Drawing round all the abnormal areas by hand is usually considered
to be the best method. However differences in the results were found when
different people performed this and even when the same person repeated the
process. An alternative, fully computerised method, sensitive to subtle differences
around the edge of the abnormalities, was tested and adjusted so as to closely
match the results from hand-drawing. A third method, involving assigning scores
to scans using a set of sample images was also developed and the scores for the
total amount of abnormality were closely related to the volumes measured by the
outlining technique.
Combining information about the WMHs and other characteristics of the people
being tested, it was possible to show that cognitive function could be partly
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predicted using the computerised measurements or the scores assigned. Overall
the results were similar to those already published, although there was a
suggestion that the brain might be able to compensate for WMHs up to a certain
level of damage.
An advanced imaging technique called diffusion tensor imaging (DTI) was also
used in the same group of people, looking for microscopic damage not visible on
routine MRI scans. DTI picks up information on water movement in the brain,
giving abnormal results when there has been any disruption to the nerve fibres.
Although it was possible to demonstrate subtle damage using this technique, the
overall ability to predict cognitive function was not improved.
From this work, the advantages and disadvantages of different WMH
measurement techniques are clarified, and a novel method of visual scoring is
suggested. In addition this work suggested that the brain may be able to




This work was supported by a Rowling Scholars Clinical Academic Fellowship
between 2015 and 2018.
Essential computer programming and processing, necessary for calculation and
comparison of imaging volumes, as well as expert quality control of all diffusion
data was provided by Dr Mark Bastin, Centre for Clinical Brain Sciences,
University of Edinburgh.
Development work necessary for the use of the automated tissue segmentation
software in the MS-SMART cohort was performed by Dr David Dickie, Institute




I am immensely grateful to all the participants in the three studies considered
here for their time and commitment to MS research, without which no part of
this work would have been possible.
Many individuals have been instrumental in helping me along the way, not least
my supervisors Peter Connick, Siddharthan Chandran and Joanna Wardlaw, who
have all provided inspiration, support and practical assistance. Mark Bastin
deserves a special thank you for huge volumes of technical support and good
sense. Robin Sellar has provided invaluable wisdom and encouragement, often
when much needed.
I am grateful to all my colleagues in the Anne Rowling Regenerative Neurology
Clinic for their excellent work in recruitment and support for clinical research,
particularly Dawn Lyle and Denise Cranley for their work on MS-SMART, Chris
Batchelor for her work on FutureMS and Shuna Colville for all her advice and
support. I am very grateful to Mara Sittampalam for recruitment and testing of
the ‘Cognition in MS’ cohort. The radiographers at the Brain Research Imaging
Centre and Clinical Research Imaging Centre have ensured the ongoing success of
the research and found time to answer my many questions. Many other colleagues
have also provided suggestions and insight, including members of the Chandran
lab group and the CCBS image analysis group.
Joanna Wardlaw, Robin Sellar, Grant Mair, Zoe Morris, Mark Rodrigues and
Lorna Gibson gave up their time to participate in the pilot(s) for the visual
rating work; Grant Mair gave up even more time for manual outlining and general
distraction. Denis Mollison provided statistical advice on all sorts of questions
thrown at him and Francesca Chappell introduced me to ‘bubble’ plots. Charlie
Mollison assisted with emergency laptop dehydration and rebuilding. I’m also
very grateful to the owners of 139 Clachtoll for its use as a writing retreat.
Finally, data analysis was carried out almost exclusively using R and the thesis
was typeset using LATEX; I’m very grateful to all the relevant package developers




List of Figures xix
List of Tables xxiii
List of Abbreviations xxiv
A note on terminology xxvi
1 Introduction 1
1.1 Multiple sclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Cognitive impairment in MS . . . . . . . . . . . . . . . . . . . . . 6
1.3 Brain imaging in MS . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.4 The cognitive clinicoradiological paradox . . . . . . . . . . . . . . 15
1.5 Overview of thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2 Description of cohorts studied 19
2.1 MS-SMART . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.2 Cognition in MS . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3 FutureMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3 Systematic review of literature: relationship between cognitive
performance and total white matter lesion burden 29
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4 Assessing the reliability of the reference standard for white
matter hyperintensity quantification 53
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
xv
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5 Development of a visual rating scale for MS imaging features 69
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.3 Results of phase I: Initial development and piloting . . . . . . . . 74
5.4 Results of phase II: Further development and re-evaluation . . . . 79
5.5 Independent validation study . . . . . . . . . . . . . . . . . . . . 87
5.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
6 Optimisation of an automated method for white matter
hyperintensity quantification 99
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
6.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
7 Determining the relationship of white matter hyperintensity
burden to cognitive performance 113
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
7.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
7.3 Results (I): Construction of a linear model based on automated
white matter hyperintensity volume . . . . . . . . . . . . . . . . . 120
7.4 Results (II): Construction of a linear model based on visual rating
lesion scores . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
7.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
8 The relationship of quantitative measures of tract microstructure
from diffusion tensor imaging to cognitive performance 143
8.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
8.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
8.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
8.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
9 Discussion 161
A Protocol for systematic review of relationship between cognitive
performance and total white matter lesion burden 177
B Record of search strategy for systematic review of literature 181
xvi
C Quality assessment criteria used in systematic review of
literature 185
D Table of cognitive tests and scoring schemes used in individual
studies reviewed 191
E Data collection form used in initial pilot study of visual rating
scale for MS imaging features 197
F Data collection form used in second pilot study and validation
of visual rating scale for MS imaging features 201
G ‘Bubble’ plots showing inter-rater agreement in second pilot





2.1 Sample image showing automated WMH segmentation. . . . . . . 23
3.1 Flowchart summarising stages of systematic review process . . . . 35
3.2 Results retrieved by year of publication . . . . . . . . . . . . . . . 36
3.3 Histogram of study sizes . . . . . . . . . . . . . . . . . . . . . . . 37
3.4 Histogram of quality scores . . . . . . . . . . . . . . . . . . . . . . 39
3.5 Forest plot of effect sizes from individual studies relating T2w
hyperintense lesion burden to overall cognitive performance . . . . 41
3.6 Forest plot of effect sizes from individual studies relating T1w
hypointense lesion burden to overall cognitive performance. . . . . 42
3.7 Funnel plot of effect sizes . . . . . . . . . . . . . . . . . . . . . . . 43
3.8 Forest plot of effect sizes from individual studies using SDMT. . . 46
3.9 Forest plot of effect sizes from individual studies using PASAT. . . 47
3.10 Scatterplot of study effect sizes against cohort mean lesion volume. 48
4.1 Sample image showing manual WMH segmentation. . . . . . . . . 57
4.2 Boxplots of cohort WMH volumes for mask sets 1 to 3. . . . . . . 58
4.3 Bland-Altman plots comparing mask sets 1 to 3. . . . . . . . . . . 60
4.4 Scatterplots of Dice index for mask sets 1 to 3. . . . . . . . . . . . 61
4.5 Boxplot and scatterplot comparing segmentation results from two
observers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.6 Bland-Altman plot, showing ratio of WMH volumes for two
observers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.7 Scatterplot of Dice index against mean WMH volume. . . . . . . 64
5.1 Histogram of item endorsement rates in initial pilot study. . . . . 75
5.2 Scatterplot of WM lesion subscore against semi-automated lesion
volume in initial pilot study. . . . . . . . . . . . . . . . . . . . . . 79
5.3 Histogram of item endorsement rates in second pilot study. . . . . 82
5.4 ‘Bubble’ plots of global white matter scores for each scan. . . . . . 84
xix
5.5 Barplots showing mean dimension subscores for each rater in
second pilot study. . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5.6 Scatterplots of WM lesion scores against semi-automated lesion
volume in second pilot study. . . . . . . . . . . . . . . . . . . . . 87
5.7 Histogram of item-total correlations in the independent validation
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.8 Sample images from MS-SMART cohort, demonstrating scans with
low, intermediate and high global white matter scores. . . . . . . 92
5.9 Histograms of summed global white matter scores assigned to scans
from two cohorts. . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.10 Histograms of summed regional white matter scores assigned to
scans belonging to each cohort. . . . . . . . . . . . . . . . . . . . 94
5.11 Overlapping histograms of total scores for scans from the two
cohorts of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.12 Scatterplot of total EPVS score against age for participants from
both cohorts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.13 Scatterplots of summed global and regional WM scores against
manual WMH volume. . . . . . . . . . . . . . . . . . . . . . . . . 96
6.1 Scatterplot of automated and manual WMH volumes at threshold
combination maximising their correlation. . . . . . . . . . . . . . 103
6.2 Contour plot showing the mean absolute percentage difference for
all tested threshold combinations. . . . . . . . . . . . . . . . . . . 104
6.3 Bland-Altman plot showing the ratio of manual to automated
segmentation volumes at the threshold combination minimising the
mean absolute percentage difference. . . . . . . . . . . . . . . . . 105
6.4 Contour plot showing the mean Dice index for all tested threshold
combinations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
6.5 Scatterplot of Dice indices against manual WMH volumes for the
optimal threshold combination. . . . . . . . . . . . . . . . . . . . 107
6.6 Contour plots for additional measures of spatial agreement for all
tested thresholds. . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
6.7 Sample image from MS-SMART participant contrasting manual
and automated segmentations. . . . . . . . . . . . . . . . . . . . . 109
7.1 Plots of individual non-imaging predictors against SDMT. . . . . 122
7.2 Plots of individual volumetric imaging predictors against SDMT. . 126
7.3 Scatterplot of residuals against fitted values and Q-Q plot. . . . . 127
7.4 Scatterplot of SDMT against WMH volume with superimposed
piecewise and loess fits. . . . . . . . . . . . . . . . . . . . . . . . . 128
xx
7.5 Plots of participant characteristics against SDMT for the combined
MS-SMART and FutureMS cohorts. . . . . . . . . . . . . . . . . . 130
7.6 Plots of individual imaging predictors, from visual rating, against
SDMT (1). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
7.7 Plots of individual imaging predictors, from visual rating, against
SDMT (2). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
7.8 Scatterplot of residuals against fitted values and Q-Q plot. . . . . 137
8.1 Group maps of the segmented fasciculi of interest. . . . . . . . . . 148
8.2 Boxplots of mean diffusivity for segmented brain compartments. . 149
8.3 Boxplots of fractional anisotropy for segmented brain compartments.149
8.4 Histogram showing distribution of PSMD. . . . . . . . . . . . . . 150
8.5 Scatterplot of PSMD against mean white matter MD . . . . . . . 151
8.6 Scatterplot of PSMD against WMH volume. . . . . . . . . . . . . 152
8.7 Boxplot of cohort MD for each of the segmented tracts. . . . . . . 153
8.8 Boxplot of cohort FA for each of the segmented tracts. . . . . . . 154
8.9 Scatterplot of mean tract FA against NAWM compartment FA. . 154
8.10 Plots of FA and MD against SDMT for NAWM and WMH tissue
compartments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
8.11 Scatterplot of PSMD against SDMT. . . . . . . . . . . . . . . . . 158




2.1 Sequence details for standard imaging protocol in MS-SMART. . . 21
2.2 Characteristics of participants enrolled in MS-SMART . . . . . . 25
2.3 Characteristics of participants in Cognition in MS study. . . . . . 26
2.4 Sequence details for standard imaging protocol in Cognition in MS
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.5 Characteristics of participants in FutureMS study. . . . . . . . . . 27
2.6 Sequence details for standard imaging protocol in FutureMS. . . . 28
3.1 Percentage of studies gaining each quality assessment score . . . . 40
3.2 Sensitivity analysis comparing study effect sizes by scanner field
strength. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.3 Sensitivity analysis comparing study effect sizes by lesion
quantification method. . . . . . . . . . . . . . . . . . . . . . . . . 44
3.4 Study effect sizes grouped by participant phenotype. . . . . . . . 45
4.1 Summary statistics for mask sets 1 to 3. . . . . . . . . . . . . . . 57
4.2 Spearman correlations, ICCs and Dice indices for mask sets 1 to 3. 59
5.1 Descriptive statistics for items in initial pilot study. . . . . . . . . 76
5.2 Intra- and inter-rater ICCs for dimension subscores in initial pilot
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
5.3 Descriptive statistics for items in second pilot study. . . . . . . . . 81
5.4 Intra- and inter-rater ICCs for dimension subscores in second pilot
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.5 Descriptive statistics for individual items in independent validation
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.6 Intra-rater ICCs for dimension subscores in independent validation
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.7 Intra-rater agreement on presence of cavitation in independent
validation study. . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
xxiii
5.8 Intra-rater agreement on presence of (juxta-)cortical lesions in
independent validation study. . . . . . . . . . . . . . . . . . . . . 91
5.9 Summary of dimension subscores for the two cohorts studied. . . . 93
7.1 Summary statistics for MS-SMART cohort. . . . . . . . . . . . . . 121
7.2 Summary of linear models predicting SDMT using volumetric
imaging markers. . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
7.3 Summary statistics for the MS-SMART and FutureMS cohorts. . 131
7.4 Summary of linear models predicting SDMT using imaging
markers derived from visual rating. . . . . . . . . . . . . . . . . . 132
7.5 Description of linear model considering FutureMS and MS-SMART
cohorts separately. . . . . . . . . . . . . . . . . . . . . . . . . . . 138
8.1 Clinical and imaging features of participants in the Advanced MRI
substudy of MS-SMART cohort. . . . . . . . . . . . . . . . . . . . 147
8.2 Summary diffusion metrics and Spearman correlations with age
and volumetric imaging markers. . . . . . . . . . . . . . . . . . . 152
8.3 Summary of linear models predicting SDMT using diffusion metrics.157
xxiv
List of Abbreviations
All abbreviations are written out in full at their first use within each chapter. For
convenience, a list of all abbreviations used is provided below.
AD Axial diffusivity
AIC Akaike information criteria
ANTs Advanced Normalisation Tools
BDI Beck depression index
BIC Bayesian information criteria
BICAMS Brief international cognitive assessment for multiple sclerosis




CNS Central nervous system
df Degrees of freedom
DTI Diffusion tensor imaging
EDSS Expanded disability status scale
EPVS Enlarged perivascular spaces
FA Fractional anisotropy
FLAIR Fluid attenuated inversion recovery
FMRI Functional magnetic resonance imaging
FMRIB (Oxford Centre for) Functional Magnetic Resonance Imaging of the Brain
FSE Fast spin echo
FSL Functional Magnetic Resonance Imaging of the Brain software library
FSPGR Fast spoiled gradient echo
GM Grey matter






MACFIMS Minimal assessment of cognitive function in multiple sclerosis
MD Mean diffusivity
ml Millilitre
MPRAGE Magnetisation-prepared rapid gradient echo
MRI Magnetic resonance imaging
MRS Magnetic resonance spectroscopy
MS Multiple sclerosis
MSFC Multiple Sclerosis Functional Composite
MS-SMART Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial
MT Magnetisation transfer
NAWM Normal-appearing white matter
NPV Negative predictive value
PACS Picture archiving and communication system
PASAT Paced Auditory Serial Addition Test
PD Proton density
PNT Probabilistic neighbourhood tractography
PPMS Primary progressive multiple sclerosis
PPV Positive predictive value
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PSMD Peak width of skeletonised mean diffusivity
RD Radial diffusivity
RRMS Relapsing-remitting multiple sclerosis
SD Standard deviation
SDMT Symbol Digit Modality Test
SE Spin echo
SPMS Secondary progressive multiple sclerosis
STROBE Strengthening the Reporting of Observational studies in Epidemiology
SVD Small vessel disease
T1w T1-weighted
T2w T2-weighted




TSE Turbo spin echo
WM White matter
WMH White matter hyperintensity
xxvi
A note on terminology
The terms ‘lesion’, ‘plaque’ and ‘hyperintensity’ have all been used in imaging
research to describe abnormally bright regions seen on T2-weighted imaging
sequences in the context of multiple sclerosis (MS). In this thesis, the generic
term ‘white matter hyperintensity’ (WMH) is preferred, widely used elsewhere
in imaging research without assumptions about underlying pathology. Reflecting
the widespread use of ‘lesion’ in clinical imaging and MS-specific research, this
term is used in the review of the literature presented in Chapter 3 and the visual







The pathological and clinical features of multiple sclerosis were bound together
as a distinct disease (‘la sclerose en plaques’) in 1868 by the French neurologist
Jean-Martin Charcot [1], launching 150 years of research into its aetiology and
treatment. Charcot was the first to associate clinical observations with the work
of the Scottish pathologist Robert Carswell and his French counterpart Jean
Cruveilhier earlier in the nineteenth century [2], but it is possible that the disease
has existed, unnamed, for considerably longer [3].
Despite significant advances in knowledge since its recognition, multiple sclerosis
(MS) today remains an incurable, disabling disease and is currently estimated to
affect around 2.3 million people worldwide [4]. In an evolving literature,whether
the incidence is currently increasing [5] or decreasing [6] is unclear, confounded
by changes in diagnostic criteria, technology and the advent of disease-modifying
treatments, but its prevalence in the UK, particularly Scotland, is among the
highest in the world [6].
1.1.2 Clinical features
MS is a highly heterogeneous condition, manifestations varying between people
and over time. Clinically, the disease is divided into different phenotypes [7] by its
pattern of attacks and disability accumulation, but these broad categories conceal
high inter-individual variability in terms of neurological deficits, rates of relapse
and progression of disability. The disease is characterised by distributed damage
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to the central nervous system (CNS), with initial symptoms most commonly
relating to sensory, motor or visual disturbances. Problems with cognition,
balance, fatigue, pain, bowel, bladder and sexual function can also occur, although
may be under-recognised.
An initial attack suggestive of the disease is termed ‘clinically-isolated syndrome’
(CIS), with further evidence of disseminated damage needed to firmly establish a
diagnosis of MS. The majority of people with MS are initially diagnosed with
a relapsing-remitting form (RRMS) in which there is full or partial recovery
between attacks. Recovery eventually becomes incomplete, leading to a secondary
progressive (SPMS) phase of the disease, in which relapses are less frequent but
accumulation of disability continues. The median time to progressive disease is
around 21 years [8]. In a minority of people, the disease follows a progressive
course from disease onset, known as primary progressive MS (PPMS).
The diagnosis of MS rests on evidence of disease dissemination in time and space,
following exclusion of alternative diagnoses that may mimic its findings. Formal
diagnostic criteria are regularly updated to reflect available evidence and advances
in diagnostic technology. Since 2001 the diagnostic criteria have included
magnetic resonance imaging (MRI) features, which can partially substitute for
clinical findings [9].
While establishing the diagnosis has become relatively straightforward, predicting
future disease activity and long term outcomes remains difficult, restricting the
ability of patients and clinicians to make informed decisions. Since the advent of
disease-modifying therapies, with their associated risks and costs, this inability
to predict untreated disease outcomes carries still greater significance.
1.1.3 Epidemiology
The variable nature of the disease extends to its geographical profile. Different
populations register very different levels of disease incidence and prevalence, with
the highest rates found in European and North American populations [4]. The
causes of this variation are not clear and may involve a complex interplay of
genetic and environmental risk factors. Differing vitamin D levels have been
suggested to explain an apparent variation with latitude, but no modification of
risk factors has proven beneficial. The estimated incidence in Scotland is 15.3
per 100,000 population, with a prevalence of 255.2 per 100,000, both higher than
the UK average [6].
MS is primarily a disease of working-age adults, with a female predominance. In
this regard the UK follows the usual pattern, with the peak incidence at 40 in
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women and 45 in men and a female-to-male ratio of approximately 2.4. Peak
disease prevalence in the UK is at 56 for women and 59 for men and at all ages is
higher in women than men, in common with many diseases with an autoimmune
component. Mortality rates are more than twice that of the general population
at all ages and overall life expectancy for people with MS is lower, at 71.6 for
women and 65.4 for men, than it is for the general population, where it is 81.8
and 78.3 respectively [6].
1.1.4 Genetics
The complex interactions between genetic and environmental risk factors in
triggering the development of multiple sclerosis remain incompletely understood.
There are clearly inherited factors, with monozygotic twins of affected people
having an approximately 30% risk of developing the disease, and other relatives
carrying an increased risk, related to genetic proximity [10]. A complex polygenic
risk profile underlies this, with no one gene identified as either sufficient or
necessary to cause the disease.
With advances in genomic screening technology, genome wide association studies
(GWAS) have allowed over two hundred genetic susceptibility loci to be identified
[11]. These mostly, but not exclusively, relate to immune system regulation,
particularly polymorphisms in the human leucocyte antigen region [12]. The
high number of susceptibility genes, all conferring modest increases in risk, make
robust studies of their individual effect on phenotype difficult. However there has
been some evidence that certain alleles may influence age of disease onset and
disease activity as measured by MRI [12,13].
1.1.5 Pathology
MS is an inflammatory demyelinating disease leading to chronic
neurodegeneration. The processes by which damage to the CNS occur are
complex and the balance between them alters through the disease course. In
its most common early form, clinical relapses correspond to acute inflammatory
attacks, with neurodegenerative processes predominating in later stages and
associated with progressive disability. Although originally considered a disease
limited to the white matter and its myelinated axons, involvement of the cortical,
deep and spinal grey matter is now also recognised, where demyelination may
occur with relatively little immune infiltrate [14].
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The initial trigger and causal pathway is unknown, but acute inflammatory
attacks are associated with breakdown of the blood-brain barrier, autoreactive
lymphocytes entering the CNS and launching an inflammatory cascade, leading to
activation and accumulation of local immune cells. The sclerotic plaques defining
the disease are the combined result of the inflammatory attacks and subsequent
repair processes, involving acute inflammation, demyelination, remyelination,
astrocytosis, axonal and neuronal loss [10, 15]. Specific targets to the immune
response have not been determined and may differ between individuals, but
the end result is loss of the protective myelin sheaths surrounding nerve axons,
depletion of the oligodendrocytes producing the myelin, and acute axonal loss.
Recruitment of oligodendrocyte precursor cells and capacity for remyelination
show individual variation [16] and exhaustion of these processes may coincide
with the transition to progressive stages of the disease.
In later stages of the disease, axonal and neuronal loss are the predominant
features [14]. The blood-brain barrier appears to remain intact, but ongoing
inflammation continues, confined within the CNS, in the form of diffuse microglial
activation and meningeal B-cell aggregates. The exact relationship between
inflammation and neurodegeneration is unclear [17].
Although valuable insights into MS have come from pathology, these studies will
always be limited by the highly variable, usually chronic nature of the disease in
the specimens studied. Obtaining biopsy specimens carries a substantial risk to
the patient and is usually only undertaken when considerable doubt exists over
the diagnosis, suggesting that these samples may represent atypical examples of
the disease. Autopsy tissue may be more easily available, but is likely to represent
the end stage of a long and complex disease, with limited information regarding
the intervening processes.
1.1.6 Laboratory models
MS is only known to occur in humans and its many complexities cannot be
fully replicated in the laboratory. However animal models of disease, ex vivo slice
cultures, and human stem cell-derived glia and neurons can all mimic components
of the inflammatory or degenerative processes, offering opportunities for exploring
disease mechanisms and testing potential neuroprotective treatments which would
not otherwise be available.
Animal research in particular allows in vivo studies with greater potential for
experimental manipulation and availability of tissue samples. Various systems,
predominantly in rodents, have been developed to mimic aspects of MS [18, 19],
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including viral, autoimmune, genetic and toxin-based models. The mutant
‘shiverer’ mice show hypo- and dysmyelination in the CNS [20], allowing study
of the associated axonopathy; experimental autoimmune encephalomyelitis, with
susceptible mice exposed to CNS proteins/peptides, is used to study autoimmune
demyelination [21]; toxin-induced damage, for example with cuprizone, can be
used to cause apoptosis in metabolically active mature oligodendrocytes and
subsequent demyelination, allowing more controlled study of the remyelination
process [22]. Advantages to use of animal models are clear, but their limitations
in attempting to model a complex disease with an as yet unknown trigger will
always restrict their translational power.
A different approach to gaining access to cell mechanisms involved in CNS
inflammation, axonal injury and repair is the use of in vitro cell cultures [19].
Advances in biotechnology have made it possible to direct the differentiation
of human stem cell-derived glia and neurons and use these to explore disease
mechanisms at cellular and molecular levels. Ex vivo slice cultures from animal
models have been used to promote rapid screening of potential drug therapies
but testing in human stem cell-derived cells is becoming possible and increases
possibilities for translation to trials in humans.
1.1.7 Treatment
A number of drugs are currently licensed for use in the UK as disease-modifying
therapies in RRMS, all acting to reduce the neuroinflammatory disease
component. First line treatments have a variety of mechanisms of
action, including inhibition of lymphocyte proliferation, reduced migration of
inflammatory cells across the blood-brain barrier and increasing the presence
of anti-inflammatory cytokines [23]. In some cases the mechanism of action is
not fully understood. These treatments have been shown to reduce the rate of
relapses, disability progression and accumulation of new inflammatory lesions on
imaging, while for the most part side effects are well-tolerated.
More recently three monoclonal antibody treatments have become available,
acting either to deplete lymphocytes or block their CNS infiltration. These
have shown greater efficacy in reducing relapse rates and disability progression,
but are associated with more serious side effects, including an increased risk of
other autoimmune-mediated conditions, as well as the life-threatening condition
progressive multifocal leucoencephalopathy [10,23].
While their short term efficacy in preventing relapses in RRMS is well-established,
what remains unproven is that any treatment can delay or prevent conversion
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to SPMS, or that a reduction in inflammatory activity prevents longer term
neurodegeneration. This absence of evidence may simply reflect the relatively
recent advent of disease-modifying therapies and the practical time frames
for running fully-blinded randomised control trials, but effective prevention or
treatments for the neurodegenerative component of the disease remains a major
unmet need.
1.2 Cognitive impairment in MS
1.2.1 Prevalence and impact
Cognitive impairment in multiple sclerosis is common. It is estimated to affect
up to 70% of people with the disease [24], although this will depend both
on the particular population and the tests used. While rarely a presenting
symptom, cognitive impairment can be present in the earliest disease stages [25].
The development of cognitive impairment can be in conjunction with physical
disability, or distinct from it, but the prevalence and severity appear to increase
with time since diagnosis [26]. Its onset is unlikely to be as apparent to a
patient or healthcare professional as a physical relapse or other forms of disability,
necessitating good screening tools. As with other aspects of this disease, the risk
factors for development of cognitive impairment have not been resolved.
Cognitive impairment is associated with lower measures of quality of life [27].
It reduces physical independence, competence in daily activities, medication
adherence and rehabilitation potential. It also predicts both under- and
un-employment [28, 29]. As a disease of predominantly working age adults,
this further increases the economic impact of MS. Early recognition of
cognitive features of the disease may allow greater opportunities for suitable
lifestyle adaptations, as well as more relevant measures to assess treatment
outcomes.
Despite its frequency and clinical significance, the pathological substrate that
causes cognitive impairment in MS is not fully understood. This is discussed
in greater detail below (Section 1.4). However, given the context above, it is
clear that a better understanding of the relationship between pathology and
phenotype would be valuable to support targeted therapeutic intervention at the
relevant biological level. From a cognitive neuroscience perspective, there may
also be value in providing novel insights on the relationship between brain tissues
and function. The extent to which white matter pathology in MS can explain
impairments of cognition is therefore the central theme of this thesis.
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1.2.2 The structure of human cognition
Human cognition is a multidimensional construct with distinct cognitive abilities
identified which can vary independently to an extent. Various models have
therefore been proposed to describe how different cognitive domains or specific
cognitive abilities are related. A common finding is that measurements on a
wide variety of cognitive tests all correlate and a general factor of cognitive
ability (‘g’) is used to explain this shared variance [30]. The Cattell-Horn-Carroll
model of human intelligence [31] is one widely-used model, developed through
factor analysis of psychometric data and proposing a three-tiered hierarchy of
cognitive skills with an overall general factor. Reduced processing speed is the
most common deficit identified in MS and deteriorates with time. It has been
suggested this is the core cognitive deficit, corresponding to ‘g’ and mediating
other deficits via disconnection of critical cortical regions [32].
This fundamental complexity of human cognitive structure presents a substantial
challenge to evaluation of the relationship between pathology and phenotype,
raising the question of how best to approach measurement. Options include at
one extreme lengthy multiple domain neuropsychological evaluation to detect
all possible deficits. At the other extreme is single domain evaluation, typically
targeting processing speed as the most responsive feature. Intermediate positions
are also possible and the optimum approach to measurement is discussed further
below.
1.2.3 Measurement approaches and patterns of deficits
Patterns of cognitive deficits vary between individuals with MS [24], with
those most frequently detected affecting information processing speed, executive
function, attention and long-term memory. Different patterns of impairment may
in part relate to the random nature of the sites of inflammatory damage. However
many of the more commonly affected functions, such as information processing
speed, appear unlikely to localise to a single brain region or small group of regions,
with preservation of widespread tissue integrity more relevant.
Recognising that comprehensive testing by an expert neuropsychologist may
not always be feasible, a number of set test ‘batteries’ have been developed,
covering a range of cognitive domains, targeted towards functions found to be
disproportionately affected in people with MS. Most cognitive test outcomes
are known to vary with sex and age and results must be interpreted in relation
to population norms. Commonly used batteries in the research setting are the
Brief Repeatable Battery (BRB) [33] and the Minimal Assessment of Cognitive
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Function in MS (MACFIMS) [34], taking approximately 45 and 90 minutes
respectively to administer. Used correctly, standardised tests should facilitate
the use of cognitive outcomes in research, including longitudinal and multicentre
trials. However Fischer et al [35] found that the criteria used to interpret test
results varied widely, affecting estimates of cognitive impairment prevalence at
different disease stages.
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
initiative has sought to standardise a shorter test battery more easily fitted
within a typical clinical consultation [36]. Taking tests from both the BRB and
MACFIMS, this has now been validated across several countries [37]. Three short
tests are recommended, with priority given to the Symbol Digit Modality Test
(SDMT), a 90 second test of information processing speed, in which numbers
are matched to arbitrary symbols, found to be highly sensitive to cognitive
impairment in MS [36]. It is to be hoped that a shorter more practical test
procedure will enable more routine testing of asymptomatic people, leading to
an improved understanding of the true prevalence and development of cognitive
dysfunction.
1.2.4 Modifiers of cognitive performance and cognitive reserve
The capacity for any individual to maintain performance on cognitive testing
with a given level of disease appears highly variable. A number of disease
and non-disease factors have been proposed to explain this, some amenable to
intervention, others not.
Theories of brain and cognitive reserve suggest that lifetime maximal brain
volume, estimated by measuring intracranial volume, protects against cognitive
decline, as do premorbid IQ and participation in enriching cognitive leisure
activities [38, 39]. Cognitive scores are also known to vary with age, sex and
education level [40]. Depression is common in MS and associated with poorer
performance on cognitive testing, including processing speed [24] and many
anti-spasticity drugs can also have cognitive side effects [41].
The relative importance of these modifying factors may vary between individuals
and over time, but failure to consider their potential impact may obscure or
confound assessment of any relationship between cognitive function and disease
markers.
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1.2.5 Impact of cognitive assessment approach on detection of
underlying pathology-phenotype relationship
At a fundamental level, the choice of cognitive assessment method may be
critical to detection and characterisation of the underlying pathology-phenotype
relationship. For cognitive abilities that are highly neuroanatomically localised,
the relationship to pathology in relevant regions may be strong, but this
relationship may also go undetected if pathology is evaluated across the
whole brain with the inclusion of additional neuroanatomical regions that are
irrelevant to function. It may be critical to identify the ‘right’ region in
which to measure pathology. The corollary of this neuroanatomical targeting is
that characterisation of pathology in discrete, potentially small, brain regions
inflates the importance of strong psychometric performance for the brain
imaging metrics used to quantify pathology. The feasibility of evaluating
the pathology-phenotype relationship for neuroanatomically localised cognitive
abilities is therefore explored throughout this thesis by evaluating whether the
psychometric performance of quantitative brain imaging of white matter in MS
is adequate.
An alternative approach is to focus on cognitive abilities that are widely
distributed from a functional neuroanatomical perspective, such as information
processing speed, a common and profound deficit in MS [24]. Tests of information
processing speed are known to be associated with widespread brain activation [42].
Although this reduces sensitivity in those patients who have isolated deficits of
neuroanatomically localised cognitive abilities, it also minimises the effects of
psychometric limitations of brain imaging quantification. Investigation of the
relationship between pathology and phenotype for distributed cognitive functions
therefore represents the optimum approach to explore fundamental relationships
between pathology in brain compartments (for example white matter) and
phenotype, although brain imaging metrics must of course be optimised for their
psychometric performance. The focus on neuroanatomically distributed cognitive
abilities is therefore central in this thesis to evaluate the relationship between
white matter pathology and cognitive impairment.
1.3 Brain imaging in MS
The advent of MRI has brought major changes to the diagnosis and monitoring
of MS. Many of the known pathological features are linked to imaging findings,
allowing less invasive research methods. The use of brain imaging techniques
to produce biomarkers of pathology in MS can be described within multiple
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different frameworks. The following introduction to brain imaging metrics in
MS classifies them by the underlying pathology for which they are generally
considered a biomarker, while acknowledging that few of them are considered
specific for a particular feature. This approach is chosen to facilitate attempts
to address the question of pathology-phenotype relationships. The necessity of
using non-specific (imperfect) biomarkers remains a challenging issue for the
field, balancing valid but low biological value descriptions of metric-phenotype
relationships against less valid but high biological value pathology-phenotype
claims.
1.3.1 Focal neuroinflammation
1.3.1.1 T2-weighted white matter hyperintensities
Acute inflammation is the most readily demonstrable of the pathological features
of MS. Characteristic white matter hyperintensities (WMHs) on T2-weighted
(T2w) MRI sequences within the brain and/or spinal cord provide supporting
evidence used in making the diagnosis and are widely accepted as a marker
of the historical burden of focal inflammation. As MRI techniques and
experience have improved, the imaging criteria for diagnosis have changed to
reflect this. The latest criteria [43] highlight abnormalities specifically involving
cortical/juxtacortical brain tissues and optic nerves as suggestive of the diagnosis
- locations which were not previously visible on imaging.
Two major barriers to use of these WMHs as a biomarker, for example in disease
and treatment monitoring, is both attributing them to MS rather than other
comorbidities, as well as their pathological heterogeneity [44] within MS itself.
A developing MS plaque comprising any combination of acute inflammation,
demyelination, remyelination or astrocytosis will appear bright on T2w imaging.
In clinical practice, combinations of features are used as imperfect predictors
of the degree of chronicity. Although non-specific, the number and volume of
enlarged perivascular spaces (EPVS) visible on T2w imaging have been linked to
the presence of acute inflammation [45], although this requires confirmation. In
investigating chronic damage, scant literature exists regarding the frequency of
lesion progression to cavitation, in which severely damaged tissue is replaced by
a fluid-filled cavity, and this is thought to be an uncommon feature in MS [46].
However the concept of ‘T1 black holes’ [47, 48] (see Section 1.3.1.3) is clearly
related as a means to identifying more severely damaged tissue. Furthermore,
a variety of other conditions are also associated with WMHs, including small
vessel disease, other vascular and inflammatory conditions and normal ageing [49].
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While particular patterns and numbers of focal WMHs have a well-established
utility in clinical diagnosis, their use in disease/treatment monitoring is less
clearly evidence-based, which may relate to this pathological non-specificity as
well as the changing role of diffuse pathology.
A further barrier to the use of measures of WMH volume is the existence of ‘dirty’
or diffusely-abnormal white matter, a category of tissue falling between those of
focal abnormalities with distinct borders and a likely inflammatory origin, and
the normal-appearing white matter (NAWM) [50,51]. This intermediate category
of white matter appearances may be extensive, particularly in chronic disease and
presents clear challenges to volumetric approaches to image analysis.
1.3.1.2 Contrast enhancement
Current disease activity can be estimated by gadolinium contrast-enhanced
imaging, with gadolinium taken up into brain tissues where the blood-brain
barrier has been breached. The rate of underlying disease activity, as measured by
contrast-enhanced imaging, is roughly an order of magnitude higher than clinical
evidence of relapses [52–54].
This increased sensitivity of imaging to disease activity and burden, as well as
its perceived objectivity, is exploited by trials where surrogate imaging outcomes
allow for increased sensitivity to the effect of interventions.
1.3.1.3 T1-weighted white matter hypointensities
The relative brightness of white matter on T1-weighted (T1w) imaging relates
to fat signal from myelin. Focal abnormalities appearing hypointense on T1w
sequences are often considered a more specific disease marker than T2w WMHs,
reflecting myelin loss and indicating more severe damage and/or a failure of repair
following acute inflammation [47, 48]. Nevertheless, both T1- and T2-visible
lesions remain non-specific, with the added confounding effect of acute white
matter oedema appearing hypointense on T1w imaging.
1.3.1.4 Cortical lesions
Cortical lesions are only partly visible on current routine imaging, likely related
to lower levels of inflammatory infiltrate, lower myelin density and partial volume
effects from proximity to cerebrospinal fluid (CSF) [17]. Advanced imaging
techniques, such as double inversion recovery and phase-sensitive inversion
11
recovery sequences, have been developed to optimise evaluation of cortical
pathology, but do not necessarily increase sensitivity or reliability [55, 56].
Nevertheless it has been suggested that they may be particularly relevant in
determining cognitive status [57].
1.3.1.5 Quantification methods
Counts of new or enlarging T2w WMHs by adequately trained human observers
have been the benchmark outcome measure for phase II trials of disease-modifying
drugs. This provides an ordinal level measurement of WMH burden, but is labour
intensive, user-dependent and limited by the presence of WMH coalescence as well
as a failure to capture information on the size or distribution of abnormalities.
The reference standard for quantitative analysis is manual outlining of all lesions,
but this is user-dependent and time-intensive. For research purposes, the field
has therefore largely moved to use various software analysis packages for a
semi- or fully-automated quantitative assessment of T2w- and/or T1w-visible
abnormality [58]. These have the advantage of providing fully quantitative, ratio
level measurements of the imaging burden of disease. With the increasing use
of such technology-based quantification techniques, it is not clear what their
psychometric performance characteristics are, a key question that is addressed in
this thesis.
A small volume of research has applied visual rating scales to the imaging
features of MS [59–64]. These studies used relatively small cohorts and were
predominantly conducted in the early years of clinical MRI use, predating the
move towards technology-based quantification. No visual rating scale for MS
imaging features has entered common use. However semi-quantitative visual
rating scales are frequently used for research in other conditions, including
those such as small vessel disease (SVD) [65] with a similar range of imaging
features. Visual rating scales may therefore have value in providing an
intermediate approach between ordinal assessment of new or enlarging WMHs
and technology-based volumetric quantification. The development of a novel
visual rating scale is described in this thesis and its performance evaluated.
1.3.2 Neurodegeneration and repair
1.3.2.1 Tissue volume
Brain atrophy is accelerated from the earliest stages of MS and progresses
with the disease [66, 67], marking the known tissue loss. Atrophy is frequently
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used as an outcome in clinical trials of potentially neuroprotective drugs [66],
using software-based volumetric measurements, either relying on registration
of longitudinally-acquired imaging or segmentation of individual scans [68].
However, as with evidence of focal damage, atrophy is a pathologically
non-specific marker, representing a global sum of rates which may differ by
tissue type and anatomical location. The changes involved are small, require
longitudinal data, preferably at distant time points, and may vary due to drugs
and hydration status [66,69].
1.3.2.2 Quantitative markers of tissue microstructure
Diffusion tensor imaging (DTI) is an advanced MRI technique that is frequently
used in MS research, providing information on tissue microstructure through
measuring the random motion of water molecules at the voxel level [70]. Healthy
white matter is a tightly packed, highly coherent structure containing myelinated
axons, with water movement predominantly constrained to follow the paths of
white matter tracts. Any damage to these tracts is associated with altered DTI
metrics. The DTI parameters fractional anisotropy (FA) and mean diffusivity
(MD) measure the directional coherence and magnitude of water diffusivity
respectively and are sensitive probes of tissue microstructure. Typical patterns
of change seen in MS are reduced FA and increased MD in affected white
matter.
As with measuring focal lesions, there are many ways to analyse DTI data and
the chosen methodology will depend on the research question. Similar to the
use of total WMH volume, DTI-derived measures of total disease burden can be
extracted for use by calculating mean voxel metrics for white matter or other
tissue compartments of interest. Several papers have examined the relationship
of mean DTI metrics within the normal-appearing white matter to cognitive
function [71–74]. All found significant associations, although these were not
consistently stronger than the relationship between cognitive performance and
WMH volume.
Tract-based spatial statistics (TBSS) [75] has become widely used for combining
and comparing data from multiple subjects. This technique involves thinning
and alignment of multiple subject DTI data to a common white matter skeleton,
allowing voxelwise comparisons of diffusion metrics with outcomes of interest.
Many groups have used TBSS to locate voxels with significant associations with
cognitive outcomes [71–74,76–91].
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Baykara et al [92] have recently proposed an alternative summary marker from
DTI data in cerebral SVD - the ‘peak width of skeletonised mean diffusivity’
(PSMD), based on TBSS and histogram analysis of the aligned voxels. PSMD
summarises the spread of values of white matter MD in a single measure,
derived from an automated pipeline. This objective metric may provide a more
biologically relevant marker of total disease burden as it allows for the known
individual variation in mean MD values, instead summarising their spread within
a scan. In their study of its use in cohorts with SVD, Baykara et al showed that it
outperformed conventional imaging markers in explaining variance in processing
speed. They also showed its stability across multiple sets of healthy control data
from studies on SVD and Alzheimer’s disease, but true normative data is not yet
available, nor has any data yet been published on the use of PSMD in studies of
MS.
Separately from TBSS, major tracts can also be tracked and segmented from
DTI data by various methods, most commonly tractography. Probabilistic
neighbourhood tractography (PNT) is one such technique [93], optimising
starting voxels or ‘seed’ points for fibre-tracking based on a comparison with
standard reference tracts. Tractography has the advantage of minimising the
confounding effect of crossing fibres on directionality markers and focussing on
tissues with more readily attributable functional significance.
1.3.2.3 Quantitative markers of tissue composition
More specific markers of neuronal health and tissue integrity have been proposed,
derived from different advanced imaging techniques. Magnetic resonance
spectroscopy (MRS) can be used to non-invasively assess changes in neuroaxonal
metabolites [94, 95], such as N-acetyl-aspartate, within lesional and non-lesional
white matter. While potentially a useful biomarker of neurodegeneration, MRS
is currently limited by its spatial resolution and the high processing demands.
Magnetisation transfer (MT) imaging is based on signal sensitivity to the presence
of tissue macromolecules, such as myelin [96, 97]. While potentially providing
useful biomarkers of myelination status for trials of neuroprotective agents,
metrics derived from MT imaging remain non-specific. As yet, no advanced
imaging technique has been recommended for clinical use.
1.3.2.4 Imaging markers of connectivity
Neuronal plasticity as a response to pathological changes is well-recognised [98],
from local synaptic reorganisation to recruitment of distant cortical sites and
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parallel pathways. Obtaining direct evidence of synaptic changes is beyond the
resolution of current in vivo imaging techniques, but larger scale alterations in
structural and functional connectivity can be inferred using information derived
from tractography as well as functional MRI (fMRI). FMRI measures dynamic
changes in regional blood flow, demonstrating recruitment and synchronicity of
activity in cortical regions either in response to a particular task or in the resting
state. It has been used to show altered connectivity even in the absence of clinical
deficits [99] and increased regional activation correlating with measures of damage
to NAWM [100,101], suggesting that adaptive changes may in part be responsible
for limiting the extent of clinical impairment.
1.4 The cognitive clinicoradiological paradox
The mismatch between radiological and clinical findings in MS is well-recognised
[52]. Although measurable imaging changes are visible on MRI from the earliest
disease stages and progress with the disease, these can so far not be used to
accurately predict accumulated disability. This disconnection has important
implications for the use of imaging in monitoring disease progression and as a
surrogate outcome of treatment success in clinical trials, limiting the efficient
collection of relevant information.
In the case of motor function, the modest correlation between imaging and clinical
outcomes can be attributed to the frequent presence of spinal pathology and
the complex hierarchy of relevant brain regions. Spinal pathology allows a focal
interruption in the system of motor control that will inevitably reduce correlation
to the total burden of pathology. In contrast, tests of distributed cognitive
functions, such as processing speed, can be designed with minimal dependence on
physical function, and the reasons for these not reflecting more closely the brain
imaging burden of disease are less clear. Moreover, MS is primarily a disease of
working age adults; the clinical features usually starting once brain development is
complete and before the onset of age-related cognitive decline. Any impairment of
cognitive function can thus be reasonably hypothesised to reflect the total burden
of brain disease. This prediction has not been borne out by the evidence. The
entire body of published research on the relationship between white matter brain
imaging features on routine MRI and cognitive performance in MS is summarised
and synthesised in Chapter 3 of this thesis.
Various authors have previously sought to summarise the extensive literature
regarding the relationship between cognitive function and WMH burden in MS
[102] without fully investigating the potential reasons for the modest association.
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Two primary considerations are important that might account for the cognitive
clinicoradiological paradox.
1. Attenuation of the observed correlation due to measurement error affecting
metrics for cognition, brain imaging or both. Despite a recommendation
in the original publication by Spearman in 1904 [103] to consider this
possibilty, it has been largely ignored by the field. Defining and optimising
the psychometric performance characteristics of brain imaging metrics is
therefore a key objective of this thesis.
2. Adjustment for known modifiers of cognitive performance (as discussed in
Section 1.2.4) has been attempted by some research groups but is by no
means universal. Adjustment for relevant covariates is therefore performed
in this thesis to support a more accurate evaluation of the underlying
pathology-phenotype relationship.
These considerations are critical to establish the true extent of any residual
mismatch between imaging and cognitive measures and should perhaps be an
obligatory step before attempting to define the further pathological features
that are responsible for any ‘missing explanatory power’. Nevertheless, the
MS imaging research community has largely moved to using advanced imaging
techniques aiming to quantify more subtle features and the volume of published
work on this subject increases yearly. However without addressing the
relative importance of measurement technique and error, cognitive modifiers and
confounders, the explanatory power of advanced imaging techniques may similarly
be limited.
1.5 Overview of thesis
1.5.1 Hypothesis
The overarching hypothesis tested in this work is that optimised measurement
of white matter MRI characteristics will lead to a more accurate determination
of the relationship between the overall imaging burden of disease and cognitive
performance.
Specific tested hypotheses are:
• The reference standard for WMH segmentation is imperfect, with error
substantial enough to obscure relevant relationships.
• Visual rating can be used to accurately capture data on imaging features in
MS relevant to cognitive status.
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• Routine MR imaging features in MS will contribute significantly to accurate
prediction of cognitive phenotype.
• The addition of DTI-derived measures of microstructural tissue abnormality
in the NAWM to predictive models of cognitive function based on routine
imaging and non-disease factors will increase the overall predictive power.
1.5.2 Aims and thesis structure
The thesis aims and the related work are outlined below.
1. To review the published literature on the relationship between imaging
measures of white matter pathology and cognitive performance in people
with MS, confirming the modest correlations found previously and exploring
methodological issues that may affect this.
A systematic review of the literature and meta-analysis is described in
Chapter 3.
2. To develop tools for reproducible quantification of WMH burden on
structural brain MRI. Differing approaches to evaluation of white matter
imaging features were identified in the literature, and three alternative
methodologies are examined in Chapters 4 to 6. The reference standard,
manual segmentation, is evaluated in Chapter 4, with an investigation of
intra- and inter-observer reproducibility. The development and evaluation
of a novel visual rating scale is described in Chapter 5. Optimisation
and evaluation of an automated segmentation software tool is described
in Chapter 6.
3. To evaluate the relationship between reproducible tools for quantifying
WMH burden on structural brain MRI and cognitive performance in people
with MS.
Using the optimised volumetric and semi-quantitative measures of WMH
burden evaluated previously, their relationship to cognitive performance is
evaluated in Chapter 7, taking into account other relevant imaging and
non-imaging features using linear modelling.
4. To evaluate the potential additional value of DTI techniques in accounting
for the relationship between brain imaging metrics of pathology and
cognitive performance in people with MS.
In Chapter 8, the ability of DTI to demonstrate measurable changes in the
NAWM is first assessed and different DTI-derived metrics are evaluated.
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Using the best predictive model developed in the previous chapter, the
additional value of DTI measures is tested.
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Chapter 2
Description of cohorts studied
Hypotheses in the work described in Chapters 4 to 8 were tested using imaging,
clinical and demographic data available locally from people with multiple sclerosis
(MS) participating in ongoing or recently completed research. Three cohorts were
chosen for study, encompassing a range of clinical phenotypes.
The ‘MS-SMART’ cohort, a group of 93 participants with secondary progressive
MS (SPMS), was used for the work described in Chapters 4, 6 and 8; as well
as the validation work in Chapter 5 and part of the linear modelling work in
Chapter 7. The ‘Cognition in MS’ (n = 60) cohort, a mixed phenotype group
recruited for a previous PhD thesis, was used in the initial development work on
the visual rating scale described in Chapter 5. ‘FutureMS’, a prospective cohort
of 67 people newly diagnosed with relapsing-remitting MS (RRMS), was used in
the validation stage of the visual rating scale work described in Chapter 5 and
the related linear modelling in Chapter 7.
2.1 MS-SMART
2.1.1 Study aims, protocol & recruitment
Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial
(MS-SMART) was an ongoing multicentre, multi-arm, randomised, double
blind, placebo-controlled trial. Participants were randomised to receive either
placebo or one of three potentially neuroprotective drugs (fluoxetine, riluzole and
amiloride) for 96 weeks. The primary outcome was magnetic resonance imaging
(MRI)-derived percentage brain volume change.
Participants were recruited into the trial after referral from their neurologist,
or self-referral following media campaigns. The main eligibility criteria were a
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confirmed diagnosis of SPMS, age between 25 and 65, an Expanded Disability
Status Scale (EDSS) score of 4.0 to 6.5, a Beck Depression Index of < 20 and
neither having taken disease-modifying therapies within the 6 months prior to
recruitment, nor having had oral or intravenous steroids within 3 months.
All participants underwent MRI at three time points. The baseline scans,
performed prior to treatment randomisation, in participants at the University
of Edinburgh site were used for work presented in this thesis and the standard
protocol for these is described below. Participants were also invited to participate
in an ‘advanced’ imaging protocol (see below for further details).
The chief investigator was Dr Jeremy Chataway (University College, London)
and the research was funded through the Efficacy and Mechanism Evaluation
Programme (a partnership between the Medical Research Council and the
National Institute for Health Research) and the MS Society. The trial
was registered with the European Medicines Agency with EudraCT number
2012-005394-31 and with the International Standard Randomised Controlled Trial
Number Registry, number 28440672.
2.1.2 Image acquisition
Baseline imaging for all of the Edinburgh centre participants was carried out
between February 2015 and May 2016 at 3T (Magnetom Verio, Siemens AG,
Healthcare Division GmbH, Erlangen, Germany) at the Clinical Research Imaging
Centre, University of Edinburgh, using a standard 12-channel head coil. Imaging
acquired included a volumetric T1-weighted (T1w) (1mm isotropic voxels)
sequence, as well as proton density (PD), T2-weighted (T2w), T1w and fluid
attenuated inversion recovery (FLAIR) (all 3mm slices) sequences, acquired as
contiguous axial slices, parallel to a line joining the inferior points of the corpus
callosum. See Table 2.1 for sequence details.
A subset of University of Edinburgh participants was also enrolled in the
Advanced MRI substudy, undergoing additional magnetic transfer imaging,
proton magnetic resonance spectroscopy and diffusion tensor imaging (DTI) at
their baseline and 96-week scans. The baseline DTI sequences were used for the
work described in Chapter 8 of this thesis.
The diffusion imaging protocol consisted of 6 T2w sequences (b = 0 s mm−2) and
sets of diffusion-weighted (b = 1000 s mm−2) whole brain single-shot spin-echo
echo-planar imaging volumes acquired with diffusion encoding gradients applied
in 56 non-collinear directions. The acquisition parameters were: field-of-view 240
x 240mm; imaging matrix 96 x 96; 60 contiguous 2.5mm thick axial slices, giving
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PD/T2w dual echo TSE 250 × 250 60 1 × 1 × 3 3050/31/- 150
& /82/-
T2w FLAIR BLADE TSE 250 × 250 60 1 × 1 × 3 9500/124/2400 150
T1w SE 250 × 250 60 1 × 1 × 3 600/8.4/- 70/180
T1w MPRAGE 250 × 250 160 1 × 1 × 1 2400/2.97/1000 8
Table 2.1: Sequence details for standard baseline imaging protocol for MS-SMART
participants. TR: repetition time; TE: echo time; TI: inversion time; TSE: turbo spin
echo; SE: spin echo; MPRAGE: magnetisation-prepared rapid gradient echo.
2.1.3 Image post-processing
Post-processing of MS-SMART imaging was performed locally, using
fully-automated processes unless specified otherwise, supervised by MB.
2.1.3.1 Tissue segmentation
The 3D T1w and 2D FLAIR sequences were co-registered to the T2w sequence
using affine transformations (12 degrees of freedom), using tools freely available
in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software
library (FSL, https://fsl.fmrib.ox.ac.uk) [104]. Using Advanced Normalisation
Tools (ANTs, http://www.picsl.upenn.edu/ANTs) [105], both the FLAIR and
T1w sequences were corrected for bias field inhomogeneities. Again using
ANTs, voxels in the T1w sequence were segmented into different tissue classes
by assigned voxel probabilities of belonging to cerebrospinal fluid (CSF),
cortical grey matter, white matter, subcortical grey matter, cerebellum and
brainstem based on the MICCAI 2012 Multi-Atlas Challenge Data atlas
(https://my.vanderbilt.edu/masi/ [106]). Volumes for each tissue compartment
were then generated using weighted sums of all voxels multiplied by the relevant
probability. A threshold probability of 0.05 was used for all compartments to
exclude noise.
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2.1.3.2 White matter hyperintensity masks
The white matter hyperintensity (WMH) masks used for the work described
in Chapters 6 to 8 were automatically generated using a method combining
statistical transformation and atlas-based segmentation, developed by DD. This
was based on work completed for a previous PhD thesis [107], with code ran in
Matrix Laboratory (MatLab) on a Linux workstation.
Initial tissue segmentations were as above, using the MICCAI 2012 Multi-Atlas
Challenge Data atlas. A standard deviation map of the FLAIR volume was
created for each individual scan and this was used to update the initial
probabilities of belonging to the white matter tissue class to produce a WMH
probability for each voxel. A probabilistic mask of WMH voxels was created by
identifying any voxel with a standard deviation greater than the user specified
threshold, based on standard deviations above the mean FLAIR intensity. It was
then possible to create hard (binary) masks of WMH by selecting an arbitrary
probability threshold and this was used for the optimisation work described
in Chapter 6, comparing the masks with binary manual segmentations. An
example of a binary WMH mask overlaid on the FLAIR sequence from one of the
MS-SMART participants is shown in Figure 2.1.
Following this optimisation work, two different FLAIR thresholds were used for
the work described in Chapters 7 and 8. First, the FLAIR threshold associated
with the highest correlation between absolute WMH volumes derived from manual
and automated segmentation in the Advanced MRI subgroup was determined.
The resulting mask was then used to generate an absolute WMH volume for all
participants, by summing probabilities voxelwise. Second, the FLAIR threshold
that maximised spatial overlap with the manual masks, as determined by the
Dice index [108], was used. This also retained the probabilistic output and was
used as a template for overlaying the water diffusion imaging parameters.
2.1.3.3 Diffusion post-processing
Diffusion-weighted images were corrected for eddy current-induced distortions
and subject motion with the ‘eddy correct’ tool (FSL). After brain tissue
extraction using the Brain Extraction Tool, diffusion tensors and scalar diffusion
parameters (fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity
(AD) and radial diffusivity (RD)) were calculated using DTIFit (FSL).
For each tissue compartment, mean water diffusion metrics were derived using a
weighted mean; each voxel metric was multiplied by its probability of belonging to
22
Figure 2.1: Sample image showing automated WMH segmentation overlaid on FLAIR
sequence from one of the MS-SMART participants.
the compartment of interest and the sum divided by the sum of probabilities. The
probabilistic WMH mask was generated using the FLAIR threshold (see Section
2.1.3.2) that showed the closest spatial agreement with manual segmentation, as
described above.
2.1.3.4 Peak Width of Skeletonised Mean Diffusivity
The novel imaging marker ‘peak width of skeletonised mean diffusivity’
(PSMD), developed for use in small vessel disease, was derived by the
method described by Baykara et al [92] using the shell script provided
at http://www.psmd-marker.com/. DTI data were first skeletonised using
the Tract-Based Spatial Statistics procedure [75], part of FSL, aligning all
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participants’ FA data into common space using nonlinear registration (FNIRT)
and the standard space FMRIB 1mm FA template. Individual subject FA data
was then projected onto the skeleton derived from the standard space template,
thresholded at an FA of 0.2. Subject MD data were then projected onto this, using
the FA-derived parameters. The final MD skeleton was masked at an FA value of
0.3 to avoid CSF contamination. The PSMD parameter was then calculated as
the difference between the 95th and 5th percentiles of the voxel-based MD values
within the white matter skeleton.
2.1.3.5 Probabilistic Neighbourhood Tractography
Twelve tracts of interest were identified from the diffusion MRI data using
probabilistic neighbourhood tractography (PNT) as implemented in the TractoR
package for fibre tracking analysis (http://www.tractor-mri.org.uk). This
technique optimises the choice of seed point for tractography by estimating the
best matching tract to a reference tract derived from a white matter atlas, using a
series of candidate seed points placed in a 7 × 7 × 7 voxel neighbourhood. Tracts
assessed were the genu and splenium of the corpus callosum, and bilaterally the
cingulum (divided into dorsal and ventral portions), corticospinal tracts, arcuate
fasciculi and inferior longitudinal fasciculi. All generated tracts were visually
assessed by an experienced observer (MB) and those that were deemed not to be
anatomically acceptable representations of the fasciculi of interest were discarded
from further analysis.
2.1.4 Clinical and cognitive assessments
Participants underwent a structured baseline assessment by trained assessors
prior to randomisation and within one month of the initial MRI. This included
assessment of the Expanded Disability Status Scale (EDSS), the Multiple
Sclerosis Functional Composite (MSFC) and the Symbol Digit Modality Test
(SDMT). The EDSS is a widely used method for quantifying neurological
disability in MS, covering eight functional systems (pyramidal, cerebellar,
brainstem, sensory, bowel and bladder, visual, cerebral/mental and ‘other’,
http://www.neurostatus.net). The MSFC [109] is a short, three part standardised
test designed for use as an outcome in clinical trials in MS, assessing upper and
lower limb function as well as cognitive function. The SDMT is a ninety second
task to assess processing speed, consisting of matching numbers to arbitrary
symbols using a given code [36]. The SDMT was assessed by three raters
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(DM, DL, DC), all trained locally and observing each other during the training
period.
2.1.5 Cohort characteristics
At the University of Edinburgh, 111 people with MS were screened for trial
eligibility. Fourteen did not meet eligibility criteria, and four withdrew before
baseline assessment; 93 participants were successfully enrolled. Of these, 43
people consented to participate in the Advanced MRI substudy and the remainder
were enrolled in the standard protocol study. Further details of the study
participants are given in Table 2.2.
Standard Advanced Overall
No. of participants 50 43 93
Female : Male 39:11 30:13 69:24
Mean age (years) ± SD 54.9 ± 6.6 55.5 ± 8.3 55.2 ± 7.4
Age range (years) 41.4 − 65.9 34.4 − 65.6 34.4 − 65.9
Mean disease duration (years) ± SD 21.0 ± 10.8 23.1 ± 10.2 22.0 ± 10.6
Table 2.2: Characteristics of participants enrolled in MS-SMART at the University of
Edinburgh, also presented separately for those having the standard imaging protocol,
and those participating in the Advanced MRI substudy. SD: standard deviation.
2.2 Cognition in MS
2.2.1 Study aims, protocol & recruitment
A cross-sectional cohort of 108 people with MS were recruited to the ‘Cognition in
MS’ study as part of a PhD research project at the University of Edinburgh Centre
for Clinical Brain Sciences. The aim of that study was to explore the prevalence
of cognitive impairment in people with MS. Participants were recruited from
secondary care in the Lothian area of Scotland, referred by local neurologists and
specialist nurses between August 2010 and August 2012. Potential participants
were screened against the following eligibility criteria: a diagnosis of MS according
to the revised (2010) McDonald criteria [110], age 18 to 65 years inclusive and
absence of psychiatric or physical comorbidity (including major affective disorder,
significant dementia or other significant comorbidities). Subjects showing any
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ophthalmological condition not related to MS that might interfere with testing
were also excluded. For this purpose subjects having a Snellen acuity worse than
20/70 were excluded.
Of 972 patients screened, 108 patients fulfilled the eligibility criteria and agreed
to participate. It was projected to accomplish a sample with the ratio of RRMS,
SPMS and primary progressive MS (PPMS) similar to their natural proportions
in the population. A subset of sixty participants agreed to undergo MRI. Data
from this subgroup were used for the work described in Chapter 5 of this thesis,
with details of the participants given in Table 2.3.
Female : Male 32:28
Disease course (RRMS : SPMS : PPMS) 27:18:15
Mean age (years) ± SD 46.4 ± 8.2
Age range 28 - 61
Mean disease duration (years) ± SD 9.7 ± 6.2
Table 2.3: Characteristics of participants enrolled in the Cognition in MS study. PPMS:
primary progressive MS; RRMS: relapsing-remitting MS; SD: standard deviation;
SPMS: secondary progressive MS.
2.2.2 Imaging protocol
All MRI data were acquired in the Brain Research Imaging Centre, University
of Edinburgh, using a GE Signa Horizon HDx 1.5T clinical scanner (General
Electric, Milwaukee, WI) equipped with a self-shielding gradient set (33
mT/m maximum gradient strength) and manufacturer supplied eight-channel
phased-array head coil, between May 2011 and July 2012. Details of the basic
sequence parameters are shown in Table 2.4. A subset of participants had an
additional T2 CUBE volume sequence.
2.3 FutureMS
2.3.1 Study aims, protocol & recruitment
FutureMS was an ongoing multicentre observational cohort study, using baseline
clinical, laboratory and genomic data to predict neuroinflammatory disease








Matrix Slices Voxel (mm) TR/TE/TI (ms)
T2w FSE 256 × 256 256 × 256 80 1 × 1 × 2 11320/102
T2∗w Gradient
echo
256 × 256 256 × 192 80 1 × 1 × 2 940/15
FLAIR FSE 256 × 256 256 × 192 40 1 × 1 × 4 9000/140/2200
T1w 3D IR-Prep
FSPGR
256 × 256 192 × 192 160 1 × 1 × 1.3 10/4/500
Table 2.4: Sequence details for standard imaging protocol for Cognition in MS
participants. FSE: fast spin echo; TR: repetition time; TE: echo time; TI: inversion
time; FSPGR: fast spoiled gradient echo.
18 years, having been diagnosed with relapsing-onset MS within the preceding
6 months and not having been started on any disease-modifying therapy.
Participants underwent brain imaging at baseline and after 12 months, with
detailed clinical assessment including the MSFC performed by trained assessors
at the same timepoints.
At the time of the visual rating work reported in Chapter 5, sixty-seven
participants had been recruited and scanned at the University of Edinburgh.
Details of these participants are given in Table 2.5.
Female : Male 49:18
Mean age (years) ± SD 39.3 ± 9.6
Age range 21.5 - 58.6
Table 2.5: Characteristics of participants enrolled in the FutureMS study. SD: standard
deviation
2.3.2 Imaging protocol
All scans were performed at 3T (Magnetom Verio, Siemens AG, Healthcare
Division GmbH, Erlangen, Germany) at the Clinical Research Imaging Centre,
University of Edinburgh, using a standard 12-channel head coil.
These 67 participants included those imaged during the scan protocol
development phase. All protocols included a volumetric T1w sequence (1mm
isotropic voxels), with FLAIR and T2w sequences either as 3D or axial 2D
acqusitions. After the initial 23 participants, all scans included both 2D and 3D
FLAIR sequences; after the initial 25 participants, all scans included a 2D T2w
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sequence, replacing a 3D T2w sequence. 3D sequences were acquired sagittally
and 2D sequences were acquired axially, parallel to a line joining the inferior
points of the corpus callosum. The axial T2w sequence had a slice gap of 30%.
Details of the final scan protocol are given in Table 2.6.
Sequence name Field-of-view
(mm)
Slices Voxel size (mm) TR/TE/TI (ms) Flip
angle (◦)
T1w MPRAGE 256 × 256 176 1 × 1 × 1 5300/3.37/1100 7
T2w 220 × 220 33 0.7 × 0.7 × 4 6000/96/- 150
T2 FLAIR BLADE 250 x 250 60 1 × 1 × 3 9500/124/2400 150
T2 SPACE FLAIR 256 x 256 176 1 × 1 × 1 5000/715/1800 -
Table 2.6: Sequence details for standard imaging protocol for FutureMS participants.
Abbreviations are as for Table 2.1.
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Chapter 3
Systematic review of literature:
relationship between cognitive
performance and total white
matter lesion burden
3.1 Introduction
Moderate correlations have been reported between the imaging quantification of
brain white matter hyperintensities (WMHs) and cognitive performance in people
with multiple sclerosis (MS). This forms part of the ‘clinicoradiological paradox’.
A number of factors may account for this, including aspects of MS pathology that
are neither measured nor closely correlated with WMHs, insensitivity of MRI
techniques resulting in ‘subvisible’ pathology, and methodological limitations
of the current approaches to quantifying WMH burden. A systematic review
and meta-analysis of the published literature describing the relationship between
cognitive function and the total burden of white matter pathology detected by
standard structural brain MRI was therefore performed. The specific aims were
to summarise the cognitive clinicoradiological paradox, confirming the modest
correlations previously described [102], and to define the potential methodological
factors that could have influenced the assessment of this relationship. The design
of the systematic review, meta-analysis and structured report were based on the




3.2.1 Protocol, information sources and search strategy
The study protocol was documented in advance (see Appendix A). Medline,
Embase, and Web of Science databases were searched for English language papers
on 1st July 2015, with no date restrictions. The search terms were: ‘magnetic
resonance imaging’, ‘multiple sclerosis’, ‘cognitive’, ‘cognition’, related terms,
including relevant medical subject headings (‘MeSH’) and abbreviations of these.
(See Appendix B for details of search strategy.) Review articles were excluded,
with relevant reviews published in the last 10 years being screened for references.
Archives of the journals Neurology, Multiple Sclerosis (Multiple Sclerosis Journal
from 2011) and the American Journal of Neuroradiology were ‘hand-searched’
for relevant articles published in the previous ten years. These journals were
identified as relevant examples of the literature, being widely read by clinicians
and academics with an interest in MS.
3.2.2 Study selection and eligibility criteria
Initial screening of abstracts was performed by a single investigator (DM). Full
articles were then retrieved and eligibility assessment performed in a standardised
manner, with a final decision over study inclusion taken in consensus with a
second investigator (PC).
Eligibility criteria were: English language and peer-reviewed publications
reporting data from adults with clinically-definite MS as primary research
with a primary aim of relating cognition to routine MRI (T1-weighted (T1w),
T2-weighted (T2w), fluid-attenuated inversion recovery (FLAIR) or proton
density (PD)) metrics of total brain white matter lesion burden.
Imaging outcomes given as total lesion volumes or areas, lesion counts or scores,
were all accepted as valid measures of whole brain lesion burden. Similarly, any
measure of cognitive function with face validity, taken as any credible test of brain
function, was accepted.
Studies were excluded if reporting exploratory or secondary analysis, or if
lesion burden was only related to longitudinal change in cognitive function.
Where studies examined both cross-sectional and longitudinal outcomes, or
cross-sectional outcomes at more than one time point, the baseline cross-sectional
analyses were used. When overlap of reported cohorts was identified and
clarification from the original investigators was not possible, a conservative
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approach was adopted with inclusion of only the earliest dated relevant
article.
Studies within the systematic review were suitable for meta-analysis if they
reported an overall effect size for the relationship of imaging metrics to a single
measure of cognition defined by either a single cognitive test, or a summary result
from a cognitive battery.
3.2.3 Data collection
Data was extracted by a single investigator (DM) using a standardised form,
which captured:
• Study structure, including design, hypotheses, recruitment pattern and time
between cognitive testing and imaging;
• Characteristics of the participants, including age, sex and disease phenotype;
• Cognitive testing methods including blinding and identity of the tester, tests
and scoring system used;
• Image acquisition methods;
• Image analysis methods including training and blinding of investigators,
software tools used, whether measures of intra- and inter-rater reliability
were provided;
• Statistical analysis methods, including controlling for potential confounding
factors
A study quality assessment tool (see Appendix C) was also developed,
based on STROBE (Strengthening the Reporting of Observational studies
in Epidemiology) guidelines [112] to evaluate the risk of bias in individual
studies.
The authors for one paper [113] were contacted for further information and
numerical data were provided.
3.2.4 Summary measures and synthesis of results
Summary measures were recorded if relating MRI metrics to an overall measure
of cognitive function or to a single cognitive test. Where summary measures
were provided both unadjusted and adjusted for potentially confounding clinical
covariates, adjusted results were used. Correlation coefficients or the difference
in lesion burden between groups defined by cognitive status were accepted as
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summary measures, with preference given to correlations if both were available
[114].
All reported summary measures were converted into effect sizes and inverted
as necessary so that negative values always indicated an association of lower
cognitive scores with higher lesion burdens. Standardised mean differences
were calculated from studies reporting group comparisons, prior to conversion
to equivalent correlations [114]. An approximation to the standard deviation
was estimated as necessary based on available measures of dispersion (e.g.
interquartile range or range) [115]. In studies with two impaired groups defined
by specific cognitive deficits, these groups were combined before calculation of a
standardised difference from a non-impaired group. The Fisher’s z transformation
[114] was used prior to calculation of an aggregate summary effect, with
conversion back to correlations for reporting of overall meta-analysis findings
and confidence intervals.
An aggregate summary effect was calculated using maximum likelihood
estimation [116] taking into account the size of the various studies; this method
allows incorporation of those studies reporting non-significant results without
providing their estimate. Separate analyses were carried out for studies measuring
hyperintense lesion burden on T2w, FLAIR and/or PD sequences, and for the
subgroup of studies evaluating T1w hypointense lesion volume.
Heterogeneity was assessed using Cochran’s Q and the I2 statistic [115]. Tests for
heterogeneity test the null hypothesis that all the included studies are evaluating
the same effect, with the I2 statistic quantifying the effect that any inconsistency
between studies has on the overall estimate.
3.2.5 Risk of bias across studies
The eligibility criteria required a stated primary aim to evaluate the relationship
between cognitive status and brain imaging metrics. This was pre-specified in
order to minimise the influence of reporting bias from post hoc analyses. Within
the included studies, all analyses that were described without results being
provided were recorded. A funnel plot was evaluated visually for asymmetry
and tested formally using Egger’s regression test.
3.2.5.1 Study quality
An alternative aggregate effect size was calculated using quality scores as an
additional scaling factor to study size. This was pre-specified, with the hypothesis
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that the aggregate effect size would differ with the methodological quality of the
study. Study quality was also investigated as a predictor of effect size, using
general linear modelling, with all component quality scores or the overall summary
score as predictors.
3.2.5.2 Sensitivity analyses
Following discovery of considerable heterogeneity in the image analysis
methodology, sensitivity analyses were carried out to investigate the effect
of scanner magnet strength and lesion quantification method. Similarly, to
investigate heterogeneity in cognitive assessment, a further sensitivity analysis
into the effect of using adjusted or unadjusted cognitive scores was carried
out.
To explore the possibility of ‘true heterogeneity’ between study effect sizes, a
sensitivity meta-analysis was carried out using a random effects model.
3.2.6 Subgroup analyses - information processing speed tests
Subgroup analyses of studies using the Paced Auditory Serial Addition Test
(PASAT) and the Symbol Digit Modalities Test (SDMT), two common tests of
information processing speed, were pre-specified to investigate whether focusing
on distributed cognitive function would improve correlations with overall lesion
burden and replicate previous findings [102].
3.2.7 Additional analyses
3.2.7.1 Disease phenotype
Between-study heterogeneity was further investigated by considering the effect of
disease phenotype on effect size. The studies from which an overall effect size
could be estimated were classified as having cohorts with relapsing-remitting,
progressive, ‘benign’ or mixed disease courses and separate effect sizes were
calculated for each group.
3.2.7.2 Effect of lesion volume
The effect of lesion volume on effect size was investigated where enough
information was provided to estimate both a study-specific effect size and a
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mean cohort lesion volume with standard error. Equivalent lesion volumes were
estimated from lesion areas using slice thickness. The effect sizes, on the z-scale
were then entered in a linear model, using lesion volume as the predictor, with
studies weighted by size.
3.3 Results
3.3.1 Study selection
A total of 3882 studies were identified from the initial literature search, 1975
of which were duplicates (see Figure 3.1). Year-on-year increases were seen in
the publication rate identified through the initial search (see Figure 3.2). No
additional studies were included following hand searching of journal archives,
taken to indicate good coverage by the initial search strategy. After review of
abstracts, 139 manuscripts were retrieved. Ninety were subsequently excluded,
most frequently (35/90 = 39%) because the primary study aim was not relevant.
A total of fifty papers met all inclusion criteria [61, 63, 72–74, 83, 113, 117–159],
spanning the period 1987 - 2015.
Thirty studies provided usable summary measures relating hyperintense
T2w/FLAIR/PD lesion burden to cognitive function. Two studies reported
a ‘non-significant’ result and one study was excluded from meta-analysis as
the reported summary measure was internally inconsistent with other reported
results and significance levels. The remaining seventeen studies did not provide
results suitable for use in meta-analysis, reporting only individual results for each
cognitive subtest (n = 12) or multiple regression modelling with simultaneous
assessment of several brain imaging metrics (n = 5). Thirteen studies reported
equivalent summary measures relating cognition to T1w hypointense lesion
burden. One study examined the relationship of lesion burden to longitudinal
change in cognition, as well as providing baseline cross-sectional data.
3.3.2 Participant characteristics
The total number of subjects from all included studies was 2891. Individual study
size ranged from 17 to 327 participants (mean 58, median 45; see Figure 3.3).
Forty-four studies specified the sex ratio, all but one having a female majority.
The range of mean participant age (provided in 47/50 studies) was 31 to 55
years. No study used age of disease onset in its eligibility criteria. Twenty-six
studies included participants with a mixture of disease courses; thirteen studies
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Figure 3.1: Flowchart showing articles retrieved and considered at each stage of the
review process.
recruited exclusively relapsing-remitting disease, six studies progressive disease,
two ‘benign’, and three did not specify the participants’ disease course.
3.3.3 Image acquisition
The majority (29/50 studies) used 1.5T scanners. Ten studies used scanners with
below 1.5T magnets for some or all participants’ imaging, seven used 3T scanners,
one used both 1.5 and 3T scanners and three did not specify the scanner field
strength. Details of the imaging protocol were given in all but seven studies.
3.3.4 Image analysis
The sequence(s) used to measure lesion volume was specified in 43 studies.
Twenty-six specified the number of people involved in the lesion analysis; this
was a single observer in 14 studies. The anatomical boundaries of evaluation





















Figure 3.2: Number of results retrieved from database search by year of publication.
The point for the year 2015 is an extrapolated value from the 6-month figure.
studies. Only five per cent of studies calculating a lesion volume or area (2/42)
normalised to intracranial volume.
A wide variety of approaches were used for the quantification of lesion burden.
These included lesion counts (two studies) or weighted lesion scores (six
studies), manual lesion outlining either on hard copies (two studies) or within
viewing software (six studies), and the use of semi-automated software methods
(thirty-one studies). Of the six studies using lesion scores, five different
scoring systems were used. One study used both manual and semi-automated
measurements (for different sequences), one used manual lesion outlining and an
absolute lesion count, and in one study the methodology was unclear.
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Figure 3.3: Histogram of study sizes
In the thirty-two studies using semi-automated measurement tools, the software
used was specified or references provided in 25 studies (78%), covering 14
different software packages. In 18 of these studies the named software was
publicly available (11 different softwares). The remaining studies did not specify
their software. A manual editing stage for software-generated lesion masks was
specified in five studies (16%) and the person performing this was described in
two studies. In the ten studies using fully manual lesion outlining, the person
performing this was described in six.
Only two studies provided an indication of inter-observer agreement and one
study intra-observer reproducibility. Seven studies gave previous measures of
reproducibility or results on training data sets.
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3.3.5 Cognitive testing
The cognitive assessor and their training were unclear in 38 studies. Of defined
batteries, the most commonly used was Rao’s Brief Repeatable Battery (12/50),
followed by the Minimal Assessment of Cognitive Function in MS (5/50), used
with modifications or additional tests in eight (67%) and two (40%) studies
respectively. Unique collections of tests were found in 27 studies. The SDMT
or PASAT were used either exclusively or as part of a wider battery in 30
studies.
Substantial variability was seen in how raw cognitive scores were processed
prior to their use in the evaluation of a possible relationship with imaging
metrics. Methods included use of unadjusted scores, standardisation and the
deployment of group classifiers. Standardisation was performed using either
historic (published or unpublished) or contemporary (matched or unmatched for
participant characteristics) control data.
Group classifiers were either based on internal (patient) or external (normative)
reference cohorts. The specific thresholds used to define impairment on individual
tests were also variable, including 1, 1.5, and 2 standard deviations from the
reference mean, and those based on centiles. Moreover, the number of failed
tests used to define overall cognitive impairment was also variable (see Appendix
D).
Consideration of the effect of potential confounders also varied between studies,
both in the recording of relevant data and whether it was adjusted for in the
analysis. Some studies adjusted for age (n = 18), sex (n = 12), education level
(n = 13) and/or affective disorders (n = 15). Drug treatments and premorbid IQ
were both adjusted for in three studies. Cognitive leisure activities were neither
measured nor adjusted for in any study.
3.3.6 Statistical analysis
Summary measures were provided through univariate correlations (n = 37)
and/or group comparisons based on cognitive status (n = 24). Four studies
divided participants into groups dependent on radiological features. Fourteen
studies constructed statistical models predicting cognitive performance based on
imaging and other laboratory, demographic, or clinical markers.
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3.3.7 Reporting quality and risk of bias within studies
A range of study-specific quality scores was seen (mean 42%, SD 11%; Figure 3.4).
Among individual elements of the composite quality score, complete reporting
was provided most frequently for eligibility criteria and outcome measures (Table
3.1). In contrast, no study provided complete reporting of potential confounding
factors, measurement methodology, or a justification of study size.

















Figure 3.4: Histogram of overall quality scores, expressed as a percentage of the
maximum possible score.
3.3.8 Results of individual studies
Studies directly reporting correlation coefficients relating cognitive performance
to T2w hyperintense lesion burden gave correlations ranging from −0.6 to
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Information reported
Studies gaining each mark (%)
0 0.5 1
Eligibility criteria 18 22 60
Individual outcome variables results 8 40 52
Overall outcome results with precision 14 40 46
Quantitative variable handling 10 48 42
Recruitment pattern 60 - 40
Participant characteristics 14 48 38
Statistical methodology 18 50 32
Blinding of assessors 32 50 18
Participant dropout 86 - 14
Objective clearly stated 42 50 8
Cognitive testing & imaging delay 36 58 6
Study design specified 84 10 6
Clearly defined outcomes 8 88 4
Potential confounding factors 36 64 0
Measurement methodology 44 56 0
Study size rationale 100 - 0
Table 3.1: Table showing percentage of studies gaining 0/0.5/1 for each component of
the quality assessment tool.
−0.23. Standardised mean differences ranged from −2.70 to +0.23, equivalent to
correlations of −0.80 to +0.11.
3.3.9 Synthesis of results
3.3.9.1 T2w hyperintense lesion burden
The aggregate effect size relating cognitive performance to T2w hyperintense
lesion burden was r = −0.30 (95% confidence interval (CI): −0.34 to −0.26;
Figure 3.5, n = 32). There was evidence of possible heterogeneity (Q = 43.62, df
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Figure 3.5: Forest plot of the individual studies using T2w/FLAIR/PD sequences,
showing their effect sizes as correlation coefficients. Box sizes are inversely proportional
to study variance. Aggregate effect size: r = −0.30; 95% confidence interval:
−0.34,−0.26.
3.3.9.2 T1w hypointense lesion burden
The aggregate effect size relating cognitive performance to T1w hypointense lesion
burden was r = −0.26 (95% CI: −0.32,−0.20; Figure 3.6, n = 13). There was
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Figure 3.6: Forest plot of effect sizes from individual studies relating T1w hypointense
lesion burden to overall cognitive performance, with 95% confidence interval (total n
= 1062). Box sizes are inversely proportional to study variance. The overall effect size
was r = −0.26 (95% CI: −0.32,−0.20).
3.3.10 Risk of bias across studies
Funnel plot inspection (Figure 3.7) and Egger’s test of asymmetry (p = 0.05)
gave equivocal results. Possible underlying sources of heterogeneity were therefore
explored [160].
In order to explore the possibility of ‘true heterogeneity’ between study effect
sizes measured using T2w/FLAIR/PD lesion burden, we performed a sensitivity
meta-analysis using a random effects model, giving an overall effect size similar
to that of our primary analysis (r = −0.33; 95% CI −0.38,−0.27, n = 30). This
method did not allow inclusion of the two studies reporting a non-significant
result.
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Figure 3.7: Funnel plot of effect sizes, on Fisher’s z scale, against the inverse of their
standard error (SE, itself inversely related to study size) with asymmetry towards
increased reporting of stronger correlations for smaller study sizes. The vertical dashed
line indicates the summary effect on the same scale (z = −0.32). The unfilled circles
correspond to the two studies reporting non-significant results.
In the case of the T1w hypointense lesion burden, an alternative random effects
meta-analysis gave a summary effect size of r = −0.30 (95% CI: −0.39,−0.20).
A funnel plot (not shown) showed asymmetry, confirmed by Egger’s regression
test (p = 0.032).
Reporting biases could not be adequately evaluated as study protocols were not
published prospectively. Despite methodological heterogeneity apparent from our
quality scoring, a significant correlation was not seen between overall quality score
and effect size, where reported (r = −0.18, p = 0.34, n = 32). General linear
modelling using the individual component scores as predictors of the study effect
size identified no statistically significant results (p = 0.07 to 0.97).
An exploratory meta-analysis using quality scores as an additional weighting
factor returned an effect size similar to that of our primary analysis (r = −0.30;
95% CI: −0.36,−0.24).
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Further sensitivity analyses, comparing scanner field strength and type of lesion
quantification method did not demonstrate a measurable subgroup difference in
heterogeneity from the small number of studies using high (3T) or low (below
1T) field scanners (see Table 3.2), or from those using lesion counts or scores (see
Table 3.3).
Field strength Studies Participants r 95% CI Q df p I2
3T 2 91 -0.43 (-0.59, -0.25) 0.33 1 0.56 0
1/1.5T 21 1478 -0.29 (−0.34,−0.24) 34.43 20 0.02 41.9%
Below 1T 4 188 -0.32 (−0.45,−0.18) 3.56 3 0.32 0
Overall 30 1952 -0.31 (−0.35,−0.26) 43.62 29 0.04 33.5%
Table 3.2: Results of sensitivity analysis, comparing study effect sizes (r) by scanner
field strength. CI: confidence interval.
Method Studies Participants r 95% CI Q df p I2
Manual outlining 6 209 -0.30 (−0.42,−0.16) 6.87 6 0.14 41.7%
Semi-automated 21 1320 -0.33 (−0.38,−0.28) 30.55 20 0.03 41.1%
Scores/counts 4 217 -0.24 (−0.38,−0.10) 0.9 3 0.92 0
Overall 30 1952 -0.31 (−0.35,−0.26) 43.62 29 0.04 33.5%
Table 3.3: Results of sensitivity analysis, comparing study effect sizes (r) by lesion
burden quantification method. CI: confidence interval.
A further post hoc sensitivity analysis was also performed using the same
methodology as the main analysis, incorporating all potentially analysable data
from the 139 studies considered at the full paper review stage. This returned an
aggregate effect size of r = −0.31 (95% CI: −0.34,−0.28; n = 65 studies, total
participant number = 3430).
3.3.11 Subgroup analyses - alternative cognitive endpoints
Exploratory meta-analyses were performed on two widely used measures of
information processing speed, the SDMT and PASAT. The a priori hypothesis
was that total lesion burden would have a stronger correlation with these tests
of distributed cognition function compared to the mixture of distributed and
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localised functions in our primary analysis. The summary effect size for SDMT
was r = −0.37 (95% CI: −0.43,−0.31; n = 13 studies) and for PASAT was r =
−0.28 (95% CI: −0.34,−0.22; n = 15 studies). See Figures 3.8 and 3.9.
A post hoc sensitivity analysis considering the effect of using raw or adjusted
cognitive scores was also performed. Twenty-one of the 32 studies included in our
primary endpoint meta-analysis were identified to have adjusted their cognitive
scores, with an aggregate effect size (between T2w hyperintense lesion volume
and cognitive performance) of r = −0.31(−0.36,−0.26). Eleven studies were
identified not to have adjusted their cognitive scores, with an aggregate effect
size of r = −0.29(−0.37,−0.21).
3.3.12 Additional analyses
3.3.12.1 Effect of disease phenotype
Twenty-nine of the 32 studies in the primary meta-analysis provided information
on the disease course of their participants. Summary effect sizes and tests of
heterogeneity for each group are displayed in Table 3.4. The mixed phenotype
group was the only group to show evidence of heterogeneity, although the sample




Studies Participants r 95% CI Q df p I2
Benign 2 109 −0.23 (−0.41,−0.04) 0.79 1 0.37 0
Relapsing-
remitting
11 946 −0.24 (−0.30,−0.18) 3.98 9 0.91 0
Mixed
phenotypes
11 626 −0.37 (−0.44,−0.30) 23.3 9 0.006 61.4%
Progressive 5 238 −0.41 (−0.51,−0.29) 3.72 4 0.445 0
Table 3.4: Summary effect sizes, with studies grouped by participant phenotype. N.B.
The relapsing-remitting and mixed phenotype groups both included one study reporting
only a non-significant result. This could be used in the calculation of a summary effect
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Figure 3.8: Forest plot of effect sizes from individual studies relating T2w hyperintense
lesion burden to SDMT performance, with 95% confidence interval (total n = 885). Box
sizes are inversely proportional to study variance. The overall effect size was r = −0.37
(95% CI: −0.43,−0.31). There was evidence of heterogeneity (Q = 30.7, df = 10, p
= 0.001, I2 = 67.4%). An alternative random effects meta-analysis gave a summary
effect size of r = −0.45 (95% CI: −0.55,−0.33). To investigate the heterogeneity,
a funnel plot was drawn. Egger’s regression test confirmed evidence of funnel plot
asymmetry (p = 0.0001).
3.3.12.2 Effect of total lesion volume on the reported strength of
association
Twenty-one of the 30 studies providing data from which to calculate an effect size
also gave relevant summary statistics for lesion volume. Five studies employed
lesion counts or scores and four studies did not provide summary statistics for
lesion burden.
Individual study effect sizes are plotted against lesion volume in Figure 3.10.






















































Figure 3.9: Forest plot of effect sizes from individual studies relating T2w hyperintense
lesion burden to PASAT performance, with 95% confidence interval (total n = 1103).
Box sizes are inversely proportional to study variance. The summary effect size was r =
−0.28 (95% CI: −0.34,−0.22). There was evidence of heterogeneity (Q = 29.2, df = 13,
p = 0.006, I2 = 55.5%). An alternative random effects meta-analysis gave a summary
effect size of r = −0.35 (95% CI: −0.44,−0.26). To investigate the heterogeneity,
a funnel plot was drawn. Egger’s regression test confirmed evidence of funnel plot
asymmetry (p < 0.0001).
reach significance as a predictor (p = 0.066) but showed a trend towards larger






















Figure 3.10: Plot of individual study effect sizes with 95% confidence intervals against
estimated cohort mean lesion volume with 95% confidence interval for estimate, based
on standard error. Regression line from linear model showing relationship between
lesion volume and effect size (p = 0.066).
3.4 Discussion
Synthesis of published findings confirms a modest correlation (r = −0.30)
between MRI measures of total brain white matter lesions and cognitive function
in people with MS. Although variability was observed between studies in the
magnitude of the reported relationship, no large (> 100 participants) single
study demonstrated a strong correlation. Technical and methodological factors
were therefore examined to determine their potential impact on the reported
correlation. These were broadly divisible into three dimensions: variability in
cognitive assessment and scoring; variability in cohorts studied; and variability
in image acquisition and analysis.
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Substantial variability was seen with respect to both the techniques used to
evaluate cognitive function and the adjustment for other variables that might
influence cognition (e.g. education, premorbid IQ and drugs). This may
however represent a largely historic issue [35], as a global movement is emerging
to harmonise evaluation and scoring through the Brief International Cognitive
Assessment for MS (BICAMS) initiative [36]. In contrast, the optimum method
to generate quantifiable measures of lesion burden from brain imaging data lacks
emergent consensus. Recent attempts to harmonise MRI acquisition protocols
[161,162] have been made, however no similar initiative exists for image analysis
techniques.
Considerable heterogeneity was observed in the clinical cohorts studied. The
importance of this lies in the possibility that the fundamental relationship
between white matter lesions and cognition may differ between cohorts depending
on their characteristics. There was some suggestion from the secondary analyses
in support of this. Larger effect sizes were found in cohorts of participants with
greater lesion burdens and later stage/progressive disease courses. If confirmed,
the existence of a dynamic association (dependent on cohort characteristics) raises
questions about the fundamental relationship between white matter lesions and
cognition. Possible reasons for this variation include interactions with other
aspects of MS pathology that emerge independently from disease duration and
progressive lesion burden, progression of lesions with disease course (e.g. greater
pathological homogeneity in chronic lesions), or that the ability to compensate
(functionally) for pathology declines in a non-linear form dependent upon time
and/or total lesion burden.
Semi-automated approaches were the most frequently used for image analysis
(62%) and merit particular consideration. While effective manual editing is
clearly dependent on adequate training of the operator, the automated (software)
component is more challenging to benchmark. Authors should routinely report
the software used. Separately, the field risks delaying progress and reducing the
potential for collaboration due to the many differing software packages used.
Of the 24 studies naming software, ten different publicly available (commercial
or open source) packages were used, and a further three packages that were
developed ‘in house’. As yet no comparative study has been performed on a
common dataset to evaluate agreement between these varied approaches. A new
consensus initiative to support an image analysis framework in MS would enable
benchmarking while also supporting ongoing innovation.
Despite the finding of substantial methodological variability between studies,
formal testing for heterogeneity in the primary meta-analysis returned an
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equivocal result. This indicates that methodological variability between studies
cannot provide a sufficient explanation for the cognitive clinicoradiological
paradox. Nevertheless, measurement errors within all published studies may
have attenuated observed correlations in the face of a higher ‘true’ correlation
[103]. Greater recognition and transparency around measurement error for both
cognitive and lesion burden quantification would therefore be beneficial to the
field.
The findings may have been limited by an overly inclusive approach to both
the evaluation of cognition and white matter lesion burden. With respect
to the former, a higher aggregate correlation was observed between white
matter lesion burden and cognition measured by the SDMT, a measure of
information processing speed, understood to reflect widely distributed brain
connectivity, than was seen for cognition as defined in the primary analysis.
Furthermore, a substantial body of potentially relevant data was excluded from
this review as the primary aim of the study was unclear or reported findings
were secondary/exploratory analyses. Notably, relatively few studies used >1.5T
field strength scanners, in part reflecting the recent shift away from exploring the
relationship between phenotype and T2w hyperintense lesion burden, focusing
instead on the possible relevance of other MRI metrics. Finally, despite best
efforts to apply a systematic approach, all reviews are conducted by researchers
who bring unconscious bias [163] and the lack of replication of the literature
search and data extraction by a second investigator is a limitation.
In conclusion, a modest correlation (r = −0.30) exists between MRI measures of
total brain white matter lesion burden and cognitive function in people with MS.
This review has highlighted the substantial variability existing in the literature
addressing this question, particularly with respect to cognitive methodologies,
cohort characteristics and imaging methodology. This variability was insufficient
to fully account for the cognitive clinicoradiological paradox and resolving this
will therefore likely require simultaneous evaluation of multiple components of
the complex pathology using optimum measurement techniques for both cognitive
and imaging feature quantification [164]. Nevertheless, measurement errors from
the existing techniques to quantify lesion burden act to attenuate the strength
of the observed relationship, obscuring any current attempt to quantify the
true strength of that relationship. Optimised measurement of lesion burden is
therefore essential. Against that background, the move to harmonise cognitive
assessment in MS is valuable, but no similar move to optimise and harmonise
quantification of lesion burden has emerged in the MRI community. This frames
the central issue that is addressed further throughout this thesis.
50
It appears that the strength of association may also vary dependent upon the
population being studied, in particular varying with respect to the total burden
of white matter pathology and the emergence of progressive disease. This raises
questions about the potential mechanism(s) of a dynamic relationship between





Assessing the reliability of the




Research studies in people with multiple sclerosis (MS) have to date frequently
used imaging-based outcomes, often involving quantification of white matter
hyperintensity (WMH) volume. This can then be used to investigate imaging
correlates of disability or monitor treatment effects. Spatial templates of WMHs
can be used to interpret advanced imaging markers, such as those derived from
magnetic resonance spectroscopy (MRS), magnetisation transfer (MT) imaging
or diffusion tensor imaging (DTI). Any lack of accuracy in the measurement of
WMHs will attenuate the results derived.
As highlighted in the previous chapter, a wide variety of approaches are used to
quantify white matter disease burden in MS and their comparability is not always
clear. In order to establish the validity of any method, its relationship to a set
of reference standard measurements should be demonstrated. Ideally this should
be within a population with a similar profile to that of its intended use.
A true evaluation of disease burden would require pathological correlation. Such
studies are valuable [165] but for practical and ethical reasons are not possible
in large numbers. They can also only ever represent a limited sample of the
varied disease courses seen in people with MS, most often those with early
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atypical inflammatory disease undergoing biopsies or from autopsy material
showing endstage disease. In the absence of pathological confirmation, the
reference standard for imaging research in practice is usually taken to be manual
segmentation by a user experienced in interpreting imaging changes. This is
frequently a neuroradiologist or another user supervised by a radiologist. However
very little data on the reliability of this reference standard has been published
and the systematic review reported in the previous chapter found poor reporting
of any reproducibility measures.
In this chapter, the accepted practice used elsewhere is followed, establishing the
reference standard in a relevant population for later use. This is undertaken
using the Advanced MRI substudy cohort of MS-SMART (see Chapter 2,
Section 2.1). Inherent to this process, but often omitted or not reported in the
literature, is an assessment of its reliability, both in providing a unidimensional
quantification of the WMH burden and a spatial template (‘mask’ or ‘map’)
of these changes. Factors affecting the reliability and stability of the reference
standard are considered. As an experienced neuroradiologist is generally accepted
as an optimal observer for providing the reference quantification, the reliability
seen between two neuroradiologists is investigated.
4.2 Methods
4.2.1 Participants and Imaging
This work was performed using the routine structural imaging sequences
performed at the baseline assessment of all participants (n = 43) recruited in
Edinburgh to the Advanced MRI substudy of MS-SMART. See Chapter 2, Section
2.1 for further details of the cohort, image acquisition and post-processing.
4.2.2 Segmentation protocol
A single observer (DM, neuroradiologist with 4 years’ experience), blinded
to all clinical and demographic information, outlined all WMHs using
freehand drawing tools available in the Mango image analysis software
(http://ric.uthscsa.edu/mango/). This segmentation was performed on
the registered fluid attenuated inversion recovery (FLAIR) sequences with
T1-weighted (T1w) and T2-weighted (T2w) sequences available for reference.
Segmentation was completed for the entire cohort over a period of seven months,
partly covering their recruitment stage, in sessions lasting up to 3 hours.
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The segmentation process was performed primarily in the axial plane, with
adjustments as necessary, using reformatted coronal and sagittal projections.
An inferior boundary for WMH segmentation was set at the foramen magnum.
Where possible, WMH boundaries were chosen to enclose areas of abnormal signal
on both T2w and FLAIR sequences. Viewing windows were optimised on an
individual subject basis to make WMHs as clearly distinct from surrounding
tissue as possible. No minimum size for WMH segmentation was set. Enlarged
perivascular spaces were not marked, unless they appeared inseparable from focal
or diffuse WMHs.
Completed masks were saved as binary files in the NIfTI (Neuroimaging
Informatics Technology Initiative) format. Absolute volumes for each WMH mask
were calculated using tools available in the FSLstats software package (FMRIB
software library (FSL) [104]).
4.2.2.1 Intra-observer reliability
Following completion of the initial WMH masks, the manual segmentation process
was repeated for the whole cohort on two further occasions, with random
reordering of the scans for each set of masks. The time interval between
segmentations of the same scan was at least six weeks.
4.2.2.2 Inter-observer reliability
A subset of 12 scans were pseudo-randomly selected to ensure even coverage of
all quartiles by WMH volume, based on the initial mask of the first observer.
The manual segmentations were repeated by a second observer (neuroradiologist
[GM] with 4 years’ experience), using the same protocol, blind to all clinical and
demographic information and the results of the initial segmentation. These were
used for investigation of unidimensional reliability and spatial agreement, using
comparisons to the third (final) manual segmentation by the first observer.
4.2.3 Statistical analysis
4.2.3.1 Unidimensional reliability
Reliability of absolute WMH volumes were compared for the initial, repeat and
second observer segmentations using intraclass correlations (ICCs; Class 2, a
random effects, two-way model based on single observations), reflecting absolute
agreement, and assessed visually using Bland-Altman plots [166] of volume ratios.
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Spearman correlation coefficients were calculated for each combination of two
mask sets.
The effect of WMH volume on reliability measures was explored graphically, using
the Bland-Altman ratio plots, and by calculating ICCs separately for the 21 scans
with the highest and lowest mean WMH volumes.
The ‘psych’ package in R software was used for calculation of ICCs.
4.2.3.2 Spatial agreement
Spatial agreement between masks was assessed using the Dice similarity coefficient
[108] generated using script written in Matlab (provided by MB). This measures
the voxel overlap between the two masks and is defined as twice the ratio of the
number of overlapping voxels to the sum of the voxels in each segmentation.
Visual evaluation of discrepancies was carried out in FSL viewing software




The baseline imaging from all 43 participants in the Advanced MRI substudy of
MS-SMART was used. There were 30 female and thirteen male participants with
a median age of 55.5 years (interquartile range (IQR): 49.9, 62.0). All participants
had a diagnosis of secondary progressive MS (SPMS) with a median total disease
duration of 23.4 years (IQR: 15.6, 27.3).
4.3.1.2 Summary statistics
Manual WMH segmentation by the initial observer was completed over a period
of 7, 2 and 4 months respectively for mask sets 1 to 3, with a delay of at least six
weeks between sets 1 & 2 and sets 2 & 3. The mean time (± standard deviation)
taken for each mask was 44± 29, 50± 26 and 38± 21 minutes for mask sets 1 to
3 respectively.
Overall cohort WMH volumes were highest for the second set of masks, with mask
set 3 intermediate between the first two. All three volume sets were positively
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skewed. Cohort WMH volumes for each of the three sets of masks are represented
in boxplots shown in Figure 4.2 and summarised in Table 4.1.
An example of a manual WMH segmentation overlaid on the FLAIR sequence is
shown in Figure 4.1.
Figure 4.1: Sample image showing manual WMH segmentation overlaid on FLAIR
sequence from one of the MS-SMART participants.
Mask Mean ± SD Median (IQR)
1 19.7 ± 20.8 12.9 (6.1, 22.6)
2 26.7 ± 23.0 21.2 (12.5, 34.7)
3 22.9 ± 22.0 16.9 (7.6, 30.1)
Table 4.1: Summary statistics for mask sets 1 to 3, given as volumes (ml). IQR:
interquartile range; SD: standard deviation.
4.3.1.3 Unidimensional reproducibility
Sets of WMH volumes for the different segmentations showed (Spearman)



















Figure 4.2: Boxplots of cohort WMH volumes for mask sets 1 to 3.
.
comparison. The overall ICC for all three mask sets was 0.94. Full results are
given in Table 4.2.
Table 4.2 also shows the comparison of ICCs for the 21 scans with the lowest and
highest mean WMH volume. Although the confidence intervals are overlapping,
higher ICCs are associated with higher WMH volumes. The Bland-Altman plots
of the volume ratios between masks from different sets are shown in Figure 4.3 and
suggest a similar finding. Greater relative discrepancies between segmentations
are seen at lower WMH volumes, with a trend towards convergence on more
similar values at higher volumes.
The improvement in agreement with successive mask sets is also apparent from
the Bland-Altman plots. The largest range of relative discrepancies and widest
confidence interval for the mean ratio is seen for the comparison between the first
two mask sets, and the range and confidence interval are smallest for the final
comparison (mask sets 2 & 3). The final comparison mean ratio below 1 (= 0.81)
reflects the overall larger WMH volumes generated in mask set 2.
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Masks r ICC (95% CI) Mean Dice
1 v. 2 0.92 0.91 (0.42,0.97) 0.68
1 v. 3 0.94 0.96 (0.88,0.98) 0.74
2 v. 3 0.93 0.96 (0.85,0.98) 0.73
Overall - 0.94 (0.83,0.98) 0.71
Lowest 21 - 0.67 (0.31,0.86) 0.65
Highest 21 - 0.92 (0.74,0.97) 0.78
Table 4.2: Spearman correlations (r), intra-class correlations (ICCs, Class 2) with 95%
confidence interval (CI), and mean Dice indices for each two-way mask comparison and
overall for the three mask sets where possible. The overall comparison is also divided
into upper and lower groups by mean lesion volume, with these examined separately.
4.3.1.4 Spatial agreement
The overall grand mean of the Dice indices for spatial overlap was 0.71, covering
all mask comparisons. Mean values for each two-way comparison are given in
Table 4.2. As with the unidimensional measures of reliability, the highest mean
values for the Dice index are seen for comparisons with the final mask set (3),
suggesting convergence on a stable segmentation.
Similar trends in spatial agreement within the cohort were seen to unidimensional
measures, with increasing Dice indices at higher WMH volumes. This trend is
shown graphically in the scatterplots of Figure 4.4. This is a recognised limitation
of the Dice index, which measures only agreement in the regions considered of
interest, where larger regions are clearly more likely to overlap, disregarding
agreement on tissue outwith these regions.
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Figure 4.3: Bland-Altman plots, showing ratio of WMH volumes for each scan (n = 43) compared between different mask sets (1 to 3). In
each case the ratio is that of the later to the earlier mask. The solid line shows the mean ratio for the mask comparison and the dashed lines
are 95% confidence intervals for the mean.
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Figure 4.4: Scatterplots of Dice index of intra-observer spatial agreement against mean
WMH volume for each two-way comparison between mask sets 1 to 3. The lower right
plot shows the mean of the Dice index for all comparisons against the mean WMH
volume for each scan.
4.3.1.5 Sources of discrepancy
The review of WMH masks with the largest discrepancies revealed that the main
source was large regions of ‘dirty’ white matter. This was white matter with
signal characteristics intermediate between that of the overlapping segmented
regions and those voxels designated ‘normal-appearing’ white matter in both
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segmentations. For many subjects, this intermediate signal tissue represented a
major portion of the white matter. Using the Mango software to adjust viewing
windows in some cases highlighted apparent edges to the abnormal white matter,
but this was not universal.
In several scans, high signal was seen to extend along the corticospinal tracts,
on one or both sides, suggestive of Wallerian-like degeneration triggered by focal
damage within the tract. This was a further contributor to the volume of white
matter with signal intermediate between that of focal inflammatory WMHs and
apparently unaffected white matter.
The FLAIR sequence had a slice thickness of 3mm and ‘partial volume’ effects
were apparent, leading to uncertainty in delineating WMHs. This was particularly
noticeable at the ventricular surface and cortical boundary, both frequent sites for
MS-related WMHs. The lateral ventricles were the relatively larger contributor
to this effect, although segmentation using primarily the FLAIR sequence had
been chosen in order to minimise this.
While failure to recognise small focal WMHs did occur, this will have only had a




The 12 scans used were the baseline imaging from a subset of the forty-three
participants in the Advanced MRI substudy of MS-SMART described earlier.
There were nine female and three male participants with a median age of 57.6
years (IQR: 45.7, 61.0) and a median disease duration of 21.9 years (IQR: 14.9,
29.5).
As quantified in the third mask set by the initial observer, the median WMH
volume of these participants was 19.5ml (IQR: 12.4, 32.8).
4.3.2.2 Summary statistics
Manual segmentation by the second observer was completed over a period of two
weeks. The median WMH volume from the manual segmentations of the second
observer were all higher than those for the initial observer, with a median volume














































Figure 4.5: Left - Boxplot of cohort WMH volumes for segmentations of twelve scans
by two observers. Right - Scatterplot of mask volumes by the two different observers.
The Spearman correlation was r = 0.78.
4.3.2.3 Unidimensional reproducibility
The (Spearman) correlation between WMH volumes was r = 0.78 and the
intra-class correlation was 0.66 (95% CI: -0.09, 0.91). However, the high
correlation between WMH volumes concealed a large discrepancy between the
two raters for two cases, in both of which one rater had identified low or very
low (< 1ml) volumes of visible disease. A Bland-Altman ratio plot is shown in
Figure 4.6, with the most extreme outlier removed (mean WMH volume = 14ml,
ratio between observer volumes = 147).
Similar to the findings for intra-observer agreement (see Figure 4.3), the potential
for large discrepancies between segmentations appeared greatest at lower WMH
volumes.
4.3.2.4 Spatial agreement
The mean of the Dice indices for spatial overlap between different observers’
segmentations was 0.54. A plot of Dice indices against mean WMH volume is
shown in Figure 4.7. As with the volume ratios, improved agreement, as measured
by the Dice index, was seen at larger WMH volumes.
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Figure 4.6: Bland-Altman plot, showing ratio of WMH volumes for each scan comparing
that of the second observer to that of the first (n = 11). One extreme outlier with a
volume ratio of 147 has been omitted. The dashed line indicates a ratio of 1 and all
ratios were above this.










Figure 4.7: Scatterplot of Dice index of inter-observer spatial agreement against mean
WMH volume (n = 12). The overall mean Dice index was 0.54
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4.3.2.5 Sources of discrepancy
As for intra-observer agreement, segmentation discrepancies again occurred at
sites where both partial volume effects and WMHs were frequent, particularly
around the lateral ventricles and involving the corpus callosum.
A second source of discrepancy related to a bias in individual observer ‘thresholds’
for considering white matter abnormal. For the majority of scans this resulted
in the second observer outlining similar regions to the first observer but with
wider boundaries, contributing to the overall marked difference in summary WMH
volumes. In two cases there was marked disagreement on whether there was
widespread diffuse involvement of the white matter. In both these cases the
initial segmentations only covered a small volume of more clearly demarcated
focal WMHs.
4.4 Discussion
Before the validity of other methods for disease quantification can be tested,
the reliability of the reference data they will be compared with should itself be
established. With only rare availability of pathological samples, expert opinion on
imaging appearances, in the form of manual segmentation, has become accepted
as the reference standard. However the reliability of this reference standard is
often ignored.
The results presented here demonstrate that the reference standard is imperfect,
and its reliability is not constant, depending on both observer and cohort factors.
There is an effect of observer experience and unconscious bias, with the potential
for substantial error. Small differences in the subjective threshold used can make
large differences to the overall output, particularly in decisions on how much
intermediate signal white matter to include within segmentations of abnormal
tissue.
An overall shift towards including more of the intermediate signal white matter
in the tissue segmentation was apparent in the second mask set. Following
completion of the initial masks, work had begun on optimising a software method
for WMH segmentation using the same cohort, which tended to include more
diffuse white matter changes. It is assumed that awareness of this influenced
subsequent manual segmentation. This highlights the significant effect of observer
biases, even when blinding is apparently complete. Practice effects would also
likely have affected the work of the second observer, although time and resources
did not provide the opportunity to confirm this.
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The comparison between two observers with similar experience following the same
protocol further highlights the difficulty of drawing sharp boundaries on images
of diffuse disease processes. For the majority of scans, small local differences in
marking edges added up to large total differences in WMH volumes. For a small
number of cases, inter-observer disagreement on whether to mark diffuse regions of
mildly raised signal led to very marked discrepancies in WMH volume. Even with
these discrepancies in determining the absolute WMH volume, the reasonable
inter-observer correlation (r = 0.78) indicates that agreement in distinguishing
between different levels of disease was less affected.
The reliability of a method applies only to the particular population in which it
has been tested, although this can clearly be used to make assumptions about its
performance in similar situations. How far all populations of people with MS can
be considered similar is debatable and even in this clinically relatively homogenous
sample of people the reliability of the segmentation was clearly dependent on
disease burden.
That the Dice index increases with WMH volume is a recognised limitation.
Although widely used in the imaging community, the Dice index was originally
developed for an entirely separate and not obviously relevant purpose, measuring
ecological associations between species [108]. Numerous alternatives to the Dice
have been developed (see Chapter 6).
Acknowledging the disadvantages of reliance on any one metric of reproducibility,
the principle that reproducibility should be tested and reported remains highly
important for standardisation of imaging research practice. Gains from research
studies will be maximised only when the optimal methods for that population
are used and their limitations understood.
It may be that the optimal method for WMH segmentation varies dependent on
the research question. Subtle and diffuse abnormality in the white matter may
be highly relevant for understanding the role of global white matter integrity in
clinical outcomes. However its inclusion in disease measures when investigating
the effect of treatments targeting acute inflammation pathways may be less
relevant. When investigating differences in advanced imaging markers, such as
those from DTI and MRS, between lesional and normal-appearing white matter,
how these tissues are delineated will clearly alter what is found.
The reference standard quantification method is imperfect and this should be
taken into account in presenting work reliant on it, including both validation of
alternative imaging tools to quantify WMH burden and research exploring the
relationship to cognitive performance. Errors associated with measurement tools
will attenuate correlations derived using their outcomes [103]. Accepting this,
66
the evidence here is interpreted to show experience resulted in a more stable
definition of normal and abnormal tissue, and as such the final set of masks was




Development of a visual rating
scale for MS imaging features
5.1 Introduction
The integration of several different and complementary sequences is universal
in clinical and research imaging protocols and is particularly useful in diseases
with complex and variable appearances. However, the measured outcomes in
multiple sclerosis (MS) are often reduced to simple binary or scalar measures,
such as stable or progressive disease, lesion or tissue volume, and information is
lost.
Advanced imaging techniques partly address this issue, providing quantitative
markers related to tissue damage, or focussing on anatomical structures of
interest, such as the involvement of cortical grey matter. These can offer useful
and objective measurement tools, but require standardisation and validation and
may not be widely or routinely available. Even simple volumetric measures from
routine imaging sequences, such as white matter hyperintensity (WMH) volume
are not yet widely available or standardised (see Chapters 3 and 4). In other
conditions, visual rating systems are commonly used to assess disease status,
offering robust markers which can more easily be translated between scanners
and centres and also to clinical practice, without the need for additional software.
With the evolution of MS treatments, there is an unmet need for scalable and
practical tools for quantification of MS imaging features that complement existing
radiology reporting systems.
Imaging appearances reflect a complex interaction of disease and host, as
well as potentially treatments; visible pathology may not accumulate in a
straightforward or predictable manner. The pathological non-specificity of WMHs
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is well-recognised [44], encompassing acute inflammatory lesions and partly or
fully remyelinated lesions, as well as permanent tissue damage, so limiting the
utility of any single measurement. The balance between inflammation, repair
and neurodegeneration is not necessarily the same in all people or at all disease
stages.
In this chapter a novel semi-quantitative visual rating scale is developed for
application to routine structural brain imaging in people with MS, the aim being
to maximise efficient capture of information regarding different aspects of visible
pathology, the degree of damage and structures involved. A series of imaging
features of potential relevance to cognitive function are considered and three
stages in the development of a rating system to assess these are described.
At each stage of the rating system development the frequency of feature presence
is recorded, both to aid interpretation of reliability measures and to better
characterise the range of disease appearances. The homogeneity of rated items is
assessed for evidence of different dimensions within the data and potential item
redundancy. Critical to its use as a research and imaging tool, measures of the
reliability of individual items and summary scores are presented. Finally, the
relationship of visual rating assessments of lesion volume to volumetric measures
is considered.
5.2 Methods
5.2.1 Initial development and pilot study
5.2.1.1 Development process - design and item selection
Brain imaging features of potential relevance to disease severity and cognitive
impairment were considered in consensus discussion by three consultant
neuroradiologists (DM, RS, JW) with academic interests in white matter
disease imaging. Existing disease-specific scales, identified in the systematic
review reported in Chapter 3, were considered for relevance, responsiveness and
practicality. Scales already in use for particular imaging features of interest were
also considered and illustrative images were assessed. Outcomes of this process
are reported in Section 5.3.1.
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5.2.1.2 Initial pilot study
The first ten consecutive scans were selected from the ‘Cognition in MS’ study
(see Chapter 2, Section 2.2 for further details). Three neuroradiologists completed
a structured rating proforma, reviewing all scans using PACS (picture archiving
and communication system) viewing software (Carestream manufacturer). One
radiologist (DM) repeated all the ratings following a four week interval, with their
initial set of ratings being taken as the reference set. All raters were blinded to
the other assessments and all clinical information.
5.2.1.3 Statistical analysis
Item endorsement rates, indicating the frequency of feature presence, were
calculated as the proportion of non-zero ratings assigned for each item.
Overall scale homogeneity was evaluated using item-(partial-)total correlations,
split-half reliabilities and Cronbach’s α, using data from the reference rater.
Reliability for individual items was assessed using intra-class correlations (ICCs;
Class 2), equivalent to a weighted kappa [167], comparing the three independent
raters, with separate examination of the single rater repeat data. Six possible
dimensions within the scale - white matter lesions, the presence of juxtacortical
and cortical lesions, lesion cavitation, atrophy and enlarged perivascular spaces
(EPVS) - were used to create subscores by summing all individual item scores
within them. Intra- and inter-rater reliability for these subscores was assessed
using ICCs.
A volumetric measure of lesion volume was also available, having been previously
generated for the original study using a semi-automated software [168]. Spearman
correlations were used for an exploratory comparison between this data and
the mean white matter lesion dimension subscore averaged across the three
raters.
Homogeneity statistics were calculated using the R software ‘psychometric’ and
‘multicon’ packages; ICCs were calculated using the R ‘psych’ package.
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5.2.2 Further development and re-evaluation
5.2.2.1 Item refinement
The results of the initial pilot study were reviewed by the same three consultant
neuroradiologists, considering item endorsement rates and reliability, rater
agreement and overall practicality for data collection and analysis.
5.2.2.2 Further pilot
Twelve scans were pseudo-randomly selected from the ‘Cognition in MS’ study,
to ensure an equal spread across quartiles of lesion volume (as determined by
the available software measurement) and reasonable ratios of sex and clinical
phenotype. Seven neuroradiologists (five consultants (DM, RS, JW, GM,
ZM) and two senior trainees (MR, LG), post-fellowship examination) were
recruited, with individual training prior to reviewing and rating all scans using
the Carestream viewing software. One radiologist (DM) repeated all ratings,
following an interval of four weeks, with their initial set of ratings being taken
as the reference set. All raters were blind to other assessments and all clinical
information.
5.2.2.3 Statistical analysis
Analysis of results was carried out as for the initial pilot. The initial ratings
of the one radiologist with repeat data were designated the reference standard
where necessary for comparison. The hierarchical arrangement of the items in
the revised scale allowed the creation of an additional summary subscore for
global (‘Fazekas-style’) white matter ratings [169] and the replacement of separate
juxtacortical and cortical lesion subscores, with a combined score. Both cavitation
and juxtacortical/cortical lesions were considered both as binary (present/absent)
features for each region and also by their total number. Systematic between-rater
biases were explored using the dimension subscores and agreement on definitions
of cavitated lesions and juxtacortical/cortical lesions were examined using
correlations of counts of the total numbers identified with those of the reference
rater.
As in the initial pilot study, a volumetric measure of lesion volume was available
and the relationship to this of the global ratings and the summed regional lesion
score was assessed graphically and through correlations.
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5.2.3 External validation study
5.2.3.1 Power calculation
Following review of the results from the pilot studies, testing of the scale in
a larger study and its relationship to cognitive status was planned. With the
assumption that a correlation of r = −0.35 with cognitive performance would be
of interest (see Chapter 3, for a review of relevant literature), a power calculation
was performed, using the G*Power software (version 3.1), indicating 61 subjects
would be needed for a 0.8 probability of finding a significant result at a significance
level of p < 0.05.
5.2.3.2 Study design and participants
Use of the visual rating scale was assessed in two separate cohorts of people
with MS, predicted to have different imaging features. Sample sizes for each
were chosen to meet or exceed the number suggested by the power calculation
described above.
Sixty-seven baseline scans from participants with early stage relapsing-remitting
MS (RRMS) in the FutureMS study (see Chapter 2, Section 2.3) were available
at the time of this work, representing people with early stage disease. Baseline
imaging for the University of Edinburgh MS-SMART participants with secondary
progressive MS (SPMS, n = 93, see Chapter 2, Section 2.1) was complete,
representing participants with more advanced disease.
The scans from these two cohorts were reviewed separately, using Mango image
viewing software (http://ric.uthscsa.edu/mango/), by a single rater (DM) blind
to all clinical and demographic information, other than study participation. All
ratings were repeated following an interval of at least four weeks.
5.2.3.3 Statistical analysis
Separate analyses were carried out for the two different cohorts. Assessment of
item endorsement rates, scale homogeneity and subscore reliability was performed
as for the previous pilot studies.
Manual lesion segmentation (see Chapter 4) was also available for a subset
of the MS-SMART cohort. Its relationship to the global white matter
ratings and summed regional lesion scores was assessed graphically and through
correlations.
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5.3 Results of phase I: Initial development and
piloting
5.3.1 Item selection
In the process of consensus development of an initial visual rating system, initial
discussion and review of the literature identified white matter lesions and atrophy
as the aspects of MS-related imaging changes of most interest to the academic
and clinical imaging communities [9, 170]. No suitable pre-existing MS-specific
imaging rating scale was identified. However analogous scales existed for other
conditions, such as the ‘Fazekas scale’ [169] for age-related white matter changes,
which is well-established and has been extensively tested.
Spatial localisation of white matter lesions, including laterality, was agreed to be
valuable data to collect, of potential relevance to cognitive impairment. Structural
brain subdivisions were agreed, with consideration to familiarity and practicality.
The potential for disagreement over lobar divisions was discussed and brief
guidance considered useful to ameliorate this.
Visible markers of the degree of damage, such as lesion cavitation, were identified
to be an aspect of imaging appearances where visual assessment could add
information to software-generated quantitative measures.
Current research interest in cortical and juxtacortical lesions was identified,
confirmed by their use in the most recently published diagnostic guidelines [9].
It was recognised that routine imaging sequences may not always demonstrate
these features, but felt that where visible they should be recorded.
Enlarged perivascular spaces, with their relationship to atrophy and potential
relevance to cognition [171] and inflammation [45], were identified as a feature
of interest. The existence of a validated rating scale [172] was recognised, albeit
developed in a vascular disease context, with no adaptations felt necessary.
Where possible, having all items rated on the same scale, 0 to 3, with uniform
directionality, was considered advantageous. Sample images being available at
the time of rating was also identified to be beneficial, where possible without
making the rating form unwieldy.
Incorporating the features described above, a data collection form was drafted,
sample images reviewed and agreed. See Appendix E for a copy of the structured
data collection form used in the initial pilot study.
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5.3.2 Participant characteristics
The ten scans rated were from six female and four male subjects, with mean
age 44.5 ± 5.3 years. The disease phenotype was RRMS in two subjects, SPMS
in two and primary progressive MS (PPMS) in six. A semi-automated lesion
segmentation software tool had previously been used in this cohort, and from this
the median lesion volume was 8.5ml (interquartile range (IQR): 6.5, 17.9).
5.3.3 Item endorsement rates
The rating scale included 68 individual items, eleven of which were not endorsed
(i.e. given a non-zero rating) in any rater-scan trial. These were one region for
WMHs, nine cavitation regions and one cortical lesion region. A histogram of
endorsement rates for all items is shown in Figure 5.1, showing that the majority
of items were endorsed in fewer than 40% of cases. Full summary statistics for all















Figure 5.1: Histogram of item endorsement rates in initial pilot study, where












Frontal (R) 0.90 1.40 0.81 0.71 0.52 0.68
Frontal (L) 0.97 1.43 0.73 0.64 0.40 0.64
Parietal (R) 0.63 0.90 0.92 0.53 0.29 0.84
Parietal (L) 0.77 1.00 0.79 0.47 0.27 0.72
Temporal (R) 0.30 0.37 0.67 0.55 0.57 0.74
Temporal (L) 0.40 0.47 0.68 0.51 0.52 0.31
Occipital (R) 0.53 0.70 0.84 0.37 0.00 0.45
Occipital (L) 0.50 0.73 0.91 0.13 0.27 0.79
Insular (R) 0.07 0.10 0.40 - 0.40 0.00
Insular (L) 0.00 0.00 0.00 - - 0.00
Periventricular (R) 1.00 1.63 0.89 0.45 0.47 0.21
Periventricular (L) 0.97 1.63 0.93 0.45 0.51 0.35
Corpus callosum 0.87 1.33 0.80 0.38 0.16 0.54
Basal ganglia (R) 0.30 0.33 0.55 0.16 0.23 0.80
Basal ganglia (L) 0.03 0.07 0.37 - 0.00 0.00
Brainstem 0.37 0.50 0.78 0.46 0.30 0.05
Cerebellar peduncles (R) 0.13 0.20 0.61 - 0.21 0.00
Cerebellar peduncles (L) 0.33 0.40 0.67 0.33 0.65 0.70
Cerebellar hemispheres (R) 0.10 0.13 0.43 - 0.13 0.00
Cerebellar hemispheres (L) 0.13 0.17 0.46 -0.16 0.39 0.64
Cavitation
Frontal (R) 0.27 0.40 0.77 -0.03 0.16 0.64
Frontal (L) 0.20 0.30 0.70 - 0.15 0.00
Parietal (R) 0.10 0.10 0.31 -0.03 -0.08 0.64
Parietal (L) 0.10 0.13 0.43 - 0.00 0.00
Temporal (R) 0.03 0.03 0.18 - 0.00 -
Temporal (L) 0.00 0.00 0.00 - - -
Occipital (R) 0.07 0.07 0.25 - 0.00 -
Occipital (L) 0.03 0.03 0.18 - 0.00 0.00
Insular (R) 0.00 0.00 0.00 - - -
Insular (L) 0.00 0.00 0.00 - - -
Periventricular (R) 0.17 0.20 0.48 0.10 0.30 -0.17
Periventricular (L) 0.10 0.10 0.31 0.10 -0.13 0.00
Corpus callosum 0.03 0.03 0.18 - 0.00 -
Basal ganglia (R) 0.00 0.00 0.00 - - -
Basal ganglia (L) 0.00 0.00 0.00 - - -
Brainstem 0.07 0.07 0.25 - 0.00 -
Cerebellar peduncles (R) 0.00 0.00 0.00 - - -
Cerebellar peduncles (L) 0.00 0.00 0.00 - - -
Cerebellar hemispheres (R) 0.00 0.00 0.00 - - -
Cerebellar hemispheres (L) 0.00 0.00 0.00 - - -
Juxta-cortical
lesions
Frontal (R) 0.73 1.37 1.10 0.63 0.69 0.77
Frontal (L) 0.80 1.17 0.95 0.78 0.51 0.87
Parietal (R) 0.27 0.40 0.81 0.80 0.61 0.85
Parietal (L) 0.37 0.53 0.86 0.87 0.62 0.89
Temporal (R) 0.33 0.40 0.67 0.30 0.29 0.57
Temporal (L) 0.20 0.27 0.64 0.45 0.29 0.84
Occipital (R) 0.13 0.17 0.46 - 0.24 -
Occipital (L) 0.20 0.23 0.50 0.82 0.52 0.64
Insular (R) 0.27 0.30 0.53 0.34 0.12 0.37
Insular (L) 0.07 0.10 0.40 0.82 0.40 1.00
Cortical lesions
Frontal (R) 0.33 0.43 0.68 -0.14 0.38 -0.17
Frontal (L) 0.17 0.20 0.48 - 0.33 -
Parietal (R) 0.10 0.13 0.43 - -0.06 -
Parietal (L) 0.13 0.17 0.46 -0.16 0.05 0.00
Temporal (R) 0.03 0.03 0.18 - 0.00 -
Temporal (L) 0.03 0.03 0.18 - 0.00 -
Occipital (R) 0.10 0.10 0.31 - 0.00 -
Occipital (L) 0.00 0.00 0.00 - - -
Insular (R) 0.03 0.03 0.18 - 0.00 -
Insular (L) 0.03 0.03 0.18 - 0.00 -
Atrophy
Deep 0.70 1.03 0.96 0.86 0.76 0.83
Superficial 0.73 1.13 0.94 0.89 0.67 0.79
Corpus callosum 0.60 0.87 0.82 0.70 0.62 0.77




Basal ganglia (R) 0.97 1.20 0.48 - 0.18 0.00
Basal ganglia (L) 0.97 1.23 0.50 - 0.11 0.00
Centrum semiovale (R) 0.80 1.57 1.17 -0.21 0.29 0.70
Centrum semiovale (L) 0.83 1.57 1.14 -0.16 0.34 0.65
Table 5.1: Descriptive statistics for each individual item in visual rating scale (initial
pilot study). Endorsement rate: proportion of non-zero ratings; SD: Standard
deviation.
5.3.4 Scale homogeneity
Cronbach’s α was 0.88 (0.74, 0.96), with a split-half reliability of 0.92±0.29. This
indicates a high degree of homogeneity in the items rated, but is also related to
the large number of individual items assessed. Certain items could be considered
redundant if their sole value was in contributing to an overall score.
It was not possible to calculate item-(partial-)total correlations for 32 items in
this sample due to either no non-zero ratings (n = 30), or no variance in the
ratings (n = 2). Where available, these correlations ranged from −0.21 to 0.89,
with a mean of 0.40. This does not provide any evidence of items with variation
in an opposing direction to that of the full scale.
Eleven items had item-total correlations of < 0.2. These were three regions for
white matter lesions, 4 cavitation regions, two cortical lesion regions and two
EPVS regions. This could be partly explained by infrequent endorsement, as five
of these items had endorsement rates < 0.2.




Intra-class correlations for all individual items are included in Table 5.1. The
intra-rater ICCs for individual items ranged from −0.17 to 1, with mean 0.76
and median 0.43. In comparison, the inter-rater ICCs ranged from −0.13 to 0.76,
with mean 0.26 and median 0.27. All cases of negative inter-rater ICCs were
related to items with very low endorsement rates (< 0.2). Similarly the two
items with negative intra-rater ICCs both had endorsement rates of 0.15 for the
reference rater.
5.3.5.2 Dimension subscores
Intra-class correlations for dimension subscores, created by summing all ratings
in each of six classes, are shown in Table 5.2. These dimension subscores focus on
the rater reliability in identifying and scoring certain imaging features, removing
any effect from disagreement over anatomical boundaries and lessening the effect
of low endorsement rates for individual regional items.
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Although likely still influenced by endorsement rates, Table 5.2 does suggest that
inter-rater and intra-rater reliability varies for assessment of different imaging
features, with reliability being higher for assessment of white matter lesions,
juxtacortical lesions and atrophy, compared with cavitation, cortical lesions and
EPVS.
The statistical significance of the association between subscores for different
raters, as indicated by the p-value, confirms that the negative ICC for intra-rater
cortical lesion rating is a non-significant result, again related to low endorsement
rates. There was an overall endorsement rate of 0.02 for cortical lesions ratings
by the reference rater.
Inter-rater ICC (p) Intra-rater ICC (p)
White matter lesions 0.53 (< 0.01) 0.83 (< 0.01)
Cavitation 0.12 (0.18) 0.56 (0.03)
Juxta-cortical lesions 0.69 (< 0.01) 0.94 (< 0.01)
Cortical lesions 0.17 (0.17) -0.20 (0.72)
Atrophy 0.69 (< 0.01) 0.91 (< 0.01)
EPVS 0.33 (0.01) 0.46 (0.02)
Table 5.2: Showing reliability, assessed with intra-class correlations (ICCs), of summary
scores for each of six subtotals within the scale.
5.3.6 Validation with pre-existing semi-automated lesion volume
From previous work using a semi-automated lesion segmentation software, white
matter lesion volumes for the scans were available. The Spearman correlation
between the mean of the white matter lesion dimension subscore for the three
raters and the volumetric measurement was r = 0.69; a scatterplot of results
is shown in Figure 5.2. Excluding the single highest value, this correlation was
r = 0.57. The relationship appeared plausibly linear when considering the full
range, but with most subjects grouped at the lower end of lesion volumes/scores
and not clearly separated out by different scores.
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Figure 5.2: Scatterplot showing the mean of the white matter (WM) lesion dimension
subscore in the initial pilot study, against the semi-automated lesion volume, annotated
with a line of best fit. The Spearman correlation was r = 0.69.
5.4 Results of phase II: Further development and
re-evaluation
5.4.1 Item refinement
Following review of the results of the initial pilot, modifications to the rating
scale were agreed in consensus. Consideration was given to improving the clarity
of item definitions, potential item redundancy and overall practicality. Improved
descriptions of some items was felt to be of benefit, with more images available
for guidance, particularly for assessing lesion cavitation.
The sample of scans selected for the initial pilot study was not thought to be an
optimal representation of the range of imaging appearances seen in MS. A high
proportion of the scans were from people with primary progressive MS, which
may be associated with lower brain lesion loads [173] and this may in part have
led to the frequently low item endorsement rates. Accepting this, endorsement
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rates were not felt to be a rigid guide to item inclusion, as this was a small sample
and uncommon features may remain relevant. Non-endorsed items were not felt
to add significantly to the time taken for rating completion.
In relation to the overall intention of the rating scale for use in routine
MRI sequences, without advanced cortical imaging, it was agreed that reliable
cortical lesion identification was not a priority. Not differentiating cortical
and juxtacortical lesions initially would be more practical, while retaining the
option to more accurately anatomically localise any cortical/juxtacortical lesion
if identified.
The lack of a global white matter rating was considered a limitation and an overall
deep white matter rating, modified from the ‘Fazekas’ scale [169] was introduced.
Overall a more hierarchical structure was thought to be optimal for both rating
and analysis and the form was redrafted to facilitate this.
See Appendix F for a copy of the structured data collection form used in the
second pilot study.
5.4.2 Participant characteristics
The twelve scans rated were from six female and six male subjects, with mean
age 47.7 ± 8.0 years. The disease phenotype was relapsing-remitting MS in five
subjects, secondary progressive MS in four and primary progressive MS in three.
One subject overlapped with those studied in the initial pilot. Using the available
semi-automated lesion volumes, as before, the median lesion volume for the scans
used in the second pilot study was 20.3ml (IQR: 10.9, 34.8). This was higher
than in the first pilot, with a greater spread of values.
5.4.3 Item endorsement rates
There were 60 items available for rating in the second pilot study. Of these, two
items (cavitation in the basal ganglia bilaterally) had zero endorsements in any
rater-scan trial. A histogram of endorsement rates for all items is shown in Figure
5.3, suggesting a trimodal distribution, with items being endorsed in nearly all,
nearly none, or around 40% of rater-scan trials. A greater dynamic range in terms
of endorsement rates was achieved than in the initial pilot.












Deep WM (R) 0.98 0.70 1.35 0.61 0.66 0.69
Deep WM (L) 0.98 0.87 1.43 0.68 0.77 1.00
Periventricular WM (R) 1.00 0.75 2.10 0.74 0.58 0.83
Periventricular WM (L) 1.00 0.58 2.13 0.74 0.61 0.92
Regional WM
Frontal (R) 0.96 0.61 1.30 0.58 0.59 0.77
Frontal (L) 0.98 0.64 1.32 0.60 0.65 0.59
Parietal (R) 0.79 0.51 1.07 0.77 0.48 0.81
Parietal (L) 0.77 0.72 1.07 0.80 0.55 0.52
Temporal (R) 0.65 0.75 0.88 0.81 0.47 0.83
Temporal (L) 0.58 0.54 0.79 0.82 0.40 0.70
Occipital (R) 0.46 0.60 0.68 0.85 0.48 0.74
Occipital (L) 0.48 0.62 0.71 0.87 0.31 0.34
Insular (R) 0.48 0.61 0.58 0.73 0.28 0.29
Insular (L) 0.33 0.66 0.48 0.78 0.59 0.80
Corpus callosum 0.86 0.65 1.23 0.73 0.27 0.77
Basal ganglia (R) 0.35 -0.23 0.38 0.56 0.49 0.52
Basal ganglia (L) 0.27 0.00 0.35 0.61 0.45 0.09
Brainstem 0.56 0.15 0.70 0.72 0.63 0.72
Cerebellar peduncles (R) 0.43 0.25 0.44 0.52 0.25 0.75
Cerebellar peduncles (L) 0.57 0.18 0.60 0.54 0.51 0.69
Cerebellar hemispheres (R) 0.44 0.13 0.44 0.50 0.54 1.00
Cerebellar hemispheres (L) 0.46 0.63 0.48 0.53 0.60 0.42
Cavitation
Periventricular WM (R) 0.37 0.48 0.68 1.09 0.45 0.33
Periventricular WM (L) 0.42 0.75 0.95 1.40 0.51 0.52
Frontal (R) 0.24 0.27 0.32 0.75 0.38 0.77
Frontal (L) 0.30 0.86 0.50 0.90 0.55 0.81
Parietal (R) 0.14 0.38 0.19 0.50 0.09 0.65
Parietal (L) 0.12 -0.36 0.15 0.45 -0.04 0.00
Temporal (R) 0.05 - 0.05 0.21 0.00 -
Temporal (L) 0.04 - 0.04 0.19 0.10 -
Occipital (R) 0.07 0.32 0.11 0.41 0.14 0.00
Occipital (L) 0.06 - 0.07 0.30 -0.04 -
Insular (R) 0.04 - 0.04 0.19 0.00 -
Insular (L) 0.07 - 0.07 0.26 0.31 0.00
Corpus callosum 0.06 - 0.08 0.35 -0.04 -
Basal ganglia (R) 0.00 - 0.00 0.00 - -
Basal ganglia (L) 0.00 - 0.00 0.00 - -
Brainstem 0.05 - 0.10 0.51 0.00 -
Cerebellar peduncles (R) 0.06 - 0.06 0.24 0.10 -
Cerebellar peduncles (L) 0.06 - 0.07 0.30 0.03 -
Cerebellar hemispheres (R) 0.04 - 0.04 0.19 -0.02 -
Cerebellar hemispheres (L) 0.04 - 0.06 0.36 -0.02 -
(Juxta-)
cortical lesions
Frontal (R) 0.85 0.42 3.10 3.69 0.54 0.33
Frontal (L) 0.80 0.54 3.64 4.50 0.40 0.46
Parietal (R) 0.51 0.64 1.01 1.44 0.32 0.84
Parietal (L) 0.54 0.58 1.23 1.56 0.55 1.00
Temporal (R) 0.50 0.79 0.77 1.01 0.31 0.66
Temporal (L) 0.39 0.81 0.70 1.08 0.38 0.68
Occipital (R) 0.31 0.59 0.45 0.77 0.35 0.45
Occipital (L) 0.36 0.70 0.49 0.74 0.29 0.42
Insular (R) 0.35 0.34 0.44 0.68 0.15 0.18
Insular (L) 0.26 0.20 0.36 0.67 0.40 -0.22
Atrophy
Deep 0.94 0.55 1.67 0.83 0.59 0.88
Superficial 0.89 -0.02 1.67 0.81 0.32 0.21
Corpus callosum 0.86 0.52 1.44 0.88 0.54 0.77




Basal ganglia (R) 0.98 -0.39 1.15 0.48 0.07 -0.14
Basal ganglia (L) 0.96 -0.35 1.18 0.56 0.18 0.30
Centrum semiovale (R) 0.86 0.44 1.27 0.77 0.31 0.27
Centrum semiovale (L) 0.86 0.13 1.32 0.87 0.31 0.75
Table 5.3: Descriptive statistics for each individual item in visual rating scale (second
pilot study). Global and regional white matter (WM) ratings and atrophy were scored
0 − 3. Cavitation and juxtacortical/cortical scores were counts. Enlarged perivascular
spaces were rated 0−4. Endorsement rate: proportion of non-zero ratings; SD: standard

















Figure 5.3: Histogram of item endorsement rates in second pilot study. The total
number of items rated was 60.
5.4.4 Scale homogeneity
Cronbach’s α was 0.92 (0.84, 0.97), with a split-half reliability of 0.94 ± 0.24. As
in the initial pilot study, this indicates a high degree of item homogeneity, but
also reflects the large number of items rated.
It was not possible to calculate item-(partial-)total correlations for 13 items, all
lesion cavitation regions, due to no non-zero ratings by the reference rater for
these regions. Where available, item-total correlations ranged from −0.39 to 0.87,
with a mean of 0.44. Six items had correlations with the full scale of between
-0.2 and 0.2: four regional WMH items (1 for basal ganglia and three in the
posterior fossa), 1 atrophy item and one EPVS item. Four items had correlations
r < −0.2, raising the possibility of variation in an opposing direction to that of
the full scale. These were one regional WMH item (basal ganglia), 1 cavitation
item and two EPVS items. Item-total correlations for all individual items, where




Intra-class correlations for all individual items are included in Table 5.3. The
intra-rater ICCs for individual items ranged from −0.22 to 1, with mean 0.54
and median 0.65. Inter-rater ICCs ranged from −0.03 to 0.77, with mean 0.34
and median 0.37.
Very low inter-rater ICCs were found for all cavitation items, with the exception
of the largest regions - periventricular white matter and the frontal lobes. There
were very low overall endorsement rates for these items, which likely explains the
five cavitation items with negative inter-rater ICCs (all with low absolute values).
Intra-rater ICCs were undefined for many of these items due to no non-zero ratings
by the reference rater.
Two items in other categories had negative intra-rater ICCs. In one case (a
juxtacortical lesion item) this was related to a low endorsement rate by the
reference rater, but in the other this was not (EPVS in the basal ganglia). All
four EPVS items had high endorsement rates, but were mostly associated with
low intra-rater and inter-rater ICCs.
Using the ICC as a measure of reliability combines assessment of two concepts -
whether raters have the same understanding of a feature being present, e.g. lesion
cavitation, and how they interpret the categories to assign different scores to the
imaging appearances. Similarity of understanding of different features is assessed
in Section 5.4.5.2 through the dimension subscores, as is rater bias towards using
higher or lower scores.
Agreement on individual item scores was examined graphically using ‘bubble’
plots, providing a visual indication of how many raters agreed with the reference
rating and each other. Bubble plots for the global white matter (‘Fazekas-style’)
ratings for each scan are shown in Figure 5.4 and for the remaining scored items
in Appendix G.
The ratings for deep white matter shown in the top row of Figure 5.4 demonstrate
closer agreement, with perfect or near perfect agreement in most cases. There
was greater variation in the scores assigned to the periventricular white matter,
although the majority of raters were in agreement with the reference rater for all
but 3/24 (= 13%) of ratings.
In the case of deep white matter ratings, Figure 5.4 highlights the narrow range
of scores used. Scans rated are plotted in order of increasing lesion volume, but
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the first eight (= 67%) were all assigned scores of 1 bilaterally by the majority of
raters. Although available, a score of zero was rarely (for deep white matter) or
never (for periventricular white matter) used, thus further narrowing the range.
The range of scores used will affect agreement, and an indication of this is also









































Figure 5.4: ‘Bubble’ plots of deep and periventricular white matter (WM) scores for
each scan. The radius of each point is proportional to the number of raters assigning
that score. Blue indicates agreement with the reference standard. The scans are plotted
in order of increasing lesion volume.
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5.4.5.2 Dimension subscores and imaging features of interest
The ICCs for dimension subscores, similar to those of the initial pilot study,
are shown in Table 5.4. One rater had not provided counts of cavitated
and juxtacortical lesions and was excluded from analysis related to these two
subscores. Unlike the initial pilot study, all p-values are low enough to reject the
null hypothesis of no association between rater scores.
Inter-rater ICC (p) Intra-rater ICC (p)
Global summary WM lesions 0.80 (< 0.001) 0.98 (< 0.001)
Regional WM lesions 0.64 (< 0.001) 0.91 (< 0.001)
Cavitation (regions) 0.29 (< 0.001) 0.69 (< 0.001)
Cavitation (counts) 0.17 (0.002) 0.62 (0.004)
(Juxta-)cortical lesions (regions) 0.53 (< 0.001) 0.87 (< 0.001)
(Juxta-)cortical lesions (counts) 0.51 (< 0.001) 0.93 (< 0.001)
Atrophy 0.55 (< 0.001) 0.72 (0.002)
EPVS 0.35 (< 0.001) 0.66 (0.002)
Table 5.4: Showing reliability, assessed with intra-class correlations (ICCs), of summary
scores for each of eight subtotals within the scale. Cavitation and (juxta-)cortical lesion
subscores were calculated both for the number of regions identified as affected as well
as the total lesion count.
As in the initial pilot study, the dimension subscore ICCs suggest that reliability
varies with the imaging feature of interest, again being lower for identifying
cavitated lesions and rating EPVS. Poor reliability may relate to rater differences
in defining the feature of interest as well as rater biases in using higher or lower
scores.
Univariate correlations of the numbers of cavitated lesions identified by raters
compared with the reference standard were examined to investigate similarity
of underlying rater definitions. One rater had not provided counts of cavitated
lesions and was excluded from this analysis. Of the remaining 5 raters, four
showed total counts for each scan which strongly correlated with the reference
standard (r = 0.68, 0.89, 0.89, 0.94) and one which only weakly correlated (r =
0.26, rater D), suggesting this rater may have used different imaging appearances
to define cavitation. Correlations for counts of fully cavitated lesions were slightly
lower (r = 0.25 to 0.78).
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Similar correlations were examined for the total number of juxtacortical/cortical
lesions identified. One rater had not provided counts of juxtacortical/cortical
lesions and was excluded from more detailed analysis. Of the remaining 5
raters, all showed total lesion counts which correlated strongly with the reference
standard (r = 0.88 to 0.95). Only two raters identified purely cortical lesions in
any scan, so more detailed analysis of this was not performed.
Systematic biases between different raters were explored using barplots of the
mean dimension subscore for each rater, shown in Figure 5.5. In the case
of identifying cavitated lesions it is apparent that there is one outlying rater
(rater D), who tended to identify much larger numbers. Excluding this rater
in calculating the ICC for the cavitation (count) subscores, resulted in an
increase to 0.64 (p < 0.001). Although less marked, the same rater also
showed a tendency to identify more (juxta-)cortical lesions and excluding them
in calculating the (juxta-)cortical (count) subscore ICC resulted in an increase to
0.61 (p < 0.001).




















































































































Figure 5.5: Barplots showing mean dimension subscores for each rater A - G (A2
is repeat rating by rater A). Cavitation and cortical/juxtacortical lesions are treated
as binary features for each region (i.e. present or absent), so the mean represents
the mean number of regions considered affected. Rater G did not provide counts of
cavitated lesions or juxtacortical lesions for all scans.
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5.4.6 Validation with pre-existing semi-automated lesion volume
Two visual markers of overall lesion burden were calculated: (1) the sum of
bilateral deep and periventricular global white matter ratings and (2) the sum of
all lesion scores for individually rated brain regions. Figure 5.6 shows the mean
value from the seven raters for these two markers plotted against the available
volumetric measure of lesion burden. The visual markers both correlated strongly





































r =  0.92
Regional WM scores
Figure 5.6: Scatterplots showing relationship of visual rating scores for white matter
(WM) to semi-automated lesion (white matter hyperintensity - WMH) volume,
annotated with lines of best fit and Spearman correlation coefficients. All scores plotted
represent the mean value of seven raters for the sum of right and left hemisphere scores.
Left: Summed deep and periventricular WM lesion scores; Right: Summed lesion scores
for individual regions
5.5 Independent validation study
5.5.1 Participant characteristics
5.5.1.1 MS-SMART
One subject in the MS-SMART cohort was excluded, as a T2-weighted (T2w)
imaging sequence was not available. Scans from the remaining 92 participants
were included. These scans were from 68 female and 24 male participants, with
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a mean age of 55± 7.5 years. The mean disease duration, taken as the time since
initial symptom, was 20 ± 10 years, median 20.5 years.
5.5.1.2 FutureMS
Sixty-seven participants had been recruited locally by the time of this work
and their imaging was included. This covered a period of development of
scan protocols. After the initial 23 participants, all scans included a 2D
fluid attenuated inversion recovery (FLAIR) sequence, and after the initial 25
participants, all scans included a 2D T2w sequence, instead of a 3D T2w sequence.
3D T1-weighted and FLAIR sequences were available for all scans.
This cohort comprised 49 female and 18 male participants, with a mean age of
39 ± 9.6 years. The mean disease duration, taken as time since initial symptom,
was 5.1 ± 5.5 years, median 2.7 years.
5.5.2 Scale homogeneity
Cronbach’s α was 0.92 (0.90, 0.94) with a split-half reliability of 0.94 ± 0.11. As
before this reflects both the high degree of item homogeneity and the large number
of items rated.
It was not possible to calculate item-(partial-)total correlations for 9 lesion
cavitation items, due to no non-zero ratings in the relevant regions. Where
available, item-total correlations ranged from 0.07 to 0.80, with a mean of
0.41±0.21. A histogram of item-total correlations is shown in Figure 5.7. Thirteen
items had correlations < 0.2, including 7 further cavitation items and all four
EPVS items. Although this is likely influenced by the low endorsement rates for
the cavitation items, this suggests that scores for these items may not vary with
the majority of the other ratings.
5.5.3 Summary statistics for individual items
Summary statistics for each individual item, including the mean, standard
deviation and endorsement rate, are given in Table 5.5. These are given both
overall and separately for the two cohorts rated. Endorsement rates varied from
0 to 1, with an overall mean of 0.33. The mean endorsement rate was 0.36 for the
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Deep WM (R) 0.75 0.91 0.65 0.73 0.90 1.40 0.76 0.80 0.84 1.19 0.75 0.80
Deep WM (L) 0.82 1.03 0.65 0.72 0.95 1.48 0.72 0.73 0.89 1.29 0.72 0.76
Perivent. WM (R) 0.84 1.36 0.88 0.69 0.91 2.03 0.94 0.85 0.88 1.75 0.97 0.82
Perivent. WM (L) 0.85 1.49 0.88 0.77 0.93 2.05 0.89 0.85 0.90 1.82 0.93 0.84
Regional
WM
Frontal (R) 0.72 0.85 0.66 0.78 0.91 1.37 0.74 0.78 0.83 1.15 0.75 0.81
Frontal (L) 0.72 0.82 0.60 0.73 0.93 1.46 0.72 0.75 0.84 1.19 0.74 0.79
Parietal (R) 0.60 0.81 0.82 0.73 0.70 1.25 1.02 0.53 0.65 1.06 0.97 0.63
Parietal (L) 0.70 1.01 0.84 0.64 0.76 1.39 0.97 0.52 0.74 1.23 0.94 0.59
Temporal (R) 0.36 0.43 0.63 0.80 0.39 0.46 0.64 0.58 0.38 0.45 0.63 0.67
Temporal (L) 0.40 0.54 0.77 0.76 0.36 0.45 0.69 0.51 0.38 0.48 0.72 0.62
Occipital (R) 0.12 0.16 0.48 0.85 0.15 0.22 0.57 0.52 0.14 0.19 0.53 0.61
Occipital (L) 0.13 0.19 0.53 0.74 0.14 0.27 0.73 0.51 0.14 0.24 0.65 0.57
Insular (R) 0.12 0.18 0.55 0.53 0.22 0.37 0.78 0.41 0.18 0.29 0.70 0.45
Insular (L) 0.10 0.19 0.61 0.46 0.24 0.39 0.78 0.49 0.18 0.31 0.72 0.50
Corpus callosum 0.75 0.94 0.69 0.60 0.39 0.42 0.58 0.57 0.54 0.64 0.68 0.62
Basal ganglia (R) 0.37 0.40 0.55 0.29 0.46 0.54 0.65 0.60 0.42 0.48 0.61 0.40
Basal ganglia (L) 0.30 0.30 0.46 0.55 0.51 0.63 0.69 0.61 0.42 0.49 0.63 0.61
Brainstem 0.36 0.45 0.68 0.83 0.50 0.64 0.75 0.79 0.44 0.56 0.73 0.81
Cereb. ped. (R) 0.18 0.22 0.52 0.80 0.24 0.32 0.63 0.80 0.21 0.28 0.58 0.80
Cereb. ped. (L) 0.24 0.30 0.60 0.70 0.36 0.41 0.61 0.67 0.31 0.36 0.61 0.68
Cereb. hemi. (R) 0.22 0.22 0.42 0.69 0.34 0.37 0.55 0.75 0.29 0.31 0.50 0.74
Cereb. hemi.(L) 0.15 0.16 0.41 0.48 0.34 0.37 0.55 0.69 0.26 0.28 0.50 0.64
Cavitation
Perivent. WM (R) 0.10 0.27 0.95 0.59 0.49 1.60 2.82 0.85 0.33 1.04 2.32 0.81
Perivent. WM (L) 0.12 0.28 0.98 0.68 0.49 1.66 2.73 0.77 0.33 1.08 2.27 0.79
Frontal (R) 0.07 0.07 0.26 0.36 0.10 0.18 0.69 0.53 0.09 0.14 0.56 0.48
Frontal (L) 0.01 0.01 0.12 -0.02 0.14 0.17 0.48 0.43 0.09 0.11 0.38 0.39
Parietal (R) 0.04 0.04 0.21 0.31 0.04 0.04 0.21 0.79 0.04 0.04 0.21 0.61
Parietal (L) 0.04 0.06 0.30 0.38 0.07 0.09 0.38 0.35 0.06 0.08 0.35 0.36
Temporal (R) 0.00 0.00 0.00 - 0.01 0.01 0.10 -0.01 0.01 0.01 0.08 -0.01
Temporal (L) 0.00 0.00 0.00 - 0.02 0.02 0.15 0.66 0.01 0.01 0.11 0.66
Occipital (R) 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -
Occipital (L) 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Insular (R) 0.00 0.00 0.00 - 0.01 0.01 0.10 1.00 0.01 0.01 0.08 1.00
Insular (L) 0.00 0.00 0.00 - 0.01 0.01 0.10 1.00 0.01 0.01 0.08 1.00
Corpus callosum 0.00 0.00 0.00 - 0.02 0.02 0.15 0.66 0.01 0.01 0.11 0.67
Basal ganglia (R) 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -
Basal ganglia (L) 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -
Brainstem 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -
Cerebel. ped. (R) 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -
Cerebel. ped. (L) 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -
Cerebel. hemi. (R) 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00




Frontal (R) 0.13 0.19 0.58 0.20 0.43 0.83 1.23 0.64 0.31 0.56 1.05 0.53
Frontal (L) 0.18 0.21 0.48 0.60 0.45 0.75 1.23 0.55 0.33 0.52 1.02 0.59
Parietal (R) 0.07 0.12 0.48 0.57 0.08 0.09 0.32 0.45 0.08 0.10 0.39 0.49
Parietal (L) 0.13 0.16 0.45 0.67 0.18 0.21 0.48 0.65 0.16 0.19 0.47 0.66
Temporal (R) 0.07 0.10 0.43 0.45 0.07 0.07 0.25 0.33 0.07 0.08 0.34 0.40
Temporal (L) 0.13 0.21 0.66 0.67 0.17 0.20 0.47 0.35 0.16 0.20 0.56 0.46
Occipital (R) 0.01 0.01 0.12 -0.02 0.04 0.05 0.27 0.58 0.03 0.04 0.22 0.48
Occipital (L) 0.00 0.00 0.00 0.00 0.07 0.07 0.25 0.39 0.04 0.04 0.19 0.37
Insular (R) 0.12 0.16 0.51 0.13 0.13 0.17 0.51 0.55 0.13 0.17 0.51 0.44
Insular (L) 0.09 0.13 0.46 0.31 0.09 0.10 0.33 0.46 0.09 0.11 0.39 0.41
Atrophy
Deep 0.48 0.72 0.88 0.80 0.82 1.49 1.02 0.84 0.67 1.16 1.04 0.85
Superficial 0.82 1.15 0.70 0.70 0.96 1.83 0.76 0.61 0.90 1.54 0.81 0.70
Corpus callosum 0.40 0.58 0.80 0.66 0.73 1.25 1.00 0.78 0.59 0.97 0.98 0.75





Basal ganglia (R) 0.91 1.00 0.43 0.39 1.00 1.20 0.43 0.43 0.96 1.11 0.44 0.46
Basal ganglia (L) 0.94 1.04 0.41 0.31 0.97 1.09 0.41 0.42 0.96 1.07 0.41 0.37
Cent. semiovale (R) 0.99 1.76 0.85 0.55 0.99 2.08 0.74 0.40 0.99 1.94 0.81 0.49
Cent. semiovale (L) 0.99 1.70 0.84 0.46 0.99 1.93 0.74 0.55 0.99 1.84 0.79 0.52
Table 5.5: Descriptive statistics for each individual item in visual rating scale (independent
validation study). Global and regional white matter (WM) ratings and atrophy were scored
0 − 3. Cavitation and juxtacortical/cortical scores were counts. Enlarged perivascular spaces





















Intra-rater ICCs for individual items are shown in Table 5.5. These ICCs had
mean 0.58, median 0.61 and range −0.01 to 1. Table 5.5 shows that the lowest
values and the greatest variability for item ICCs were found for the cavitation
items, which also had the lowest endorsement rates.
5.5.4.2 Dimension subscores and features of interest
The ICCs for the dimension subscores are shown in Table 5.6. All p-values
associated with the ICCs are < 0.00001, indicating that the null hypothesis of no
association between repeat scores can be rejected with a high degree of probability.
The intra-rater reliability appears notably lower for the EPVS ratings, with a
similar value to that seen in the previous pilot study.
Overall agreement on whether lesion cavitation was present or absent on each
scan is summarised in Table 5.7, showing that the initial rating identified at least
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FutureMS MS-SMART Overall
Global WMH 0.90 0.90 0.92
Regional WMH 0.94 0.79 0.86
Cavitation 0.74 0.85 0.86
(Juxta-)cortical lesions 0.83 0.71 0.75
Atrophy 0.78 0.87 0.86
EPVS 0.52 0.55 0.56
Table 5.6: Intra-rater ICCs for dimension subscores. MS-SMART: secondary
progressive MS cohort (n = 92); FutureMS: Relapsing-remitting MS cohort (n = 67).
The data for the cavitation and (juxta-)cortical lesion dimensions relates to the total
counts.
one cavitated lesion on 45% of scans (72/159), with disagreement from the repeat






Table 5.7: Summary table showing whether cavitation was identified as being present
on the initial and repeat scan ratings.
Overall agreement on whether there was involvement of juxtacortical or cortical
tissue is summarised in Table 5.8, showing that the initial rating identified at
least one (juxta-)cortical lesion on 59% of scans (= 94/159), with disagreement






Table 5.8: Summary table showing whether (juxta-)cortical lesions were identified as
being present on the initial and repeat scan ratings.
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5.5.5 Cohort descriptive statistics
Sample images, showing scans from the MS-SMART cohort assigned low,
intermediate and high global lesion scores, are shown in Figure 5.8. Summary
statistics for each item are given broken down by cohort in Table 5.5 and
for dimension subscores in Table 5.9, demonstrating significantly different
distributions between cohorts for each subscore. Histograms comparing the two
cohorts for the two summary WM subscores, equivalent to the first two dimension
subscores, are shown in Figures 5.9 and 5.10. The histograms in Figure 5.11 show
the sums of all items scored for the two cohorts. While there is a clear tendency
for lower scores for scans from participants with earlier stage disease, there is still
considerable overlap and disease stage cannot be distinguished from these scores
alone.
Figure 5.8: Sample images from MS-SMART cohort, demonstrating scans with (from
left to right) low, intermediate and high global white matter scores.
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Figure 5.9: Histograms of summed global white matter scores assigned to scans
belonging to each cohort.
FutureMS MS-SMART Mann-Whitney test
Mean SD Mean SD U p
Global WMH 4.8 2.5 7.0 2.9 4448 < 0.001
Regional WMH 8.2 6.7 11.3 7.0 3978 0.002
Cavitation (count) 0.7 1.9 3.8 5.9 4397 < 0.001
(Juxta-)cortical lesions (count) 1.3 2.8 2.5 3.3 3944 0.002
Atrophy 2.6 2.2 4.9 2.7 4592 < 0.001
EPVS 5.5 1.9 6.3 1.7 3870 0.005
Table 5.9: Summary of dimension subscores for the two cohorts studied. The data
for the cavitation and (juxta-)cortical lesion dimensions relates to the total counts.
SD: Standard deviation; EPVS: Enlarged perivascular spaces; U: Test-statistic from
Mann-Whitney U test, with associated p-value.
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Figure 5.11: Overlapping histograms of total scores for scans from the two cohorts of
interest.
5.5.5.1 Enlarged perivascular spaces
Enlarged perivascular spaces are associated with ageing in healthy populations,
although not necessarily in people with MS [45]. A scatterplot of their association
with age in the participants studied here is shown in Figure 5.12. The (Spearman)
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correlation was r = 0.40, and the relationship seemed similar in both cohorts
when examined separately (r = 0.40 and r = 0.26 for FutureMS and MS-SMART
participants respectively). However there was no significant relationship with

















Figure 5.12: Scatterplot of total EPVS score against age for participants from both
cohorts.
5.5.6 Validation with reference standard
Scatterplots of the two summary white matter scores (the summed global WM
score and the summed regional WM score) are shown plotted against manual
WM lesion volume in Figure 5.13 for the scans from the 43 participants in
the MS-SMART Advanced MRI substudy. For the regional WM scores, the
relationship appeared plausibly linear, but for the global ‘Fazekas-style’ scores
there appeared to be a ceiling effect at high lesion volumes.
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r =  0.87
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r =  0.79
Regional WM scores
Figure 5.13: Scatterplots of summed global and regional WM scores against manual
white matter hyperintensity (WMH) volume (n = 43), annotated with Spearman
correlation and line of best fit for regional WM plot.
5.6 Discussion
Different forms of assessment will be appropriate to different situations.
Automated methods of image analysis used in research are not currently
applicable or practical on an individual patient basis and bear little resemblance
to assessments used in clinical practice. While offering sensitive and reproducible
measures, computer software may not be able to access and utilise potentially
relevant features, apparent to human assessors. Judgments regarding the
importance of particular imaging features and patterns may be better made by
trained observers. However qualitative assessments are less easily subjected to
statistical analysis and may be less sensitive to small changes, so information may
be lost to research studies.
The failure of unidimensional quantitative imaging markers to fully explain
disability in people with MS is well-established and pursuing greater measurement
accuracy for any single outcome is unlikely to solve this. While the MS imaging
community has largely moved on to investigation of advanced imaging techniques,
there may nevertheless be additional information already available within routine
sequences that is not currently captured. The aim of developing a structured
imaging assessment was to recapture information regarding a broader range
of imaging features for use in research, combining aspects of the descriptive
reports provided in clinical radiology and the quantitative measurement tools
more frequently used in research. The investigation reported in this chapter
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demonstrates that relevant information on white matter lesion burden can be
recorded reliably using visual rating.
The visual rating system described here is entirely novel to MS and was developed
using standard image viewing software, with no additional time needed for image
processing. The overall time taken varied with the level of disease burden, but the
global summary white matter ratings, adapted from the ‘Fazekas’ scale, showed a
close relationship to quantitative markers with very little associated time burden.
The practical advantages of a rating system allowing straightforward translation
between clinical practice and research as well as between centres is clear. However
at present there is no similar system used in MS imaging research.
The relationship of semi-quantitative markers of lesion burden to the reference
standard volumetric measurement showed a high correlation, similar to that found
in the context of vascular disease [174], and was clearly able to distinguish between
different levels of disease. While sensitivity to small increments in lesion volume
may not be achievable from visual assessments, the utility of these is unproven,
and simple stratification based on visual ratings may prove equally useful. Van
Straaten et al [174] compared different vascular disease rating scales and suggested
that those with wider ranges could be more useful to differentiate between clinical
groups but Fazekas scores were more useful to define groups based on imaging
appearances. The flexibility of the rating system developed here for MS imaging
could allow both these uses, dependent on context and time availability, with
a shorter version based only on the adapted Fazekas scores likely to be more
suitable when aiming to maximise subject numbers.
The limited range of responses available for most items was still found to allow
reasonable dispersion of measurements, even within quite different cohorts. It
was also possible to detect clear differences between cohorts at different disease
stages, although the study was not specifically designed to address this.
Understanding the reproducibility of any measurement tool is critical for its use.
Straightforward assessment of rater agreement and reliability was possible and
appeared reasonable for the majority of features of interest. These measures
will be specific to the cohort it is used in, but here it has been tested in two
cohorts with differing imaging appearances and proved robust. The issue of
whether observers need to be experts, such as neuroradiologists, remains open.
There was however evidence at all stages of the development and testing process
that some features could be identified more consistently than others. Global
and regional lesion scores, atrophy scores and identification of (juxta-)cortical
lesions showed consistency both for inter- and intra-rater agreement. This is
perhaps partly attributable to familiarity, reflecting similarities with clinical
practice. Conversely, identification of lesion cavitation and scoring of EPVS
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proved more variable. There was some evidence that individual rater biases may
have influenced this, with stronger intra-rater reliability, and further training and
feedback could be used to address this.
A trade off with practicality may have limited the results of this study.
Standardisation between raters could be improved with the development of
training datasets and time for feedback, group training sessions and access to
more guidance pictures during data collection. These would be valuable areas
for future testing. The number of raters was relatively low, although large
within the context of a reproducibility study. Opportunistic use was made of
available scans, which did not all follow the same protocol, although they were
chosen to provide a range of disease burden. Reflecting this pragmatic cohort,
no sequences were acquired which were highly sensitive to cortical lesions (e.g.
phase-sensitive inversion recovery and double inversion recovery). Despite these
limitations, the system appears robust, demonstrating reasonable reliability and
a clear relationship to reference measurements. The rating system presented here
builds on the extensive experience of using the same or similar markers in other
fields.
Although significant differences were identified between cohorts, as expected, this
was not the purpose of the work. There was no rater blinding as to the study
cohort participants belonged to and the imaging, although performed on the
same scanner, did not follow identical protocols. Further work would be needed
to determine if the rating system described could be used to distinguish between
disease phenotypes.
In pursuit of the thesis aim of extracting the most relevant information on white
matter health from imaging and relating this to cognitive function, the visual
ratings described here are used for this purpose in Chapter 7.
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Chapter 6
Optimisation of an automated
method for white matter
hyperintensity quantification
6.1 Introduction
The practical advantages of using semi- or fully-automated software to generate
image analysis outputs are readily apparent. Software-based segmentation
techniques can be incorporated into image processing pipelines, supporting
the generation of standard outcomes at different times and potentially across
different sites. Manual segmentation as an alternative is a subjective process,
both time-consuming and user-dependent, as shown in Chapter 4. This is
particularly the case when the extent of abnormalities is large, with unclear
margins. There is extensive use of software-based techniques for white matter
hyperintensity (WMH) segmentation [58,175] in multiple sclerosis (MS) imaging
research, although many of these are not publicly available and no one technique
has become standard.
Dichotomised maps of ‘normal’ and ‘abnormal’ white matter can be produced
using signal intensity thresholds or contour-following methods that identify steep
gradients of changing white matter signal. However WMHs do not necessarily
have absolute boundaries resolvable on magnetic resonance imaging (MRI) and
locating the best approximation is likely to become an increasing problem in later
stage MS, when white matter surrounding focal lesions may become progressively
and diffusely abnormal. Pathological-radiological correlation studies are rare,
with small subject numbers, and therefore optimisation of any imaging-based
method of segmentation must be based on a more practical approach. The
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software tested here allows recognition of the uncertainty at the border between
normal and abnormal tissue by assigning probabilities to each voxel of belonging
to each classification.
This chapter presents an investigation into optimising a novel method in MS
imaging for generating both unidimensional WMH volumes and three-dimensional
masks. The optimal software for segmenting WMHs in MS would produce
outputs with the closest match to a reference standard, but the measures used
to determine this optimal fit may depend on the use for which the output is
required. For that reason an in house hyperintensity segmentation software was
used to allow complete flexibility during the optimisation process. First, the
unidimensional output (total quantity of abnormal tissue) is considered, either to
best distinguish between different levels of disease or to best match the reference
data in absolute terms. Secondly the spatial agreement is evaluated, using metrics
that examine specifically the degree of overlap of segmented abnormality, as well
as those also accounting for agreement on excluded, ‘normal’, tissue. The imaging
data used for this work were taken from participants in a chronic progressive
disease stage, in which diffuse and widespread white matter involvement was
considered likely.
6.2 Methods
6.2.1 Participants and Imaging
The scans used for this work formed part of the baseline assessment of the
43 people enrolled at the University of Edinburgh centre for the MS-SMART
Advanced MRI substudy. See Chapter 2, Section 2.1 for further details of the
cohort and their imaging.
6.2.2 Reference standard
All software outputs were compared to manual segmentations performed
on fluid attenuated inversion recovery (FLAIR) axial sequences by a single
neuroradiologist, blinded to all clinical and demographic information. (See
Chapter 4 for further detail of assessment of this reference standard.) To
ensure comparability of segmentation volumes, the reference segmentations were
multiplied by the atlas-derived (cerebral) white matter probability mask before
any comparison. This removed any segmented hyperintensities that involved
posterior fossa structures or extended into subcortical grey matter, which the
software was not designed to assess.
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6.2.3 Automated segmentation
The white matter segmentation method is described in Chapter 2, Section 2.1.3.1.
Probabilistic maps of WMHs were derived through statistical conversion of the
FLAIR sequence, multiplied by the atlas-based white matter probabilistic mask.
The threshold below which all FLAIR intensities were immediately assigned zero
probability was altered between the range of 0.7 to 1.7 standard deviations
above the mean intensity, based on prior experience. Cumulative distribution
transformation of the standard deviation (SD) maps produced an initial map
of probabilities where each voxel value represented the probability of that voxel
being classified as a WMH based on its intensity. A second, probability-based
threshold could be set, above which all voxels were considered WMHs, creating
a binary segmentation. Probability thresholds (Pt) from 0.05 to 0.9 were tested,
i.e., all voxels with probability greater than or equal to Pt were given a binary
classification as 1 (WMH) and those less than Pt were given a binary classification
as 0 (not WMH). Probabilities below 0.05 were excluded at all thresholds to
remove noise.
Masks were examined in FSL viewing software [104] to identify sources of
discrepancy between automated and manual segmentations, but no manual
adjustments were made to the automatically generated masks.
6.2.4 Statistical analysis
6.2.4.1 Unidimensional agreement
Agreement on the total WMH volume between manual and automated
segmentations were assessed using Spearman correlations and percentage
differences between output volumes. The threshold combinations which optimised
these parameters were identified. Agreement was also examined visually using
Bland-Altman plots of the volume ratio between the two segmentations.
6.2.4.2 Spatial agreement
All voxels within the white matter mask were classified as to whether they
were identified as WMH on the manual segmentation only, the automated
segmentation only, both or neither. Sums of these voxel categories were used to
generate spatial agreement metrics, including Dice indices for each comparison.
As described previously (Chapter 4, Section 4.2.3.2), this measures the voxel
overlap between the two masks and is defined as twice the ratio of the number of
overlapping voxels to the sum of the voxels in each segmented mask. Concerns
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that the Dice index increases with the size of the regions of interest, not taking into
account the size of regions excluded by both segmentations, were addressed by
additionally calculating sensitivities, specificities, negative and positive predictive




The scans used were the baseline imaging from participants in the Advanced MRI
substudy of MS-SMART. Automated tissue segmentation failed for one scan,
which had been acquired with atypical imaging parameters, and data from this
participant was excluded. The remaining 42 scans were successfully segmented.
This represented data from 29 female and thirteen male participants, with a
mean age of 55.5 ± 8.4 years. All participants had a diagnosis of secondary
progressive MS (SPMS) with median disease duration of 22.1 years (interquartile
range (IQR): 15.5, 27.0). The reference standard WMH volumes (as described in
Chapter 4) had median 17.1ml (IQR: 7.3, 30.6).
6.3.2 Unidimensional reproducibility
6.3.2.1 Reliability
Correlations (Spearman) with the manual lesion volume were high (> 0.9) for
80% of the threshold combinations examined, only falling below this when both
low FLAIR SD and probability thresholds were used. This demonstrated that the
software method reliably distinguished between participants with different levels
of disease. The maximum correlation found was r = 0.96 (thresholds: FLAIR
SD = 1.0, probability = 0.7). A scatterplot of volumes derived at this threshold
combination against the reference manual segmentation is shown in Figure 6.1.
As expected from the correlation, this showed a tight correspondence between
the variables. However the software-derived volume tended to be lower than the
manual volume, with the line of best fit having a gradient of 0.73.
6.3.2.2 Absolute agreement
The mean absolute percentage difference in WMH volumes between the manual
and automated segmentations was minimised at 26.2% with thresholds FLAIR
102





















Figure 6.1: Scatterplot showing automated and manual WMH volumes (n = 42) at the
threshold combination (FLAIR SD = 1.0, probability = 0.7) chosen to maximise their
correlation (Spearman r = 0.96), with line of best fit.
SD = 1.1 and probability = 0.6. The effect of varying these thresholds on the
cohort mean percentage difference is shown in the ‘contour’ plot in Figure 6.2
and a Bland-Altman plot of the ratios between volumes produced using the two
methods for the optimal threshold combination is shown in Figure 6.3. Although
the majority of points lie within the 95% confidence intervals, the Bland-Altman
plot shows a trend towards improving agreement at higher WMH volumes. This
would be expected when a larger proportion of the white matter is involved. There
also appears to be a tendency for the automated segmentation to produce smaller
WMH volumes at higher levels, compared with the manual segmentation. This
may relate to the assignment of probabilities below the tested threshold by the
software in regions with unclear WMH margins, compared with the binary manual
segmentation. Alternatively it may reflect the method through which individual
thresholds are chosen. Specifically, individual thresholds for lesion identification
were based on SD multiples from the individual mean of whole brain FLAIR
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signal. For those individuals with a greater of pathology, the threshold may be
substantially higher.

















Figure 6.2: Contour plot showing the mean absolute percentage difference for all tested
combinations of FLAIR SD and probability thresholds. Values along contours indicate
approximate levels of mean absolute percentage differences along them. An asterisk
marks the threshold combination at which this is minimised.
By considering two measures of unidimensional reproducibility, either seeking to
maximise the correlation or minimise the (percentage) volume difference between
masks, two different, although close, threshold combinations were found to be
optimal.
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Figure 6.3: Bland-Altman plot showing the ratio of the reference standard (manual)
WMH volumes to that of the automated segmentation volumes (n = 42) at the threshold
combination minimising the mean absolute percentage difference (thresholds: FLAIR
SD = 1.1, probability = 0.6). The solid horizontal line indicates the mean volume ratio
(= 1.01) with dashed lines indicating the 95% confidence limits.
6.3.3 Spatial agreement
6.3.3.1 Dice index
The mean Dice index for spatial overlap was assessed at all tested threshold
combinations and the effect of this is shown in the contour plot in Figure 6.4.
The 0.6 boundary encloses a range of threshold combinations which led to a mean
cohort Dice of 0.6 or greater. This was maximal, at a value of 0.62, for thresholds
FLAIR SD = 1.3, probability = 0.4.
A scatterplot of the Dice index against manual WMH volume at the optimal
threshold combination is shown in Figure 6.5. At this optimal threshold, the
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Figure 6.4: Contour plot showing the cohort mean Dice index for all tested combinations
of FLAIR and probability thresholds. Values along contours indicate approximate levels
of the mean Dice along them. An asterisk marks the threshold combination at which
the mean Dice is maximal.
individual scan Dice indices still showed wide variation; they increased with
increasing WMH volume, a recognised feature of the Dice index, which does
not adjust for agreement by chance alone.
6.3.3.2 Youden’s index
The classification of each white matter voxel was determined by its status on
manual and automated segmentations; summing these allowed the calculation of
sensitivities, specificities, positive (PPV) and negative predictive values (NPV)
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Figure 6.5: Scatterplot of individual scan Dice indices (n = 42) against manual WMH
volume for the optimal threshold combination (FLAIR = 1.3, probability = 0.4). The
mean cohort Dice was 0.62.
for each scan. Contour plots showing the effect of varying thresholds on these
measures are shown in Figure 6.6.
Youden’s Index combines information from the sensitivity and specificity, thus
taking into account the number of white matter voxels not assigned to the WMH
mask by either the automated or manual segmentation (ignored by the Dice
index). This was maximised at 0.87 for a threshold combination of FLAIR
SD = 1.3, probability = 0.0 (the lowest probability threshold, only excluding
probabilities designated noise). This gave a sensitivity of 0.95 and a specificity
of 0.92, a ‘perfect’ NPV (1.00) but a very low PPV (0.23), highlighting the fact
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Figure 6.6: Contour plots for additional measures of spatial agreement for all tested
FLAIR SD and probability thresholds. The blank square for threshold combination
1.7/0.9 in the PPV plot is due to one scan being assigned a WMH volume of 0ml
by the software, leading to an undefined PPV. PPV: positive predictive value; NPV:
negative predictive value.
that a high sensitivity and specificity may not necessarily produce a close match
to the reference segmentation.
6.3.4 Sources of discrepancy
A major source of discrepancy contributing to large volume differences was in
assigning boundaries to diffusely abnormal white matter, where signal varied
gradually towards an unclear edge. Thresholds could be altered to maximise
agreement on these scans but this was not necessarily optimal for scans showing
much lower volumes of disease, with sharper edges to WMHs. Additionally both
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manual and automated segmentations were based primarily on the axial FLAIR
sequence which had a 3mm slice thickness and partial volume effects between
slices led to further blurring of WMH boundaries.
The corpus callosum was a recurrent source of spatial discrepancy, caused in part
by partial volume effects from its proximity to CSF and exacerbated by frequent
atrophy. For manual segmentation it would normally be best reviewed in the
sagittal plane but the 3mm slice thickness had made this difficult.
An example image is shown in Figure 6.7 highlighting some of the causes of
discrepancy.
Figure 6.7: Sample image from MS-SMART participant showing manual WMH
segmentation in turquoise, automated WMH segmentation in blue and overlapping
regions in white. There is agreement on the majority of the tissue, although the
automated segmentation boundary tends to be extend further. Only the automated
segmentation has identified abnormal tissue in the corpus callosum. Conversely,




Multiple sclerosis is a diffuse disease of the central nervous system and hard
lines drawn around visible regions of diseased brain are unlikely to represent
true anatomical or pathological boundaries. This creates a persistent problem
for quantification of MS pathology by brain imaging and cannot currently be
addressed by defining a ‘ground truth’ (reference standard) with external validity.
One approach to handling this problem is to incorporate a metric of uncertainty
into the automated segmentation process, allowing the user to determine group
classifications using a threshold of their choice. The novel method described here
respects the gradient of abnormality, reflecting this in the voxelwise probabilistic
output, which distinguishes it from most other currently used segmentation
softwares.
The ‘correct’ statistical method used to optimise agreement remains an open
question and even simple measures are often not reported (see Chapter 3 for
a review of relevant literature). Taha & Hanbury [176] summarise the many
different metrics used in the imaging literature. Whether the background (‘true
negative’) rate is included, or not, as in the commonly used Dice index, affects
assessment of good and bad segmentations. Several different desirable factors
have been considered in this chapter, but others are possible with varying degrees
of practicality. The mean Dice index found here (0.62), as well as the sensitivity
and specificity, are comparable to that found in other validation studies [58],
which mostly tested their software in smaller cohorts. The work described here
demonstrates that this software can be optimised for particular cohorts and using
the statistical measure of choice.
The probabilistic output can be used in different forms without repeating the
segmentation process. For the purposes of linear modelling (see Chapter 7), the
threshold producing an absolute WMH volume with the highest correlation (a
measure of linear association) to manual segmentation, was selected. However
for overlaying the diffusion maps (see Chapter 8), the probabilistic output was
retained, with each voxel diffusion parameter multiplied by its probability of
belonging to the tissue compartment of interest.
In most people with advanced multiple sclerosis, the majority of their brain WMH
burden will be in supratentorial white matter, which was the case for this cohort.
The results presented show that the automated software could accurately identify
these. However lesions in the posterior fossa were not assessed, as appears to
be the case with most segmentation softwares, although this information is not
readily available in the public domain. While this cohort had low posterior fossa
lesion volumes, as assessed with manual segmentation, this will not necessarily
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be the case in others. Lesions in the corpus callosum, a characteristic feature
of MS, could not be assessed reliably, likely related to the 3mm slice thickness
and associated partial volume effects with adjacent cerebrospinal fluid (CSF).
This made confident manual segmentation of corpus callosum lesions difficult,
and a conservative approach was adopted. Notable mismatches were observed
here with the software classifying large proportions of the corpus callosum as
abnormal in most subjects. This issue could be addressed by manual adjustment
after software segmentation; not doing so here was chosen in order to separately
assess the manual and automated methods.
Further validation of this software in independent datasets with different disease
appearances is needed for it to be used more widely. Its performance here was
tested using two-dimensional FLAIR sequences, but as there is a shift to greater
use of volumetric three-dimensional acquisitions this will need re-evaluation. A
limitation of this work is the lack of direct comparison with existing approaches to
WMH segmentation, which in the majority of cases was due to the algorithms not
being publicly available at the time. In the future it would be useful to compare
the software tested here with that available in the Lesion Segmentation Toolbox
(http://www.applied-statistics.de/lst.html) for use in the Statistical Parametric
Mapping (SPM) software (http://www.fil.ion.ucl.ac.uk/spm/) as well as the
BIANCA software [177], part of FSL, which has recently become available.
The method developed in this chapter was implemented in a fully-automated
fashion to produce both binary and probabilistic maps of WMHs; the specific
advantages are twofold. Thresholds both for the relative FLAIR signal intensity
and the probability level can be adjusted for particular scans, subjects or
larger studies, in order to optimise outputs for particular criteria of interest,
generating binary masks and WMH volumes as required. Additionally, when
an absolute boundary to WMHs is not required, the underlying probabilities
assigned can be retained in the output, generating WMH volumes by summing
these voxelwise and used in an analogous fashion with co-registered masks derived
from advanced imaging techniques. Both WMH volumes and probabilistic masks
generated by this method are used in the following two chapters in order to










This chapter describes work using the tools developed in Chapters 5 (a
visual rating scale for the imaging features of multiple sclerosis (MS)) and 6
(automated quantification of white matter hyperintensities (WMHs)) to evaluate
the relationship between the burden of WMHs and cognitive performance in
people with MS.
Linear regression models were developed to evaluate a first hypothesis of a linear
relationship between the WMH burden and cognitive performance in people with
MS. A hierarchical approach was used for model construction, first addressing the
relationship between cognitive performance and non-disease related covariates of
relevance (see Chapter 1). The potential contribution of disease-related imaging
metrics was then tested through addition to this ‘core’ model.
The second hypothesis tested was of a non-linear relationship between the burden
of WMHs and cognitive performance in people with MS. This possibility was
identified through evidence from previously published studies (see Chapter 3) that
the pathology-phenotype relationship may be stronger at higher levels of disease
burden. The question of a potentially dynamic relationship between pathology
and phenotype was therefore addressed by exploring non-linear relationships
and interactions between variables. If confirmed, this finding would raise the
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possibility that redundancy and neuroplasticity are able to compensate for
pathology at low levels, with diminishing capacity as the disease progresses.
7.2 Methods
7.2.1 Construction of a linear model based on hyperintense white
matter hyperintensity volume
7.2.1.1 Cohort and available data
Data from the baseline assessments of participants in MS-SMART, a cohort of
subjects with secondary-progressive MS (SPMS), were used for construction of a
predictive model of cognitive performance. (See Chapter 2, Section 2.1 for further
details of the cohort.) Scores for the Symbol Digit Modality test (SDMT) were
available from their baseline assessment and were taken as a measure of cognitive
ability for use as the dependent variable in all statistical models.
7.2.1.2 Participant characteristics
Information was available on all participants with regards to sex, age and
disease duration. Where possible, data from other known modifiers of cognitive
performance were also considered for inclusion in the predictive model.
Due to inconsistencies in recording of education status, either as full-time
equivalent years in education or as the highest level of educational attainment,
a decision was made to dichotomise education data. Participants were classified
by the presence or absence of educational exposure beyond compulsory schooling
(i.e. entry to higher education), with a cut-off of twelve full-time equivalent years
of education used where this was unclear.
Certain licensed drugs are known to be potential modifiers of cognitive
performance. For each participant, all prescribed drugs were recorded at baseline,
and these were classified into three groups according to whether they were likely
to be associated with better or worse cognitive performance, or if there was no
reason to expect any effect on cognition. On this basis, participants were split
into three groups.
Participants’ scores on the Beck Depression Index (BDI) were recorded during
screening for study entry (up to one month prior to baseline assessment) as part
of the study eligibility criteria.
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7.2.1.3 Imaging data
The following volumetric data were available from the standard study baseline
imaging protocol and subsequent automated tissue segmentation: intracranial
volume (ICV), total brain volume and white matter (WM) volume.
After the investigations described in Chapter 4, the automated software was
used to generate WMH volumes for all MS-SMART participants, using the
threshold that maximised correlation with the (third) manual segmentation in
the Advanced MRI substudy cohort. This was run on the entire MS-SMART
cohort for consistency.
7.2.1.4 Univariate relationships
Scatterplots of individual predictors against SDMT scores were examined for
outliers and evidence of non-linear relationships. Spearman correlations between
all individual numerical predictors and SDMT scores were calculated. For
binary predictors, t-tests were used to test for significant differences between
groups.
7.2.1.5 Model construction
Generalised linear modelling was used, with an assumption of normally
distributed errors. A strong prior literature exists regarding the influence of
age, sex and educational status on SDMT performance [40]. The side effects
of the drugs classified as having a potentially detrimental effect on SDMT
are also well-established. A hierarchical approach to model construction was
adopted, with an initial model based on age, sex, drugs and education status
only. Education status and being prescribed drugs with a potentially detrimental
effect on cognition were both modelled as binary predictors.
Initial model:
SDMT = β0 + β1age + β2sex + β3education + β4cognitive inhibiting drugs
Intracranial volume reflects peak adult brain volume and represents a
fundamental non-disease metric, with a known relationship to cognition and
cognitive decline [38,39]. In a second model using both imaging and non-imaging
metrics, ICV was therefore included as the sole imaging metric, to produce the
optimal predictive model without markers of disease burden.
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Second phase model:
SDMT = β0 + β1age + β2sex + β3education + β4cognitive inhibiting drugs
+ β5intracranial volume
The initial disease marker considered was WMH volume, modelling the impact
of focal inflammatory disease. This was added to the prior model containing
non-disease-related variables to form the third phase linear model.
Third phase model:
SDMT = β0 + β1age + β2sex + β3education + β4cognitive inhibiting drugs
+ β5intracranial volume
+ β6WMH volume
In the final (fourth) linear model, WM volume was added in an attempt to model
the impact of neuroaxonal loss. White matter volume was chosen in preference
to total brain volume as possibly the more relevant to a distributed function such
as processing speed and the effect of WMH burden.
Fourth phase model:





Individual predictor scatterplots were examined for outliers. Correlations between
all individual predictors were calculated. For all models constructed, histograms
of the residuals, Q-Q plots and plots of residuals against predicted values were
assessed.
7.2.1.7 Investigation of non-linear relationships
The possibility of a non-linear relationship between WMH volume and SDMT
being a better fit for the data was initially explored graphically using a loess
fit [178], a locally-weighted smoothing function.
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Two breakpoints were suggested by the smoothed plot, splitting the cohort
into thirds. A piecewise linear regression model was therefore constructed with
optimal breakpoints (one or two) sought iteratively. These piecewise linear
regression models were constructed to evaluate both the univariate relationship
between SDMT and WMH volume and this relationship within the context of
other relevant covariates.
7.2.1.8 Sensitivity analyses
Disease duration was omitted as an independent variable in construction of the
primary model, with a view to assessing the accumulated disease burden through
imaging variables alone. In order to assess whether this could be an important
predictor in itself, or provide greater explanatory power than imaging-derived
predictors, sensitivity analyses were performed with the addition of disease
duration to both the full model and that using only non-imaging variables, with
assessment of model fit.
Related to disease duration, the possibility that age could act as a surrogate
variable for pathological changes occurring over time was also considered. The
age range of the cohort was not one at which substantial effects of cognitive
ageing would be expected and this could have the unwanted effect of attenuating
power to detect an effect of accumulated pathology due to its covariance with age.
Correlations between age and imaging markers of brain pathology (WM volume
and WMH volume) were considered. The effect on the goodness of fit parameters
of models containing imaging markers was considered when age was omitted, with
or without the addition of WM volume as an alternative variable.
The effect of adding total brain volume rather than WM volume as an additional
imaging marker, following ICV and WMH volume was also considered.
7.2.1.9 Model comparisons and fit
Parameters of goodness of fit were compared for all models, including values for
adjusted R2, Akaike information criteria (AIC) and Bayesian information criteria
(BIC), with the Wald test used to quantify the statistical significance of additional
model predictors.
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7.2.2 Construction of a linear model based on visual rating lesion
scores
7.2.2.1 Cohort and available data
Data from the visual assessments of imaging from the baseline assessments of
participants in FutureMS, a cohort of subjects with early relapsing-remitting MS
(RRMS), and MS-SMART were used for construction of a predictive model of
cognitive performance. (See Chapter 2 for further details of the cohorts and
Chapter 5 for details of the visual assessments of their imaging.) Scores for
the SDMT were available from the baseline assessment for each study and were
taken as a measure of cognitive ability. There was no prior hypothesis that any
imaging feature under consideration would have a different relevance for groups
with early and later stage disease and the two cohorts were modelled together as
one group.
7.2.2.2 Participant characteristics
Information was available on all participants with regards to age, sex and
disease duration. Where possible, data from other known modifiers of cognitive
performance were considered for inclusion in the predictive model. Participants
were again classified according to whether they were prescribed drugs that could
have a detrimental or beneficial effect on cognition. Data on education status
and BDI were not available for the FutureMS cohort.
7.2.2.3 Imaging data
The complete initial set of rater scores from the independent validation study
reported in Chapter 5 were available. Each of the dimension subscores
constructed, representing summed scores for particular features of interest, were
considered as predictors. Binary predictors, based on presence or absence of
juxtacortical/cortical (JC) lesions and cavitated lesions, were also considered.
Relevant to the focus on diffuse cerebral white matter disease, the atrophy score
used was the mean of the deep and superficial cerebral atrophy scores, i.e. not
incorporating the posterior fossa and corpus callosum ratings.
7.2.2.4 Univariate relationships
Plots of individual predictors against SDMT scores were examined for outliers and
evidence of non-linear relationships. Spearman correlations between all individual
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predictors and SDMT scores were calculated. For binary predictors, t-tests were
used to test for significant differences between groups.
7.2.2.5 Model construction
Generalised linear modelling was used, with an assumption of normally
distributed errors. A hierarchical approach to model construction was adopted
as previously, with an initial model based on age, sex and prescribed drugs.
Two summary white matter lesion/hyperintensity (WMH) scores (the global
summary ‘Fazekas-style’ score and the summed regional white matter score) were
available. The global summary score was chosen as a predictor for construction
of a second model, as it was considered to be more representative of the total
burden of cerebral white matter disease, given the summed regional score’s
over-representation of smaller regions and inclusion of grey matter and posterior
fossa structures. Finally, further dimension subscores and binary predictors based
on these were considered in turn as additional predictors.
7.2.2.6 Assumption checking
Individual predictor scatterplots were examined for outliers, with consideration
of appropriate handling where necessary. Correlations between all individual
predictors were calculated. For all models constructed, histograms of the
residuals, Q-Q plots and plots of residuals against predicted values were
assessed.
7.2.2.7 Linear modelling for separate cohorts
The univariate relationships between the independent variables in the main
model and SDMT performance were considered separately for the two smaller
cohorts, in order to explore whether predictor variables had different effects at
different disease stages. The overall model was constructed separately for the two
cohorts to examine the effect of the individual predictors within a multivariate
context.
7.2.2.8 Sensitivity analyses
As for the modelling based on volumetric imaging markers, disease duration was
not initially included with the aim of assessing the accumulated disease burden
using imaging markers. The effect of its inclusion on model fit was tested both as
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an additional predictor in the full model and within a smaller model based only
on non-imaging predictors. The potential for age and being prescribed drugs with
a detrimental effect on cognitive performance to be acting as surrogate markers
of disease stage was also considered. This was addressed both in the separate
modelling for the two cohorts described above and investigating the effect of
removing age from these smaller models.
7.2.2.9 Model comparisons and fit
Parameters of goodness of fit were compared for all models, including values for
adjusted R2, AIC and BIC, with the Wald test used to quantify the statistical
significance of additional model predictors.
7.3 Results (I): Construction of a linear model based on
automated white matter hyperintensity volume
7.3.1 Data completeness and participant characteristics
Scores for the SDMT were available from their baseline assessment for 91 of
the 93 participants in MS-SMART. For the two instances of missing data, one
participant was unable to complete either the Paced Auditory Serial Addition
Test or SDMT due to cognitive limitations and for the other participant confusion
during test completion invalidated the result. A histogram of SDMT scores
showed no evidence of substantial deviation from a normal distribution.
Data on premorbid IQ and cognitive leisure activities were not available in
this cohort. Data on educational status were unavailable for 17 participants.
Four prescribed drugs (diazepam, clonazepam, baclofen and amitriptyline) were
identified as potentially having a detrimental effect on cognitive performance and
36 participants were taking at least one of these. Two participants were prescribed
modafinil, with a potentially beneficial effect on cognitive performance.
In two participants, volumetric imaging predictors were unavailable, in one case
due to a T2-weighted sequence not being available and in one case due to failure
of software segmentation.
Descriptive statistics for this cohort are presented in Table 7.1, including
participant characteristics and volumetric imaging markers.
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n Summary figures
Age (years) 93 57.2 (49.0, 61.0)
Sex (F/M) 93 69/24
Disease duration (years) 93 20.4 (14.0, 28.7)
BDI 93 6 (4, 11)
Drugs (Beneficial/Detrimental/Neither) 93 2/37/54
Education ≤ 12/> 12 years 76 31/45
SDMT (mean ± SD) 91 43.2 ± 11.7
ICV (ml) 91 1308 (1243, 1395)
Brain volume (ml) 91 1136 (1063, 1209)
WM volume (ml) 91 425.4 (403.3, 453.0)
WMH volume (ml) 91 32.0 (23.4, 45.5)
Table 7.1: Summary statistics for MS-SMART cohort, used in predictive modelling. All
continuous/numerical variables are given as median (interquartile range) other than for
SDMT. The second column (‘n’) indicates the number of subjects for whom that data
was available. BDI: Beck Depression Index; ICV: intracranial volume; WM: white
matter; WMH: white matter hyperintensity.
7.3.2 Participant characteristics as predictors of cognitive
performance
7.3.2.1 Univariate relationships
The relationships of the non-imaging characteristics presented in Table 7.1 to
SDMT performance were examined. Only two participants were prescribed
medication with a potentially beneficial effect on cognitive performance
(modafinil), and their SDMT scores were the lowest and second highest in the
cohort. This raised concerns over the timing of taking medication on the day of
testing and it was not possible to ascertain this information.
Plots of individual non-imaging predictors against SDMT score are presented
in Figure 7.1 for the MS-SMART cohort (n = 91). Numerical predictors gave
Spearman correlations with SDMT of r = 0.01 for age, r = −0.04 for disease
duration and r = −0.10 for depression score. There was no evidence of a
non-linear relationship from the scatterplots and none of the correlations were
significantly different from zero at the 5% level. For the binary predictors (sex
(p = 0.63), educational status (p = 0.19) and being prescribed drugs with a
potentially detrimental effect (p = 0.08)), t-tests did not show any significant
differences between groups. Group differences both for those taking potentially
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detrimental drugs and those having a higher level of education were nevertheless
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Figure 7.1: Plots of individual non-imaging predictors against SDMT (n = 91, for all
except Education status (n = 74).) The bottom left plot shows participant SDMT
scores grouped by whether they were prescribed at least one drug with either a
potentially detrimental or beneficial effect on cognition or neither, no participant being
prescribed both.
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7.3.2.2 Construction of multiple linear regression model
Due to the uncertainties over the use and timing of medication with a potentially
beneficial effect on cognition, the two participants prescribed modafinil were
excluded from all predictive models using medication information.
Although pseudo-dementia due to depression is recognised, people with scores
on the BDI thought high enough for this to have an influence on cognitive
performance were not eligible for MS-SMART. No obvious relationship was found
in the range of the MS-SMART cohort so BDI scores were also not included in
the model.
Disease duration showed a significant correlation with age (r = 0.45) and was
not used as an additional independent predictor, in preference of assessing
accumulated disease burden through imaging markers.
7.3.2.3 Multiple linear regression model summary
A description of the model containing age, sex, education status and use of drugs
with potentially detrimental effects as independent variables is presented in the
first column of Table 7.2. In comparison with a model based on the intercept
alone (the mean SDMT score), there was no definite evidence (p = 0.17) that the
model based on four non-imaging predictors was a better fit to the data. With
respect to individual predictors, there was some support for a possible influence
of educational status (p = 0.12) and detrimental drugs (p = 0.08) on SDMT
scores.
7.3.2.4 Interactions between variables
In the model described in column 1 of Table 7.2, each independent variable
was added separately, without interaction terms, allowing more straightforward
interpretation of coefficients. An alternative model, using the same non-imaging
predictors but allowing interactions between them, did not improve model fit
given the number of parameters (AIC 561.1, BIC 599.8) although there was





1 2 3 4
Constant 50.51 3.85 14.69 21.51
p < 0.0001∗∗∗ p = 0.85 p = 0.40 p = 0.25
Age −0.14 −0.22 −0.13 −0.16
p = 0.43 p = 0.21 p = 0.38 p = 0.29
Sex −0.83 −7.71 −8.89 −7.74
p = 0.78 p = 0.04∗∗ p = 0.01∗∗∗ p = 0.03∗∗
Education (over 12 years) 4.32 4.44 4.40 4.64
p = 0.12 p = 0.10∗ p = 0.06∗ p = 0.05∗∗
Detrimental drugs −4.87 −6.00 −3.36 −3.28
p = 0.08∗ p = 0.03∗∗ p = 0.15 p = 0.16
ICV (ml) 0.04 0.04 −0.002
p = 0.01∗∗∗ p = 0.01∗∗∗ p = 0.96
WMHV (ml) −0.29 −0.29
p = 0.0001∗∗∗ p = 0.0001∗∗∗
WMV (ml) 0.10
p = 0.35
AIC 557.1 534.6 516.5 518.9
BIC 570.8 550.3 534.5 539.1
Observations 72 70 70 70
R2 0.09 0.21 0.41 0.42
Adjusted R2 0.04 0.15 0.35 0.35
Residual Std. Error 11.05 10.42 9.10 9.11
(df = 67) (df = 64) (df = 63) (df = 62)
F Statistic 1.68 3.49∗∗∗ 7.29∗∗∗ 6.36∗∗∗
(df = 4; 67) (df = 5; 64) (df = 6; 63) (df = 7; 62)
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table 7.2: Summary of linear models with SDMT as dependent variable and participant
characteristics and imaging markers derived from routine sequences as independent
variables. Numbers shown in the main table are model coefficients followed by
associated p values. Predictor abbreviations are as in Table 7.1.
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7.3.3 Imaging markers as predictors
7.3.3.1 Univariate relationships
Imaging-derived variables summarised in Table 7.1 were considered initially as
univariate predictors of SDMT performance. These gave Spearman correlations
with SDMT of r = 0.28 for ICV, r = 0.33 for brain volume, r = 0.29 for WM
volume and r = −0.48 for WMH volume. All correlations were significantly
different from zero at the 1% level. For comparison with published literature
(see Chapter 3), the Pearson correlation between SDMT and WMH volume was
r = −0.45, with 95% confidence interval (−0.61,−0.27). When adjusted for ICV,
the correlations with SDMT were r = 0.33 for brain volume, r = 0.15 for WM
volume and r = −0.49 for WMH volume.
Plots of individual imaging predictors against SDMT score are presented in Figure
7.2 for the MS-SMART cohort (n = 89). The scatterplots were open to multiple
interpretations, but there was no strong evidence of a non-linear relationship for
any of the variables, with the possible exception of WMH volume.
7.3.3.2 Construction of multiple linear regression model
Intracranial volume, brain volume and WM volume were all highly correlated (r
= 0.93 to 0.96). Brain volume and WMH volume were significantly negatively
correlated (r = −0.26, p = 0.01).
7.3.3.3 Multiple linear regression model summary
The model with the addition of just ICV was a significantly better fit to the
data (p = 0.005) than the model based on non-imaging participant characteristics
alone. The addition of WMH volume as a predictor produced a further significant
improvement in model fit (p < 0.00001). The further addition of WM volume did
not improve model fit (p = 0.35), an unsurprising result given the high covariance
of WM volume and ICV (r = 0.95). Descriptions of these models are presented
in columns 2 to 4 of Table 7.2.
7.3.3.4 Interactions between variables
A limited model using only the imaging predictors did not improve model fit when
allowed interaction terms, given the number of parameters (increased AIC and
BIC), although there was a suggestion that WM volume interacted with WMH


















































Figure 7.2: Plots of individual imaging predictors against SDMT (n = 89).
7.3.4 Model assumption checking
For the model described in column 3 of Table 7.2, a scatterplot of residuals against
fitted values and a Q-Q plot are shown in Figure 7.3, with some suggestion that
the fitted residuals deviate from normality at the tails of the distribution. This has
implications for the use of a model predicting phenotype outside the mid-range
and also raises the possibility of an underlying non-linear relationship.
There was a high correlation between ICV and WM volume (r = 0.95), consistent
with the lack of improvement in model fit with the introduction of WM volume
as a predictor.
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Figure 7.3: Left - plot of residuals against fitted values for linear model including
participant characteristics, ICV, WM volume and WMH volume (column 3 of Table
7.2). Right - Q-Q plot of residuals for the same model.
7.3.5 Potential non-linearity in the relationship between WMH
volume and SDMT
A scatterplot of SDMT against WMH volume is shown in Figure 7.4 with the
added loess fit, suggesting three phases to the relationship. The fitted results
of a piecewise regression produced by splitting the WMH data into thirds, also
shown superimposed, were able to closely match the loess fit. Compared with a
simple univariate model allowing only one slope, the model obtained by fitting the
data piecewise in thirds showed a non-significant improvement in fit (p = 0.11;
AIC 675.9, BIC 683.4 for simple model, compared with AIC 675.3, BIC 687.8 for
non-linear model). Within the multivariate model, equivalent to that summarised
in column 3 of Table 7.2, allowing three slope parameters for WMH volume also
resulted in a non-significant improvement in model fit (p = 0.18; AIC 515.9, BIC
538.4).
7.3.6 Sensitivity analyses
Disease duration did not improve model fit when considered as an additional
















Figure 7.4: Scatterplot of SDMT against WMH volume. Superimposed lines show the
piecewise regression fit produced by dividing the cohort into thirds by WMH volume
and the loess fit.
A trend towards significance was seen in the (Spearman) correlation between age
and WM volume (r = 0.20, p = 0.06), but not with WMH volume (r = 0.09, p
= 0.38). However omitting age from the models described in columns 3 and 4 of
Table 7.2 did not result in significant changes in model fit (p = 0.38 and p = 0.28
respectively) and the result of adding WM volume as a predictor to the smaller
model remained a non-significant improvement in model fit (p = 0.47).
Adding total brain volume rather than WM volume as an additional imaging
marker was associated with a non-significant improvement in model fit compared
to the model described in column 3 of Table 7.2 (p = 0.11, AIC 515.7, BIC 537.7).
WMH volume remained the only significant imaging-derived predictor, although
brain volume showed a trend towards significance (p = 0.12).
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7.4 Results (II): Construction of a linear model based on
visual rating lesion scores
7.4.1 Data completeness and participant characteristics
A score for the SDMT was available for 91 of 93 MS-SMART participants (as
described in section 7.3.1) and all FutureMS participants. A histogram of SDMT
scores showed no strong evidence of deviation from a normal distribution.
Descriptive statistics for the combined FutureMS (n = 67) and MS-SMART (n
= 93) cohorts are shown in Table 7.3, including participant characteristics and
visual rating markers. Seven participants in FutureMS were prescribed at least
one of the previously-identified drugs with a potentially detrimental effect on
cognition. The participants from MS-SMART were the same as those described
in the previous section, with the addition of one participant for whom automated
scan segmentation had failed. Education status and depression scores were not
available for the FutureMS cohort, so were not considered as predictors. Data
on pre-morbid IQ and cognitive leisure activities were not available for either
cohort.
7.4.2 Participant characteristics as predictors
7.4.2.1 Univariate relationships
The relationships of the non-imaging characteristics presented in Table 7.3 to
SDMT performance were examined. Plots of individual non-imaging predictors
against SDMT score are presented in Figure 7.5 for the combined cohort. As
described in section 7.3.2.1, two participants in MS-SMART were prescribed
medication with a potentially beneficial effect on cognition, with widely different
SDMT scores. Again, to avoid misinterpretation of this predictor, these
two participants were excluded from all predictive models using medication
information.
Numerical predictors gave Spearman correlations with SDMT of r = −0.53 for
age and r = −0.51 for disease duration (both with associated p < 0.0001).
There was no evidence of a non-linear relationship from the scatterplots. There
was no significant difference in SDMT performance between sexes (p = 0.74).
Participants prescribed drugs with a potentially detrimental effect on cognition
performed less well than participants not prescribed any drugs with potential































































Figure 7.5: Plots of participant characteristics against SDMT for the combined
MS-SMART and FutureMS cohorts (n = 158, for all except disease duration where
n = 157).
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Combined cohort FutureMS MS-SMART
n Summary n Summary n Summary
Age (years) 160 49.1 (41.4, 58.2) 67 40.1 (32.4, 45.9) 93 57.2 (49.0, 61.0)
Sex (F/M) 160 118/42 67 49/18 93 69/24
Disease duration (years) 159 13.5 (3.5, 46.2) 66 2.7 (1.0, 7.0) 93 20.4 (14.0, 28.7)
Drugs (B/D/N) 160 2/44/114 67 0/7/60 93 2/37/54
SDMT 158 51.1 ± 14.7 67 61.7 ± 11.2 91 43.2 ± 11.7
Global WMHs 159 6 (4, 8) 67 5 (3,6) 92 7 (5,10)
Regional WMHs 159 9 (5, 14) 67 7 (3,11) 92 10 (6,16)
Atrophy 159 1.5 (0.5, 2) 67 1 (0.5,1.5) 92 1.5 (1,2)
Cavitation (Y/N) 159 71/86 67 16/51 92 56/36
Cavitation (count) 159 0 (0, 3) 67 0 (0,0) 92 1.5 (0,6)
JC lesions (Y/N) 159 93/64 67 30/37 92 64/28
JC lesions (count) 159 1 (0, 2) 67 0 (0,2) 92 1 (0,3)
EPVS 159 6(5, 7) 67 5 (4,7) 92 6 (5,7)
Table 7.3: Summary statistics for the MS-SMART and FutureMS cohorts, used in
predictive modelling based on visual ratings. All continuous/numerical variables
are given as median (interquartile range), other than SDMT, given as mean ± SD.
The columns headed ‘n’ indicate the number of subjects for whom that data was
available. Medication is classified by whether participants were prescribed drugs with
potentially beneficial (B) or detrimental (D) effects on cognition, or neither (N). JC
lesions: juxtacortical/cortical lesions; EPVS: enlarged perivascular spaces; WMHs:
white matter hyperintensities.
7.4.2.2 Construction of multiple linear regression model
As in Section 7.3.2.2, age, sex and being prescribed drugs with a potentially
detrimental effect were considered important predictors of cognitive performance.
Age and disease duration were significantly correlated (r = 0.70) and,
as previously, disease duration was not used as an additional independent
predictor.
7.4.2.3 Multiple linear regression model summary
A generalised linear model to predict SDMT score was constructed using the
available non-imaging participant characteristics. A description of the model is
presented in the first column of Table 7.4, which gave an adjusted R2 of 0.34.
This provided a significant improvement in fit to a model based on the intercept




1 2 3 4 5
Constant 83.90 87.59 86.90 84.75 87.60
p < 0.01∗∗∗ p < 0.01∗∗∗ p < 0.01∗∗∗ p < 0.01∗∗∗ p < 0.01∗∗∗
Age −0.63 −0.51 −0.48 −0.48 −0.51
p < 0.01∗∗∗ p < 0.01∗∗∗ p < 0.0001∗∗∗ p < 0.01∗∗∗ p < 0.01∗∗∗
Sex −1.80 −2.17 −2.08 −1.54 −2.16
p = 0.40 p = 0.28 p = 0.30 p = 0.43 p = 0.29
Detrimental −6.97 −5.69 −5.67 −4.57 −5.67
drugs p = 0.002∗∗∗ p = 0.01∗∗∗ p = 0.01∗∗∗ p = 0.03∗∗ p = 0.01∗∗∗
Global −1.56 −1.31 −0.80 −1.51







AIC 1207 1186 1187 1174 1188
BIC 1223 1204 1208 1196 1209
Observations 155 155 155 155 155
R2 0.36 0.45 0.45 0.49 0.45














(df = 3; 151)
30.27∗∗∗
(df = 4; 150)
24.61∗∗∗
(df = 5; 149)
29.09∗∗∗
(df = 5; 149)
24.09∗∗∗
(df = 5; 149)
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table 7.4: Summary of linear models with SDMT as dependent variable and participant
characteristics and imaging markers derived from visual rating as independent variables.
Numbers shown in main table are model coefficients followed by associated p values.
Cavitation and (juxta-)cortical (JC) lesions are binary predictors.
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7.4.2.4 Interactions between variables
An alternative model to that described in Table 7.4 , column 1, using the same
non-imaging predictors but allowing interactions between them, did not improve
model fit given the number of parameters (AIC 1210.6, BIC 1238.0).
7.4.3 Imaging markers
7.4.3.1 Univariate relationships
Imaging-derived variables summarised in Table 7.3 were considered initially as
univariate predictors of SDMT performance. These gave Spearman correlations
with SDMT of r = −0.47 for global WMHs, r = −0.39 for regional WMHs, r
= −0.43 for atrophy, r = −0.58 for the number of cavitated lesions, r = −0.37 for
the number of JC lesions and r = −0.13 for enlarged perivascular spaces (EPVS).
All of these except EPVS (p = 0.10) were significantly different from zero at
the 1% level. For the binary variables, presence of cavitation (p < 0.0001) and
JC lesions (p < 0.001), t-tests showed a significant difference in SDMT between
groups.
Plots of individual imaging predictors against SDMT score are presented in
Figures 7.6 and 7.7 for the combined cohort (n = 157). Cavitation and JC
lesions are considered both by number and as binary features in Figure 7.7. The
scatterplots in Figure 7.6 were open to multiple interpretations, but there was no
strong evidence against the assumption of a linear relationship with SDMT. There
appeared to be a more complex relationship between SDMT and the number of
cavitated and JC lesions, as shown in Figure 7.7. There may be an excess of people
with no or few cavitated/JC lesions, suggesting a more appropriate analysis would
use binary classification.
7.4.3.2 Construction of multiple linear regression model
The global summary (‘Fazekas-style’) and summed regional WMH scores were
significantly correlated (r = 0.8) and, as described previously, the global summary
score was considered the more relevant and was used as an additional predictor
to non-imaging characteristics to form a second model.
Enlarged perivascular spaces were not found to be directly related to cognitive
scores in this cohort, so were not considered as part of a multiple regression model.
All other imaging features of disease, including additional lesion characteristics,
were assessed as independent predictors in addition to the global WMH score. The























































































































Number of juxtacortical 
lesions
Figure 7.7: Plots of individual imaging predictors against SDMT (n = 157). JC lesions
and cavitation are given both by count and as binary predictors.
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r = 0.55). In order to avoid inflating a measure of white matter lesion burden, the
involvement of (juxta-)cortical tissue was considered only as a binary predictor
variable. In view of the possibly non-linear relationship between lesion cavitation
and SDMT, this was also considered only as a binary predictor. The atrophy
score was significantly correlated with the global WMH score (r = 0.58).
7.4.3.3 Multiple linear regression model summary
The addition of global summary WMH scores to a model based only on
non-imaging characteristics resulted in a significant improvement in model fit
(p < 0.0001).
Models with further imaging variables considered in turn as additions to the
model are summarised in Table 7.4, columns 2 to 5. Introducing cerebral
atrophy as a predictor resulted in a non-significant improvement in model fit (p
= 0.22). Presence of lesion cavitation as a binary predictor produced a significant
improvement (p = 0.0002) in model fit. The presence of JC lesions (p = 0.77) as
a binary predictor did not improve model fit.
7.4.3.4 Interactions between variables
Considering a simple model with only the two imaging predictors found to
be significant predictors in larger models (global WMH score and presence of
cavitation), there was no improvement in model fit (increased AIC and BIC)
when allowed an interaction term.
7.4.4 Model assumption checking
For the model described in column 4 of Table 7.4, a scatterplot of residuals against
fitted values and a Q-Q plot are shown in Figure 7.8, with a minor suggestion that
the fitted residuals deviate from normality at the tails of the distribution.
7.4.5 Linear modelling for separate cohorts
A significant correlation remained between global WMH score and SDMT when
considered for each of the cohorts individually. This was stronger in the later
stage cohort (r = −0.39) than the early stage cohort (r = −0.24) although this
difference was not significant (p = 0.30).
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Figure 7.8: Left - plot of residuals against fitted values for linear model including
participant characteristics, global WMH score and presence of cavitation as a binary
predictor (column 4 of Table 7.4). Right - Q-Q plot of residuals for the same model.
The model structure described in column 4 of Table 7.4, was repeated separately
for the two cohorts, to explore whether the predictor variables had different effects
at different disease stages. The results are reported in Table 7.5.
In these smaller models the independent variable coefficients and their associated
significance differed from the single cohort analysis. Age was a significant
predictor of SDMT score in the younger, early stage disease cohort, but not in the
older, later stage cohort. Medication was no longer significant for either cohort.
For the imaging variables, the global WMH score only showed a trend towards
being a significant predictor in the later stage group, whereas lesion cavitation
remained the more significant predictor.
7.4.6 Sensitivity analyses
The addition of disease duration as a predictor variable, expressed either as a
proportion of age or unadjusted, resulted in a significant improvement in model
fit (p < 0.01) to a model based on non-imaging predictors alone. As an additional
variable in a full model containing non-imaging and imaging predictors, disease







p = 0.00∗∗∗ p = 0.00∗∗∗
Age −0.44 −0.02
p = 0.002∗∗∗ p = 0.92
Sex −1.44 −2.13
p = 0.62 p = 0.39
Detrimental drugs −3.35 −2.01
p = 0.42 p = 0.37
Global WMHs −0.43 −0.78
p = 0.47 p = 0.09∗
Cavitation −5.57 −7.87
p = 0.11 p = 0.004∗∗∗
Observations 67 88
R2 0.27 0.27
Adjusted R2 0.22 0.22
Residual Std. Error 9.94 (df = 61) 9.81 (df = 82)
F Statistic 4.62∗∗∗ (df = 5; 61) 5.94∗∗∗ (df = 5; 82)
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table 7.5: Description of linear model from column 4, Table 7.4, recalculated for
FutureMS and MS-SMART cohorts separately.
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SDMT performance correlated with age only in the younger cohort, suggesting
disease effects were involved rather than cognitive changes expected with ageing.
Additionally, being prescribed drugs with a potentially detrimental effect on
SDMT performance showed significant differences between the two cohorts (37/93
= 40% of MS-SMART; 7/67 = 10% of FutureMS) and may also have acted as
a surrogate marker of disease duration and severity. To address these issues,
the smaller models for the separate cohorts, as in Table 7.5, were repeated
without including age as a predictor. In the FutureMS model, this resulted in
a significantly worse overall fit (p < 0.001; adjusted R2 = 0.08), but made little
difference to overall fit of the MS-SMART model (p = 0.91; adjusted R2 = 0.23).
The significance levels for the remaining individual predictors in each model did
not change substantially from those in the models containing age as a variable
(as in Table 7.5).
7.5 Discussion
The results here confirm the relevance of white matter hyperintensities as
a disease marker in multiple sclerosis. Routine imaging features contribute
significantly to accurate prediction of cognitive status in people with MS, with
convergent results achieved using two very different image analysis approaches.
The relationship found here between cognitive outcome and both WMH volume
and the semi-quantitative visual rating marker of WMH burden is stronger than in
most published studies, but within the wider reported range of those using SDMT
(see Chapter 3, Figure 3.8). In the model using quantitative imaging markers,
WMH volume remained the most significant predictor of cognitive performance
after controlling for other disease and non-disease-related variables.
There is a suggestion that this relationship is not the same at all levels of disease
burden. The quantitative data shows little effect of WMH volume on cognitive
performance at low levels. Similarly for the semi-quantitative data, a stronger
correlation between WMH score and SDMT performance was found for the later
stage participants, with greater disease burden, than those in the early disease
stages. Although this was not a statistically significant finding, it is nevertheless
in keeping with the reported literature (see Chapter 3, section 3.3.12.2) in which
stronger effect sizes were found in cohorts with higher mean WMH volumes.
Such observations are consistent with an interpretation that below a certain
level of disease burden, neuronal adaptation, repair or redundancy may be able
to compensate for the level of damage, with reducing capacity as the disease
progresses.
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The cohort in which volumetric markers were tested comprised people with later
stage disease in whom accelerated atrophy was clearly present. Total brain
volume, rather than WM volume, showed a trend towards significance as an
additional predictor, suggesting the importance of grey matter or posterior fossa
pathology. However, neither white matter nor total brain volume proved to
be significant predictors in models containing other imaging-derived variables.
This may reflect the dominant effect of WMHs, becoming clearer in larger
cohorts, but both these measures of tissue volume may also be poor markers
of neurodegeneration given their high covariance with ICV (r = 0.95/0.96). This
allows the potential for more direct markers of widespread tissue integrity to
contribute to measurement of the overall disease burden instead and is explored
more in the following chapter. However the work here provides no strong evidence
that pathology accumulation and its impact on SDMT is anything other than
unidimensional.
The semi-quantitative visual rating markers provided an alternative source of
information regarding the extent and degree of pathology. A simple binary marker
of whether lesion cavitation was apparent proved to be a significant predictor of
cognitive outcome and this remained significant when considered separately in
both the individual cohorts. This could be interpreted as identifying people
with more aggressive disease or those who are no longer able to adequately
repair inflammatory damage. While related to the more widely used measure of
T1-weighted (T1w) hypointense lesion volume, this assessment is not only simple
and more selective, but also removes the confounding factor of acute inflammatory
lesions also appearing hypointense on T1w imaging.
The results using the visual rating assessments must be interpreted with caution
given their use of two different cohorts. The reasoning behind doing so was
to use the largest possible group in which to test the assessment outcomes,
however blinding as to cohort was not possible and the imaging sequences were not
identical. Examining the cohorts separately suggests that different features may
have greater relevance at different disease stages. In the cohort with RRMS, age
was the sole significant predictor of cognitive outcome, again consistent with the
proposal that initial compensation for accumulated brain pathology is possible.
In the later stage group, non-imaging variables were less important than imaging
ones, with presence of cavitation proving the only significant predictor at the 5%
level. Although the global WMH score was a significant predictor in the larger,
combined, cohort, this was not the case for the individual smaller cohorts. This
may reflect a lack of sensitivity to smaller increments in disease burden related
to the limited range of possible scores.
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The relationship of atrophy to cognition in people with MS is established [102],
although not using visual ratings, and here the atrophy scores were significantly
correlated with SDMT performance. However they were not significant predictors
in the multiple regression model, again possibly related to a dominant effect
of WMHs and their high covariance. Although cortical lesions may be more
important than white matter lesions in determining cognitive status [179], these
two measures are also likely closely associated [113]. It was not possible to reliably
separate purely cortical lesions on the routine sequences available for the visual
rating study, and the presence of juxtacortical/cortical lesions was not found to be
a significant independent predictor in the regression model of cognition. Enlarged
perivascular spaces, although related in other populations [171], were not found
to be directly related to cognitive scores in this cohort.
Limitations to the work here are acknowledged, not least the absence of more
extensive information regarding both co-morbidities and non-disease factors
which could influence cognition. The impact of a disease cannot be fully
understood only in terms of the accumulated pathology, without consideration
of wider factors relating to the person with the disease. This work was an
opportunistic use of available data and it remains possible that imaging factors
may be of lesser importance after controlling for other possible modifiers of
the relationship between pathology and phenotype. This highlights a recurrent
problem in the literature (see Chapter 3) with lack of consensus in recognising and
recording factors that may be important and inconsistencies in data collection
even for those that are accepted. No relationship between depression scores
and SDMT performance was found for the cohort in which it could be tested,
but this may have been influenced by the cut-off used in the study entrance
criteria. Modafinil is used to treat fatigue in people with MS and has previously
been associated with an improvement in SDMT performance [180]. Although
only prescribed to two participants in the cohorts studied here, the results
were ambiguous, possibly relating to timing of medication, which was not
recorded.
As previously mentioned, a desire to use the largest possible dataset influenced the
decision to test the visual assessments in a composite cohort. While recruitment
strategy should not have influenced the findings from either group, the use of two
cohorts with very different characteristics may have exaggerated the importance
of any differences in imaging features. Relevant to the consideration of whether
there exists a non-linear ‘threshold’ effect of WMHs, the use of a group with very
little evidence of accumulated disease may have partly obscured identification of
any threshold. Replication as well as further testing in groups at all stages of the
disease is certainly required.
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WMH burden, representing a history of focal neuroinflammatory damage, is
clearly a useful marker of disease in people with MS, with these results suggesting
that its importance may vary at different stages of the disease. Relevant to
their known lack of pathological specificity, the visual rating results indicate that
further simple information regarding the degree of damage represented by WMHs
contributes usefully to an overall estimate of disease burden. Nevertheless, there
remains unaccounted for variance in cognitive performance, which may require
improved assessment of the neurodegenerative component of the disease. Tissue
volume measures did not prove useful here as independent predictors, possibly
related to the relatively small changes involved and their high covariance with
intracranial volume. Quantitative markers related to tissue integrity in the
normal-appearing white matter, such as those derived from diffusion imaging,
may be more sensitive and these are explored in the following chapter.
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Chapter 8
The relationship of quantitative
measures of tract microstructure
from diffusion tensor imaging to
cognitive performance
8.1 Introduction
Variation in cognitive performance in people with multiple sclerosis (MS) is not
fully accounted for by current measures of the white matter disease burden that
are visible on routine structural imaging, as shown in previous chapters. This
remains the case even after optimisation of white matter hyperintensity (WMH)
quantification and adjustment for participant characteristics and modifiers of
cognitive performance. It is however also recognised that diffuse pathological
changes in white matter may not be associated with measurable changes on
routine imaging sequences and that alternative techniques may be more sensitive
to these processes. Diffusion tensor imaging (DTI) is an example of a quantitative
magnetic resonance imaging (MRI) technique that has been shown to be sensitive
to changes in the so-called ‘normal-appearing’ white matter (NAWM), leading
to the testable hypothesis that DTI-derived biomarkers may result in stronger
associations between imaging and clinical measures.
The work presented in this chapter addresses the question of how far any
DTI-derived white matter metric can explain variance in cognitive performance
and whether this is separate from information already available from routine
structural imaging sequences. The NAWM and WMH compartments within the
white matter are examined separately, with the prediction that any additional
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explanatory power will come from diffuse changes in the NAWM, since focal
inflammatory disease burden is accounted for in WMH volume. However the
possibility of DTI metrics providing additional information about the degree of
tissue damage within the WMHs is also considered.
In this chapter the validity of different potential markers of tract health is first
established, ensuring that they capture a range of values with the potential to be
used in predictive models. Their covariance with disease and non-disease factors
is then explored and the relationship of DTI-derived markers to a measure of
processing speed, the Symbol Digit Modality Test (SDMT), is examined. Finally
they are entered into predictive models, developed in the previous chapter, to
determine whether they contribute additional information to markers already
available.
Three specific hypotheses are tested: (1) that DTI metrics are a valid marker
for distinguishing between WMHs and NAWM; (2) that DTI metrics provide
stronger correlations with cognitive performance than volumetric measures from
routine structural imaging; and (3) that in predicting cognitive performance from
imaging and non-imaging features, DTI metrics increase explanatory power based
on improved measurement of the neurodegenerative disease component.
8.2 Methods
8.2.1 Participants and imaging
Baseline scans from participants in the MS-SMART Advanced MRI substudy
(described in Chapter 2, Section 2.1) were used in this work. The imaging and
post-processing of diffusion data are described in Chapter 2, Sections 2.1.2 and
2.1.3. Averaged (mean) fractional anisotropy (FA) and mean diffusivity (MD) for
the software-segmented WMH and NAWM tissue compartments, the peak width
of skeletonised mean diffusivity (PSMD) and the tract-averaged FA and MD from
the twelve automatically segmented major fasciculi of interest were all considered
as potential predictors of cognitive status.
8.2.2 Validity of DTI-derived metrics
Plots of all potential DTI-derived predictors were considered for their validity
in distinguishing between different tissues, including mean diffusion parameters
derived from segmented tissue compartments and from each of the tracts
extracted. Differences between DTI metrics for the segmented compartments
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were examined using Mann-Whitney U tests. The relationship of the novel marker
PSMD to the average (mean) overall white matter MD was considered.
8.2.3 The univariate relationships between quantitative
DTI measures of tract microstructure and cognitive
performance
Spearman correlations between all individual predictors and SDMT scores were
calculated. Plots of individual predictors against SDMT scores were examined for
outliers and evidence of non-linear relationships. The participant characteristics
of influential observations (individual participants) were investigated, as to
whether they exhibited extreme values of other SDMT predictors.
8.2.4 Additional value of DTI-derived metrics to WMH burden in
predictive models
8.2.4.1 Model construction
General linear modelling was used as in the previous chapter, with an assumption
of normally distributed errors. The initial models developed in Chapter 7, based
on non-imaging and routine structural imaging-derived volumetric predictors,
were recalculated for the MS-SMART Advanced MRI substudy cohort only. Each
DTI-derived predictor was then considered in turn as an additional independent
variable in the model.
8.2.4.2 Assumption checking
Covariance of DTI metrics with age, sex and routine structural imaging-derived
parameters, particularly WMH volume, was considered, in order to exclude
collinearity. Correlations between all individual predictors were calculated.
Cook’s distances were examined for highly influential data points, with
consideration of appropriate handling where necessary. For all models
constructed, histograms of the residuals, Q-Q plots and plots of residuals against
predicted values were assessed in order to check model assumptions and fit.
8.2.4.3 Model comparisons and fit
Parameters of goodness of fit were compared for each model, including values for
adjusted R2, Akaike information criteria (AIC) and Bayesian information criteria
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Forty-three participants were recruited to the Advanced MRI substudy of
MS-SMART and their baseline imaging data were used (see Chapter 2).
A score for the SDMT, taken as a marker of information processing speed,
was available for all participants. Data on premorbid IQ and cognitive leisure
activities were not available for this cohort. Data on educational status
were unavailable for eight participants. Only one participant was prescribed
medication with a potentially beneficial effect on cognitive performance
(modafinil) and due to concerns over the timing of taking medication on the
day of testing, as described in Chapter 7, this participant was excluded from
analysis.
Tissue segmentation failed for one scan, due to issues with image registration.
This participant was excluded from any further analysis based on tissue
compartment metrics. Tract segmentation and skeletonisation using Tract-Based
Spatial Statistics (TBSS, [75]) to derive PSMD were unaffected.
Following visual assessment of the tracts generated by probabilistic
neighbourhood tractography (PNT; (http://www.tractor-mri.org.uk)) for quality
control [MB], it was determined that anatomically acceptable representations of
all tracts of interest were present in 34 subjects. Of the remaining nine scans,
one tract in each could not be accurately extracted. Affected tracts were the
splenium (n = 2), the left arcuate fasciculus (n = 2), the left (n = 4) and right (n
= 1) corticospinal tracts. For these participants, their mean tract metrics were
calculated using the remaining eleven tracts. The participants with missing tract
data showed trends towards higher WMH volumes, higher tract MD and lower
FA (p = 0.06 to 0.11), all suggesting a higher level of disease burden. Group
maps of all tracts extracted are presented in Figure 8.1.
Descriptive statistics for this cohort are presented in Table 8.1, including
participant characteristics and volumetric imaging markers acquired from both
routine structural sequences and DTI.
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n Summary figures
Age (years) 43 58.0 (49.9, 62.0)
Sex (F/M) 43 30/13
Disease duration (years) 43 23.4 (15.6, 27.3)
BDI 43 6 (5, 11.5)
Drugs (Beneficial/Detrimental/Neither) 43 1/14/28
Education ≤ 12/> 12 years 35 13/22
SDMT (mean ± SD) 43 43.5 ± 12.1
ICV (ml) 42 1309 (1265, 1395)
Brain volume (ml) 42 1154 (1066, 1205)
WM volume (ml) 42 429.3 (403.4, 451.4)
WMH volume (ml) 42 31.1 (23.7, 44.4)
Mean WMH MD (µm2s−1) 42 1122 (1055, 1191)
Mean WMH FA 42 0.309 (0.296, 0.325)
Mean NAWM MD (µm2s−1) 42 768.8 (753.3, 802.8)
Mean NAWM FA 42 0.340 (0.308, 0.351)
Mean tract MD (µm2s−1) 43 861.6 (833.0, 930.0)
Mean tract FA 43 0.442 (0.415, 0.464)
PSMD (µm2s−1) 43 351.8 (309.8, 398.7)
Table 8.1: Clinical and imaging features of participants in the Advanced MRI substudy
of MS-SMART cohort. All continuous/numerical variables are given as median
(interquartile range) other than for SDMT. The second column ‘n’ indicates the
number of subjects for whom that data was available. BDI: Beck Depression Index;
FA: fractional anisotropy; ICV: intracranial volume; MD: mean diffusivity; PSMD:
peak width of skeletonised mean diffusivity; SDMT: Symbol Digit Modality Test;
NAWM: normal-appearing white matter; WM: white matter; WMH: white matter
hyperintensity.
8.3.2 Validity of acquired diffusion metrics
8.3.2.1 Compartment-averaged diffusion metrics
Distributions of MD and FA for all segmented tissue compartments are shown
in the boxplots of Figures 8.2 and 8.3. All differences in location and spread
of values between compartments were consistent with predictions based on their
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Figure 8.1: Group maps of the segmented fasciculi of interest projected onto Montreal
Neurological Institute standard space T1w volume, showing consistency of tract
segmentation across the cohort. Top row: genu, splenium, arcuate fasciculi (bilateral);
middle row: bilateral dorsal cingulate and corticospinal tracts; bottom row: bilateral
inferior longitudinal fasciculi and ventral cingulate.
known tissue characteristics, for instance cerebrospinal fluid (CSF) showed the
highest water diffusivity and brainstem showed the highest directional coherence,
supporting the validity of the segmentation.
Tissue labelled as abnormal (WMH) by the segmentation was associated with
increased MD and decreased FA (both p = 0.001) values when compared with
the NAWM compartment.
8.3.2.2 Peak width of skeletonised mean diffusivity
Peak width of skeletonised mean diffusivity is derived from skeletonised white
matter and summarises the spread of MD values. The histogram in Figure
8.4 shows the distribution of PSMD in the MS-SMART Advanced MRI cohort,




















Figure 8.2: Mean diffusivity (MD) in segmented brain compartments (n = 42). From
left to right, the tissue compartments are: brainstem, subcortical grey matter (GM),
cerebellum, cortical GM, cerebrospinal fluid (CSF), normal-appearing white matter















Figure 8.3: Fractional anisotropy (FA) in segmented brain compartments (n = 42).
Tissue compartments as per Figure 8.2.
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= 33/43, 77%). Although true normative data does not yet exist for PSMD,
these values correspond approximately to the ranges found by Baykara et al [92]
in healthy older populations.













Figure 8.4: Distribution of PSMD (n = 43).
Figure 8.5 shows PSMD plotted against the mean MD for the entire white
matter compartment (encompassing both WMHs and NAWM). Higher values for
white matter mean MD are clearly associated with a higher PSMD (Spearman
correlation: r = 0.77), i.e. a greater range of voxel MD values. The scatterplot
suggests a possible non-linear relationship, with a clearly positive gradient only
at higher levels, indicating that the two metrics are not supplying duplicate
information.
A similar relationship is shown in Figure 8.6 where PSMD is plotted against
WMH volume, with a positive, approximately linear relationship above a WMH
volume threshold of around 30ml. This supports an interpretation that an
increased inflammatory disease burden is associated with diffuse white matter
abnormality.
8.3.2.3 Within tract diffusion metrics
Boxplots summarising the mean MD and FA in all tracts extracted are presented
in Figures 8.7 and 8.8. The spread of values for each tract is partly due to
its size, as is apparent with the relatively small ventral cingulate; due to its
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Figure 8.5: Scatterplot of PSMD against mean white matter MD (n = 42). The
Spearman correlation was r = 0.77.
shape this tract has to be extracted separately from the rest of the much larger
cingulate. The large spread and generally higher MD values for the splenium are
related to higher inter-subject variation in anatomy and contamination from CSF
proximity.
Mean tract FA was higher for each participant than the mean FA for the
NAWM compartment, as shown in Figure 8.9, despite segmented tracts including
tissue from both WMH and NAWM compartments. This confirmed that the
most directionally coherent tissue had been extracted using the tractography
approach.
8.3.3 Covariance of diffusion metrics with other variables
8.3.3.1 Age and Sex
A comparison of mean diffusion metrics for male and female participants is given
in Table 8.2. The median age (years) of the female participants was 58.1 (IQR:
48.8, 61.8) and for the male participants 57.7 (53.5, 62.0). Significant (p < 0.05)
sex differences were found for NAWM and tract-averaged MD and FA. Spearman
correlations for diffusion metrics and participant age were all non-significant, with

















Figure 8.6: Scatterplot of PSMD against WMH volume (n = 42). The Spearman
correlation was r = 0.80.












NAWM MD (µm2s−1) 42 786 759 0.02 0.01 -0.33 0.56 −0.08
NAWM FA 42 0.331 0.348 0.03 0.08 0.37 −0.73 0.07
WMH MD (µm2s−1) 42 1144 1084 0.06 0.14 −0.20 0.61 0.11
WMH FA 42 0.304 0.316 0.28 −0.32 0.13 −0.27 −0.32
PSMD (µm2s−1) 43 369 334 0.10 −0.11 −0.29 0.80 −0.13
Mean tract MD (µm2s−1) 43 892 834 0.001 0.09 −0.23 0.64 −0.07
Mean tract FA 43 0.425 0.451 0.009 0.03 0.32 −0.73 0.01
Table 8.2: Median diffusion metrics by sex, with associated p-value from Mann-Whitney
U test; Spearman correlations with age, ICV, white matter (WM) volume and WMH
volume. Asterisks (*) indicate that WM and WMH volumes were adjusted for ICV.
Sex differences and correlations significant at the 5% level are highlighted in bold.






























































Figure 8.7: Boxplot of cohort MD for each of the 12 segmented tracts (total n = 43).
From left to right the tracts are genu, splenium, arcuate fasciculi, dorsal cingulate,
corticospinal tracts, inferior longitudinal fasciculi and ventral cingulate. All tracts are




























































Figure 8.8: Boxplot of cohort FA for each of the 12 segmented tracts (total n = 43).
















Figure 8.9: Scatterplot of mean FA for the extracted tracts against the corresponding
NAWM compartment value. The Spearman correlation was r = 0.82.
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8.3.3.2 Covariance with routine structural imaging markers
Intracranial volume also showed a significant correlation with several DTI-derived
markers, particular NAWM MD and FA. This is a recognised feature of DTI
relating to partial volume effects and the use of fixed voxel sizes [181], and
may confound measurement in individuals with smaller ICV. In addition, all
DTI-derived markers relating to white matter microstructure were significantly
(p < 0.001) correlated with WMH volume, with the exception of WMH FA
(p = 0.07). This suggests a possible unidimensional pathological pathway
linking inflammation and neurodegeneration. Spearman correlation coefficients
are presented in Table 8.2 and all correlations significant at the 5% level are
highlighted in bold.
8.3.4 The direct relationship of quantitative measures of tract
microstructure from DTI to cognitive performance
8.3.4.1 Compartment-averaged diffusion metrics
The relationships of the mean FA and MD within the NAWM and WMH tissue
compartments to the SDMT score are shown in the scatterplots of Figure 8.10.
These were all in the expected direction, with higher water diffusivity and
lower diffusion anisotropy being associated with lower test scores, however no
(Spearman) correlation was statistically significant from zero (p > 0.1).
8.3.4.2 Peak width of skeletonised diffusivity
The overall relationship of PSMD and SDMT score was in the expected direction,
with a Spearman correlation of r= −0.34 (p = 0.03). This was similar to that
found for WMH volume and SDMT in this population (r = −0.33; p = 0.03).
However there appeared little relationship with SDMT score at lower values of
PSMD, up to around 400 µm2s−1, suggesting that the overall association may be
driven by the higher values. The participant characteristics of those individuals
with high values of PSMD were examined with no notable differences seen. A
scatterplot of PSMD against SDMT is shown in Figure 8.11.
8.3.4.3 Within tract diffusion metrics
Scatterplots of the mean FA and MD for all tracts against SDMT are shown in
Figure 8.12. The Spearman correlations were r = 0.37 (p = 0.01) for FA and r
= −0.23 (p = 0.14) for MD.
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Figure 8.10: Plots of FA and MD against SDMT for NAWM and WMH tissue
compartments (n = 42), annotated with lines of best fit. No correlation was
significantly different from zero.
8.3.5 Addition of DTI-derived metrics to lesion burden in predictive
models
Following recalculation in this smaller cohort of the linear model developed in
Chapter Seven using participant characteristics and routine imaging markers to
predict SDMT score, WMH volume was found to be the only significant predictor
(p = 0.01) with sex being the next most significant (p = 0.05). This model is
summarised in column 1 of Table 8.3. The addition in turn (columns 2 to 6) of
each diffusion measure listed in Table 8.2, excepting those related to WMHs, did




1 2 3 4 5 6
Constant −3.44 0.87 13.45 4.15 −11.64 −22.58
p = 0.92 p = 0.99 p = 0.76 p = 0.91 p = 0.82 p = 0.60
Age (years) 0.06 0.06 0.06 0.07 0.06 0.05
p = 0.80 p = 0.80 p = 0.81 p = 0.79 p = 0.81 p = 0.83
Sex −10.42 −10.43 −10.69 −9.93 −10.21 −10.48
p = 0.06∗ p = 0.06∗ p = 0.05∗∗ p = 0.07∗ p = 0.07∗ p = 0.06∗
Educ. (over 1.19 1.20 1.51 1.57 1.09 0.98
12 years) p = 0.78 p = 0.78 p = 0.72 p = 0.71 p = 0.80 p = 0.82
Detrimental −4.79 −4.64 −5.87 −4.67 −5.23 −3.93
drugs p = 0.25 p = 0.33 p = 0.21 p = 0.27 p = 0.27 p = 0.37
ICV (ml) 0.04 0.04 0.05 0.04 0.04 0.04
p = 0.10∗ p = 0.12 p = 0.09∗ p = 0.16 p = 0.10∗ p = 0.15
WMHV (ml) −0.31 −0.30 −0.40 −0.22 −0.33 −0.21
p = 0.02∗∗ p = 0.05∗∗ p = 0.05∗∗ p = 0.29 p = 0.07∗ p = 0.24
NAWM MD −0.01




(µm2s−1) p = 0.59
Mean tract MD 0.01
(µm2s−1) p = 0.84
Mean tract FA 49.99
p = 0.50
AIC 256.0 258.0 257.5 257.6 257.9 257.4
BIC 268.0 271.5 271.0 271.1 271.4 270.9
Observations 33 33 33 33 33 33
R2 0.40 0.40 0.40 0.40 0.40 0.41
Adjusted R2 0.26 0.23 0.24 0.24 0.23 0.24
Residual 10.35 10.55 10.47 10.49 10.54 10.45
Std. Error (df = 26) (df = 25) (df = 25) (df = 25) (df = 25) (df = 25)
F Statistic 2.83∗∗ 2.33∗ 2.42∗∗ 2.41∗∗ 2.34∗ 2.44∗∗
(df = 6; 26) (df = 7; 25) (df = 7; 25) (df = 7; 25) (df = 7; 25) (df = 7; 25)
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table 8.3: Summary of linear models with SDMT as dependent variable and participant
characteristics and imaging markers as independent variables. Numbers shown in
the main table are model coefficients followed by associated p values. Predictor
abbreviations as per Table 8.1.
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Figure 8.11: Scatterplot of PSMD against SDMT (n = 43), annotated with line of best
fit. The Spearman correlation was r = −0.33.
8.4 Discussion
Using diffusion tensor imaging, it has been possible to extract valid markers
of tissue microstructure in the white matter of people with multiple sclerosis.
Differences found between segmented WMH and NAWM compartments were in
the expected direction, supporting the tissue segmentation and the extraction
of more diseased tissue in the WMH compartment. The relationship between
DTI-derived markers and age found in healthy populations [182] was not found
in this population, although the age range (34 to 65) was one in which this would
be expected. Variation in the degree of pathological changes appears to have
overpowered the normal changes from healthy ageing.
The majority of the water diffusion measures examined here were found to relate
to the SDMT, a marker of cognitive ability. However they were all highly
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Figure 8.12: Scatterplots of mean tract FA and MD against SDMT (n = 43) annotated
with lines of best fit.
covariant with WMH volume and it was not possible to demonstrate that DTI
provided any additional predictive value once WMH volume had been accounted
for. While it is tempting to interpret changes measured in normal-appearing
tissue as representing a distinct, neurodegenerative, disease component, it has not
been possible here to separate this from the effect of the inflammatory pathology.
Further work in larger cohorts may be able to clarify this. Based on the results
here, there is no evidence to reject a unidimensional disease model in which
focal inflammatory damage leads to widespread abnormalities in white matter
integrity.
Where the relationship appears more complex is in the suggestion of a threshold
effect seen with PSMD, above which inflammatory disease burden has a
deleterious effect on white matter integrity. Baykara et al [92] found similar
ranges of PSMD in three separate healthy populations and no difference in PSMD
between healthy controls and people with mild cognitive impairment and low
WMH loads. The results in this chapter, implementing PSMD measurement
for the first time in people with MS, appear remarkably similar. At levels seen
in healthy populations, PSMD appeared unrelated to SDMT. Overall this new
marker showed a stronger relationship to SDMT than any other measure derived
from mean diffusivity values. Further work should include testing the relationship
of PSMD to the more widely used marker of mean skeletonised MD and comparing
the strength of their correlation with cognition.
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The strongest overall correlation with SDMT for any diffusion metric tested
was found for mean tract FA. Focussing on the integrity of major tracts and
so minimising the confounding effect of crossing fibres may maximise the chances
of uncovering a true relationship between tract integrity and cognition. One
limitation to this work was using values averaged across all tracts, with equal
weighting to large and small tracts, including those known to have higher
variability. The tracts which could not be extracted occurred in individuals with
a more severe disease burden, potentially attenuating a detectable relationship
to the phenotype. A method of dimension reduction, for instance using principal
component analysis to extract a general factor of tract integrity [183] might help
with this issue, but the number of subjects was prohibitive in this case. While
it would have been possible to select only those tracts thought likely to have
cognitive functions, tractography was used here to provide a marker of global
white matter microstructure and examine its relation to a marker of distributed
cognition, so an inclusive approach seemed reasonable. The tracts extracted
represented a wide range of projections, incorporating commissural and projection
fibres, previously accurately and reproducibly segmented using PNT.
A further limitation to this work is the small study size. Interpretations discussed
here will need confirmation in larger cohorts, where it may be possible to separate
out cognitive effects related to both the WMH and NAWM tissue compartments.
The lack of healthy control data also limits interpretation of some findings,
although regression modelling was used to control for as many non-disease factors
as possible. Bias may also have been introduced during study recruitment, as
participants undergoing the advanced imaging protocol in MS-SMART were a
self-selecting subgroup.
It is often assumed that using advanced imaging markers to quantify pathological
changes in the normal-appearing white matter will provide a more accurate
assessment of the total burden of disease. However these results show that using
DTI in a population with fairly advanced disease has not supplied the missing
link in the cognitive clinicoradiological paradox. In a population in which chronic
neurodegeneration is expected to be the predominant active disease component,
it has not been possible to separate out its effect from already available measures




The clinicoradiological paradox persists. Using optimised imaging measures of
disease burden in multiple sclerosis has demonstrated a stronger relationship
between white matter hyperintensities and cognitive performance than most
reported in the literature, but this can still only partially account for the observed
variation. Clinically relevant tests of brain function and established neuroimaging
techniques cannot be made to agree, suggesting a flaw in our methods or the
questions we ask of them. However it must be remembered that given the many
factors, both known and unknown, affecting any psychological test and thus
attenuating associations with other disease markers, the correlations found here
are within the upper third of those published in psychological research [184].
Before considering the potential causes for the remaining mismatch and future
directions for research, we should consider whether in fact this matters. When
straightforward cognitive tests can be performed in the clinic, why should
prediction of function from imaging be useful?
The great unmet need in multiple sclerosis (MS) is for truly disease-modifying
drugs - those with a proven impact on longterm clinically relevant outcomes. A
need to understand the pathology underlying these outcomes is clear. Currently
available drugs act to reduce the shorter term impact of neuroinflammation,
while carrying the risks associated with manipulation of the immune system.
The development of new drugs, from initial laboratory investigations and animal
studies through to large cohort trials, is time and resource intensive. The
heterogeneity of MS and the difficulty in predicting individual disease outcomes
is well known. For a disease with substantial heterogeneity in disease course
and outcome, large numbers of people must be monitored for long periods to
convincingly demonstrate success and imaging-derived surrogate outcomes are
widely used to make this process more efficient. In clinical practice, with the
aim of minimising delays in starting appropriate and effective treatments and in
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discontinuing non-effective treatments, the availability of sensitive and objective
biomarkers of developing pathology becomes increasingly important.
The majority of new medications are specifically targeted against
pathophysiological processes known to be relevant in MS, such as
neuroinflammation, myelin repair and neurodegeneration. The need for reliable
biomarkers here is twofold; firstly evidence of the effect of any intervention on
these processes, in order to confirm our understanding of its action, and secondly
an understanding of the relationship between developing pathology and the
associated clinical phenotype. The clinicoradiological paradox exposes important
gaps in our understanding of where the relevant pathology lies and without
knowledge of the biological processes through which drugs act, we are restricted
to a passive ‘watch-and-wait’ approach to drug development, waiting for
clinically-measurable long term outcomes in response to treatments, effectively
a ‘black box’ approach to neurology. With an ultimate goal of targeting drugs
against pathology, the need for relevant biomarkers is clear.
With wider relevance, beyond the goal of effective treatments for MS, the gaps
in our knowledge relating measurable pathology to clinical outcomes expose
significant limitations in our understanding of brain function, both in health
and disease, and specifically the anatomical and physiological basis for cognition.
Decades of research in neuropsychology have provided evidence linking specific
functions to their associated brain regions, but the continued limitations in our
ability to predict clinical outcomes from neuroimaging demonstrate how much of
the brain’s complexity yet remains incompletely understood or beyond the reach
of current investigative tools. Studying failure of a function can tell us much
about the brain in health.
i
Any approach to tackling the cognitive clinicoradiological paradox involves many
decisions regarding what is both relevant and possible to measure. Both cognition
and radiological assessment of the brain are complex areas and can be studied
at multiple levels. An explicit declaration of assumptions made in addressing
these areas is therefore necessary to understanding the advantages of specific
approaches and potential reasons for discrepancies with other research.
Decades of psychological research have established that cognition is best
considered as a multidimensional construct, composed of a number of distinct
functions with some degree of shared variance. Although certain patterns
of deficits are recognised as characteristic of MS, significant inter-individual
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variation exists, increasing the numbers needed to demonstrate the relationship
of cognitive performance to any biomarker or the effect of any intervention.
Impaired information processing speed is the most frequently detected deficit
in MS and has been proposed as the ‘core’ cognitive deficit [28], mediating
others through disruption to connections between critical cortical regions. A
biological interpretation to this model is clear in the context of a disease known
for its primary attack on the myelin sheathing of white matter axons. The most
common approaches to assessing cognition in MS, either single tests incorporating
processing speed or mixed ‘batteries’ of different tests allowing calculation
of an overall cognitive index, implicitly recognise this idea of separate but
linked cognitive functions. The recently proposed Brief International Cognitive
Assessment for Multiple Sclerosis (BICAMS) monitoring tool [36] is consistent
with this, proposing the use of up to three tests of common deficits, with priority
if time is limited given to assessment of processing speed through the Symbol
Digit Modality Test (SDMT).
Different approaches to cognitive assessment are appropriate in addressing
different research questions. Focussed assessment of particular domains will be
suitable in attempting to localise particular functions. Measures of distributed
functions or summary measures from multiple separate functions, more likely to
relate to the global disease burden, will have more relevance in disease monitoring
and development of disease-modifying treatments. The practicalities of cognitive
assessment should also not be ignored; the best evidence will come from tests
that are reliable, acceptable to patients and straightforward to administer.
Developing an imaging framework of disease burden is similarly complex and
can be approached from many angles. Imaging models may focus on anatomical
structures of interest, putative biomarkers of particular pathological processes,
or technique-based approaches may seek to capture only the sum total of
abnormality using a particular imaging modality without explicit interpretation of
the underlying mechanisms involved. Volumetric and semi-quantitative markers
can be extracted from routine imaging sequences and fully quantitative markers
are becoming available from advanced imaging techniques, such as magnetic
resonance spectroscopy and diffusion tensor imaging (DTI). The psychometric
performance and clinical relevance of these newer markers has yet to be
established. Nevertheless at face value an attractive approach may be the use of
multiple features, providing more relevant information than focussing on single
markers.
For the purposes of this thesis, a decision was made to address the relationship
between cognitive function and imaging features using measures relating to
the total burden of brain disease. Cognitive assessments were selected from
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the available datasets at the highest level, using a reliable and established
marker of information processing speed. Radiological assessment of the brain
was primarily from a structural perspective, aiming to capture quantitative and
semi-quantitative information from the largest possible brain region for which
reliable metrics are available, the cerebral white matter, using commonly available
imaging sequences. The potential for additional value in using quantitative
markers derived from DTI to assess microstructural abnormalities beyond the
resolution of routine imaging sequences was also considered.
i
Apparent from the systematic review process reported in Chapter 3 was the
vast volume of already existing literature addressing the issue of the relationship
between cognition and imaging in MS and the variability in the methodology of
its investigation. Variety has its advantages - one method may yield insight where
others fail - but it does not follow that all investigations are equally valid and it
remains the case that individual small studies must be interpreted with caution.
While many approaches may be relevant in addressing specific research aims, the
investigators’ model describing the hypothesised relationship between cognition
and imaging, together with consideration of the appropriate level of analysis,
was rarely explicitly stated. Significant gaps in the literature were identified
regarding the psychometric performance of the assessment methods used and
any consideration of a non-linear relationship between cognition and imaging
features.
In many cases specific cognitive tests were chosen to address particular research
interests. Where summary measures of cognitive performance were sought, there
was some evidence of moves towards the use of common tests and similar or
overlapping test batteries. This was far from the case in their interpretation and
derivation of scores for use in analysis. A lack of control or normative data was
not always acknowledged and even when available its interpretation was often
unclear. The recording of potential modifiers of cognitive performance, such
as medication use and level of education, was also highly variable, as were the
methods for its inclusion, if at all, in analyses. However, acknowledging the
methodological heterogeneity in cognitive assessment in the existing literature,
a gradual move towards harmonisation of testing does appear to be underway,
with the increased use of common tests and continuing validation work on the
BICAMS monitoring tool.
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Moves towards consensus in image analysis methods are less apparent. Scientific
progress relies on replication of key results and dependence on ‘in-house’ software
outputs that cannot be easily accessed by other groups is clearly not optimal,
potentially prohibiting smaller research groups from contributing to the field.
The most frequently found image analysis outputs were derived from software
requiring some degree of observer input and data on reproducibility of these
methods was extremely limited. Previously published data on the psychometric
attributes of particular software may exist but needs to be clearly cited, while
bearing in mind that variation is likely if applied to a new population, or used by
new operators. It is unclear whether the near silence surrounding measurement
error relates to an embarrassment regarding its disclosure, or confusion over the
‘correct’ method for its assessment. Either way it should not be allowed to hinder
progress.
Moves towards greater consensus in the MS image analysis community seem vital
and overdue, with clearer reporting of methodology a prerequisite. Uniformity
of methodology is not necessary as long as different softwares lead to the
same results. Enhanced awareness of the role of measurement error and
greater transparency in reporting of reproducibility metrics is key. With an
inherently highly heterogeneous disease, attenuation of potentially significant
results due to limited understanding of tool performance makes inefficient use
of resources. Wider availability of analysis tools would be beneficial, allowing
easier comparison between methods and accumulation of data regarding their
performance in different populations. This led to the recommendations [185]
that the development of standardised datasets should be prioritised to facilitate
method comparison and benchmarking. The equivalence of all segmentation
softwares remains to be established and comparison of methodologies may
highlight particular advantages. While preference should be given to use of widely
applicable and accessible software methods, restricting practice to a limited set of
analysis tools is not necessarily beneficial. Straightforward techniques should be
favoured, but discouraging innovation would risk missing out on insights arising
from exploration of newer techniques. Some features may still be best assessed
using non-automated methods, such as visual scores.
The overall effect size derived from the meta-analysis of the published literatures
suggested that variance in cognitive performance had not been fully accounted
for by measures of WMH burden. However concerns over methodological
heterogeneity meant this result was interpreted with caution. No study was
found considering a non-linear relationship. Re-evaluation of this relationship
between cognition and imaging measures of disease therefore seemed critical,
with appropriate levels of measurement both for cognition and imaging and using
metrics with clearly defined performance characteristics.
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i
Expert manual segmentation on imaging has become the accepted reference
standard for quantifying disease burden, however this should not be confused
with any claims to represent ‘ground truth’. Pathological specimen examination
may demonstrate certain features more clearly, but these studies will also
carry measurement error, be limited by availability of samples and may not be
applicable to the majority of cases of people living with MS. Other features may be
better demonstrated by in vivo imaging techniques and with robust measurement
will have greater potential for wider use in disease monitoring.
Manual segmentation is an imperfect tool, but remains the standard validation
procedure for new techniques in tissue segmentation. While this may seem a
pragmatic decision in the face of limited availability of pathological samples,
it may also support a misplaced belief in the stability of its outputs. Results
based on one manual segmentation may not match those performed elsewhere,
at different times or in different circumstances. The investigation reported in
Chapter 4 shows that significant shifts in measurements across a cohort can occur
even with a single observer, and large discrepancies can be found between two
observers with similar training.
There are many reasons why two manual segmentations may provide different
estimates of disease burden, both in terms of disease volume and spatial location.
Is the aim of segmentation to identify all areas of white matter that appear
abnormal, all those that are thought to represent a previous acute inflammatory
attack or simply the most hyperintense voxels? If only asked to identify voxels
of a certain brightness, then a computer is clearly going to be the best choice for
generating outputs, but the validity of this information is unclear. Expert human
observers may provide advantages in interpreting more subtle abnormalities and
normal variants and artefacts, as well as adjusting for changing background
intensity. Decisions on the significance of diffusely abnormal (‘dirty’) white
matter may be important in quantifying the totality of disease, but are unlikely to
be straightforward. The inherent subjectivity and resulting discordant measures
is hardly surprising.
Even with the most diligent approach to tackling reproducibility in manual
segmentation, the consistency offered by fully automated methods may make
them more appropriate for use in generating reliable biomarkers, particularly in
large cohort studies, although demonstrating this over time may be more difficult.
Where manual segmentation is used for direct comparison with phenotype
or for benchmarking a new technique, a greater awareness of the associated
measurement error is necessary. Transparency in reporting reproducibility
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measures, development of standard datasets and specification of observer training
should be encouraged.
i
Several of the earliest papers relating cognition to imaging changes identified in
the systematic review reported in Chapter 2 used visual rating scales in some
form, but these appear to have been largely abandoned in the more recent
literature in favour of volumetric outcomes. Visual rating scales have become
widely accepted in other conditions, particularly so for the white matter changes
associated with small vessel disease (SVD) and ageing; the data here suggest
that they may be useful in MS. An opportunity for using visual ratings as an
outcome of interest or a stratification tool is clear and presents many potential
advantages.
A limited number of imaging appearance categories, such as in the widely used
‘Fazekas’ scale for white matter changes in SVD, may seem too restrictive to fully
explore research findings. However given the issues surrounding reproducibility in
volumetric measures, described above, a false reliance on small changes in WMH
volume may be misleading. Visual ratings of white matter disease severity have
been found to show a high correlation with volumetric measures in both SVD [174]
and for MS in the work described in Chapter 5. The measurement tool used
should be fitted to the purpose and a decision on the use of volumetric or visual
rating measures may depend on the incremental change in WMH burden that
is considered relevant. Whether visual ratings are suitable for use as a research
outcome may depend on the sensitivity required, but clearly offer advantages, not
least time efficiency and ease of collaboration across sites.
Additional value from visual assessments may come from their ability to assess
more than one aspect of disease appearances. The heterogeneous manifestations
of MS, in terms of both the disease and the response of the central nervous
system, varying between people and over time, is unlikely to be fully captured in
a unidimensional outcome. There is an apparent disconnection between imaging
interest in the pattern and location of visible abnormalities in the earlier stages,
and the reductive, volumetric approach in established disease. Whether this
reflects a lack of confidence in the ability of any measurement tool to capture the
complexity of disease appearances, or merely a lack of knowledge of alternatives,
is unclear.
In the work described here, using the largest available cohort made up of people
with early and late stage disease, it appeared that a measure of lesion burden
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and an indicator of the presence of cavitation, i.e. more severe damage, were
both significant independent predictors of cognition. This work should however
be interpreted with caution, given its development in two cohorts with different
clinical characteristics as well as different imaging protocols, and will need
testing in further groups. If confirmed, this would suggest all WMHs should
not be considered equal and failure of remyelination may be a critical factor in
determining disability.
A final substantial advantage for visual ratings is their potential for translation:
between research and clinical work, between scanners, between centres and
countries. Although the potential for widespread use of a visual rating scale
in MS clearly exists, a significant obstacle will be standardisation. Individual
observers will always show variation in their assignment of scores to the countless
possible imaging appearances and methods must be found to both minimise and
quantify this variation. More work will be needed in the development of training
datasets for new raters and the effect of making more sample images available
for guidance. Given the limited number of sample images provided in the work
described here, the results are encouraging.
The visual rating work described in Chapter 5 was large for a reproducibility
study, but clearly needs testing in new and varied cohorts, with the involvement
of more observers. Larger studies will also be needed to show if any of the less
common features identified have relevance in their relationship to phenotype.
Additionally, the hierarchical structure for rating features as used here would
allow for alternative shorter assessments, and these may be more appropriate for
particular research purposes. Given the modest correlation consistently found
between imaging appearances and phenotype, a straightforward assessment of
WMH burden with a limited number of categories may prove sufficient for purpose
where this needs to be taken into account.
i
Where volumetric and spatial representations of the disease burden are needed,
the use of automated segmentation methods, such as the one presented here,
clearly offers potential. Consistent output measures may be obtainable in
large cohorts, avoiding the need for time consuming and subjective manual
segmentation. However the validity of any segmentation tool is more difficult
to establish and although consistent, a software output optimised to best
resemble a reference segmentation will be affected by the reliability of that
segmentation.
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Clarity in the literature over the ‘correct’ metric for demonstrating acceptable
reproducibility is not apparent. This may relate to confusion over the strengths
and weaknesses of different metrics or a reflection that different aspects of
reproducibility may be relevant in different situations. High sensitivity or
specificity does not necessarily mean a close fit to the reference segmentation
and the appropriate measurement tool may not necessarily be the most sensitive
one. Work towards a consensus approach in the image analysis community on
reporting metrics of agreement and reliability would be beneficial, remembering
that any of these will depend on the cohort in which the technique is tested. While
it would be impractical to retest all tools before each new use, an awareness of
how far they have been tested and in which cohorts is necessary to understanding
the validity of results gained.
In the absence of a true pathological reference for comparison, the retention of
a probabilistic element to the output may be beneficial in interpreting results
based on a segmentation, such as overlaid quantitative metrics. The process of
manual segmentation forces a binary decision on the normality of each voxel,
which may not be a realistic expectation of any imaging sequence. Without
greater availability of pathological samples for comparison, proving the validity
of either manual or automated segmentations will remains challenging, but the
removal of any subjective element to the process is clearly advantageous.
An alternative approach to establishing validity would be optimising the
segmentation process to maximise the association of its outputs with phenotype,
essentially allowing test scores or clinical findings to aid interpretation of imaging
features. While it may be possible to adjust segmentation parameters to increase
the association between cognitive and imaging findings, this would clearly require
validation in large cohorts and careful interpretation. If successful, this would lead
to a reframing of the clinicoradiological paradox - a higher proportion of variance
in cognitive outcomes may be explained using imaging outputs, but not those
with any easily interpretable pathological significance.
i
The results presented here based on routine imaging sequences, using both
the volumetric and semi-quantitative tools for disease burden analysis, showed
a stronger relationship with cognitive performance than the overall result of
the meta-analysis of the published literature. Many factors will have affected
this, but the measurement tool used and its optimisation appear relevant
considerations.
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Nevertheless, variance in cognitive performance is far from fully explained by
any measure of WMH burden. The difficulties described in defining consistent
edges to WMHs suggest the possibility that changes within the surrounding white
matter may also be relevant, leading to the current interest in using quantitative
imaging techniques to examine them.
i
If consideration of the inflammatory component of the disease burden in MS
cannot fully explain phenotypic changes, then a more detailed examination of
the neurodegenerative component appears a logical next step in appreciating
the total disease burden. If neurodegeneration progresses with at least partial
independence from inflammatory damage, then biomarkers of this process may
contribute additional explanatory power in predicting cognitive performance. The
work described in Chapter 8 used DTI-derived biomarkers of tissue microstructure
to quantify diffuse changes outwith the regions of inflammatory damage visible
on routine imaging.
A variety of metrics have been derived from DTI data and a focus on particular
tissue structures may be appropriate to different research questions. Disruptions
to microscopic tissue architecture are inferred from these markers but the choice
of the ‘correct’ metric to use is not always clear; all remain non-specific and
must be interpreted with caution. For the purposes of this thesis, the focus
was on capturing the diffuse and ill-defined changes within the white matter
that could not be quantified on routine imaging sequences. Straightforward
DTI metrics within the ‘normal-appearing’ white matter compartment, derived
using automated segmentation, were considered first. Tractography was used to
extract the most highly coherent white matter, recognising that tissue complexity,
particularly crossing fibres, may confound measurements elsewhere, and the
major white matter tracts may be highly relevant in influencing processing
speed. A novel metric, peak width of skeletonised mean diffusivity (PSMD),
derived using the Tract-Based Spatial Statistics (TBSS) procedure, was used
as an alternative method of assessing the most coherent tissue within the white
matter skeleton and summarising the spread of mean diffusivity values rather than
any average measure. Where feasible, imaging tools which are as close to fully
automated as possible offer clear advantages and PSMD has been proposed with
a fully automated processing pipeline freely and publicly available for ongoing
evaluation. The results here are thought to be its first use in the context of
MS.
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The DTI-derived metrics tested were found to show a range of values across
the cohort with the majority of these correlating with a marker of cognitive
performance. However, no correlation was stronger than that found for measures
of WMH volume and no additional value was found within models predicting
cognitive performance from imaging and non-imaging data.
Nowhere in this work, with the possible exception of the visual rating assessment,
has it been possible to show that using two measures of white matter disease
severity is ever better than one, in determining cognitive performance. The
high correlations between all markers of disease, including those interpreted to
represent the inflammatory and neurodegenerative components, mean that very
large cohorts would be needed to show any separate effects from each. While
they may have separate effects, it is possible that one pathological component
is of greater importance in determining cognitive function and whichever we
attempt to measure is providing a surrogate marker for it. The work here
provides no evidence to reject a disease model in which inflammatory damage
is the driver for diffuse white matter degeneration and together these lead to a
decline in cognitive performance. In a wider context, reports of exploratory uses
of advanced imaging techniques must ensure a description of their covariance with
more straightforward and established measures of disease burden.
i
White matter pathology, as detectable by current imaging techniques, accounts
for only a small proportion of the variance found in cognitive performance of
people with MS. This prompts a reconsideration of whether the relationship
between pathology and cognition has been addressed within the appropriate
framework and using the optimal tools.
Given that many cognitive functions show regional localisation, the decision
of which outcome to use may be highly relevant. All analysis presented in
this thesis is based on an assumption that information processing speed is a
distributed function, reliant on widespread white matter integrity. The SDMT is
straightforward, quick and unlikely to be affected by physical disability or fatigue.
It has recently been proposed as the single most useful test for the BICAMS.
However an alternative approach could be the use of multiple cognitive tests and a
method of dimension reduction, such as factor analysis, for extracting a marker of
overall performance. This may be advantageous, but is likely to be a more lengthy
and resource intensive procedure, requiring specialised skills and potentially
limiting participation and applicability. As with all tests, the attenuating effect
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of poor reliability on observed correlations with other disease-related variables
must be considered.
Cerebral white matter was selected for study here as the structural unit of interest
relevant to distributed cognitive function and the value in disease markers derived
from structural imaging techniques for this region was considered. This leaves
open the question of how far white matter pathology can be considered to be
fully characterised by these markers and whether it is necessary to consider
other structures, for instance cerebellum, deep nuclei and cortical grey matter, in
searching for pathological correlates of cognitive performance. A trend towards a
significant improvement in model fit was found when adding total brain volume
rather than just white matter volume as a predictor, which would support
this.
The inherently multicontrast nature of magnetic resonance imaging (MRI)
suggests that any unidimensional measure extracted will be limited in the
representation it provides and this seems even more likely when dealing with
a complex and highly variable disease; imaging features are another aspect of MS
to show its characteristic heterogeneity. While summarising all this variability
into practical research outcomes may seem unfeasible, the retreat to only using
unidimensional WMH volume may be too simplistic. The assessment of full and
partial lesion cavitation considered in Chapter 7 acknowledged that WMH volume
alone is a crude marker of pathology, encompassing a range of degrees of tissue
damage. The model fit improved with this addition of cavitation presence as a
predictor, but this result should be interpreted with caution given its reliance on
imaging data from two very different cohorts.
Additional tissue characterisation, such as that derived from advanced techniques
including magnetisation transfer imaging and magnetic resonance spectroscopy,
may be relevant and necessary in determining the total disease burden. Beyond
the resolution of all current in vivo imaging techniques are pathological and
adaptive synaptic changes, with information about these inferred on a much larger
scale by functional MRI techniques. Adaptive changes are known to occur in MS
and this capacity for neural plasticity may vary greatly between individuals and
across the disease course.
A large number of non-disease variables, such as age, education and medication,
are known to affect performance in cognitive tests. As far as possible these have
been taken into account in the analyses described, but the data available was far
from complete and a greater awareness of the need for considering these factors
is clearly necessary. No consensus opinion on a full group of variables affecting
cognitive performance is yet available and a list of variables to consider may grow
as research on this topic develops. It is possible that factors such as fatigue and
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motivation at the time of testing that are very difficult to measure may be highly
influential on cognitive outcomes. Given the incomplete assessment of cognitive
modifiers here, perhaps a correlation of test scores and WMH volume of close to
0.5 is higher than might be expected, and whether this can be improved in more
complete datasets should be investigated.
i
The most straightforward methods for examining the relationship between
two numerical variables are tests of their linear association, but there is no
fundamental reason regarding the neural basis for cognitive performance why this
should be the case. Compensatory neural reorganisation is found in many brain
diseases and there is evidence from functional imaging to support its occurrence
in MS. Repair processes can take place to some extent, possibly up to the point at
which recruitment of new and functional oligodendrocytes is exhausted. Network
redundancy may also be built into the brain, explaining the accumulation of
‘silent’ inflammatory lesions without any recognised clinical event. These factors
make it more plausible that a certain degree of pathology can exist without any
associated deterioration of performance in skills relying on widespread neuronal
integrity. The model of a ‘dose-response’ curve may be more appropriate than a
linear relationship, with a decline in information processing speed only occurring
above a certain level of disease burden.
The model of a non-linear relationship between WMHs and cognitive performance
is supported by the work presented here, although further investigation of this
possibility is clearly required. The varying effect sizes reported in the published
literature (see Chapter 3) appeared partly related to the magnitude of the WMH
burden itself, greater effect sizes being reported in cohorts with overall larger
volumes of disease. In the MS-SMART cohort, a group of individuals with
established disease and a wide range of WMH volumes, this also appeared to be
the case, with a steady decline in cognitive performance associated with WMHs
only at higher levels.
The DTI-derived data also supports the idea of a ‘threshold’ effect of WMHs.
Using the novel marker PSMD to measure the spread of MD values across
the white matter skeleton, there was tentative evidence that this spread is
relatively stable, and similar to published control populations, up to a certain
WMH volume. Beyond this, PSMD increased, suggesting diffuse damage to
the white matter, and these values were associated with declining cognitive
performance.
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If this non-linear effect of disease burden on phenotype is confirmed, the
consequences may be important. It would provide support for aggressive
treatment approaches in the early disease stages, with an aim of preventing the
disease burden reaching a threshold at which compensatory mechanisms and/or
repair processes are no longer adequate to prevent disability accumulation. On a
more prosaic level, a dynamic relationship between disease burden and phenotype
further reinforces the need for published research to provide full descriptions of
cohorts studied, particularly their WMH burden. Results should be interpreted
only with reference to people at similar disease stages.
i
Harmonisation of standardised cognitive assessments in MS has been proposed
and widespread validation studies of these tests are underway. A similar consensus
in the approach to image analysis methodology and its reporting is not yet
apparent. Heterogeneity in research methods for investigating this heterogeneous
disease adds to the confusion in the overwhelming body of published research
and is unlikely to indicate the most efficient use of resources. Encouraging the
reporting of reliability metrics for all measurement tools used is a critical first step
and an understanding of the role of measurement error in attenuating observed
results will guide correct interpretation of future results.
In defining a basic model linking measures of pathology with cognition, further
work on identifying all potential modifiers of cognitive performance, including
those unrelated to disease burden, is necessary. Recording of variables already
known to be relevant should become standard along with their consideration as
part of any analysis. Different factors may be critical at different disease stages
and results should be extrapolated to new cohorts with caution.
In considering where the remainder of the variation in imaging correlates of
cognitive performance lies, optimisation of measurement tools is vital. Synthesis
of markers derived using different imaging techniques, such as multimodal white
and grey matter assessment, may yet prove useful, although the advanced
imaging markers tested here were not shown to carry any additional benefit to
routine imaging markers in terms of predicting cognitive outcomes. A major
breakthrough in understanding cognitive function in MS may await advances in
imaging that can quantify brain architecture at the synaptic level.
Even with optimised measurements, the relationship to cognitive outcomes
is unlikely to be straightforward and system redundancy, capacity for repair
and reorganisation are possibilities requiring further investigation. Sources of
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variation beyond the reach of current in vivo imaging techniques, such as synaptic
and molecular adaptation may be necessary considerations in producing a closer
approximation to the true burden of disease burden. Hidden capacities of the
human nervous system may allow the cognitive clinicoradiological paradox to




Protocol for systematic review of
relationship between cognitive
performance and total white
matter lesion burden
AIM
To systematically review the published evidence
describing the relationship between standard structural
MRI measures of white matter lesion burden in people




• ISI Web of Knowledge
• Embase
SEARCH TERMS
• ‘multiple sclerosis’ and
• ‘cognitive’ or ‘cognition’ and
• ‘magnetic resonance imaging’ or ‘MRI’ or ‘MR
imaging’
SEARCH FILTERS
• Articles published in the English language
• Research using human subjects











• Primary literature (reviews and data published only
in abstract form excluded)
• Study of adult patients only (age ≥ 18 years)
• Neither including nor restricted to clinically isolated
syndromes
• Not a duplicate publication
• Not presenting previously published data
• Contemporaneous capture of imaging and cognitive
data
• Not subsequently retracted
• Primary aim of the study is to explore the




• Screening of references from review articles
identified in the initial search.
• Hand search of archives of the journals Neurology,
Multiple Sclerosis and the American Journal of




• Study quality assessment (see Appendix C), based
on STROBE guidelines
• Study design, number of participants, interval
between cognition & imaging
• Participant characteristics: age, sex, disease
phenotype
• Cognitive testing methods: tests/batteries used;
blinding, identity and training of tester; use of
normative data; recording of potential confounders
- age, sex, education level, premorbid IQ, cognitive
leisure activities, affective disorders and drug
history
• Image acquisition: magnet field strength, details of
sequences performed
• Image analysis methods: preprocessing steps;
sequence used to measure lesion burden; lesion
quantification technique; softwares used; blinding,
identity and training of analyst; reliability measures
• Statistical analysis methods; controlling for
confounders
• Summary statistics for lesion burden




Record of search strategy for
systematic review of literature
Medline
Searched via OVID platform, on 01/07/15, with 671 references retrieved. The
search strategy is shown below.
Searches Results
1 multiple sclerosis.mp. or Multiple Sclerosis/ 56333
2 magnetic resonance imaging.mp. or Magnetic Resonance Imaging/ 353245
3 mri.mp. 144054
4 mr imaging.mp. 32694
5 2 or 3 or 4 382327
6 cognitive.mp. or Cognitive Reserve/ or Delirium, Dementia,
Amnestic, Cognitive Disorders/ or Cognitive Science/ or Mild Cognitive
Impairment/
208670
7 Cognition Disorders/ or Cognition/ or cognition.mp. 133903
8 6 or 7 260390
9 1 and 5 and 8 742
10 limit 9 to english language 672
11 limit 10 to retracted publication 1
12 10 not 11 671
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Embase
Searched via OVID platform, on 01/07/15, with 1145 references retrieved. The
search strategy is shown below.
Searches Results
1 multiple sclerosis.mp. or multiple sclerosis/ 94203
3 cognition/ or cogniti*.mp. 426368
4 1 and 2 and 3 1844
5 limit 4 to english language 1755
6 limit 5 to (conference abstract or conference paper or conference
proceeding or ‘conference review’)
610
7 5 not 6 1145
Web of Science
Searched on 01/07/15, with 1250 references retrieved. The search strategy is
shown below.
Searches Results
1 TOPIC: (magnetic resonance imaging) OR TOPIC: (mri) OR TOPIC:
(mr imaging)
343471
2 TOPIC: (cogniti*) 426125
3 TOPIC: (multiple sclerosis) 90559
4 3 AND 2 AND 1 1396
5 3 AND 2 AND 1 Refined by: DOCUMENT TYPES: (ARTICLE OR
EDITORIAL MATERIAL OR REVIEW)
1324
6 3 AND 2 AND 1 Refined by: DOCUMENT TYPES: (ARTICLE





To ensure recent papers not yet indexed on Medline were also included, the
PubMed database was also searched using the same search terms, with 816
references retrieved. The search strategy is shown below.
((((((magnetic resonance imaging) OR MRI)) OR MR imaging)) AND




Quality assessment criteria used
in systematic review of
literature
The quality assessment criteria described below were modified from the STROBE
(Strengthening the Reporting of Observational studies in Epidemiology) [112]
checklist.
Where all key points are met, 1 point is awarded. Where the study meets most
but not all of the applicable criteria, or only part of the relevant information is
provided, a score of 0.5 is awarded.
Introduction
OBJECTIVE: State specific objectives, including any prespecified
hypotheses.
The study should have a clearly stated objective mentioning white matter lesion
volume as a metric of interest (awarded 0.5).
Full credit will only be given where the objective specifies what imaging
sequence(s) will be used to measured lesion volume and what cognitive measure
is used to examine the relationship between the two outcomes.
[0] [0.5] [1]
Methods
STUDY DESIGN: Present key elements of study design early in the paper.
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The study design should be presented clearly, i.e. retrospective or prospective
recruitment, case-control studies, or a sub-study of part of a larger study.
Prospective recruitment to address the study objective is considered preferable
and a clear statement of this is needed for 1 point. A retrospective study design
will be awarded 0.5.
Where participants are taken from a cohort being used for multiple (sub)studies, a
maximum of 0.5 can be awarded, unless cognition and imaging relationships are
clearly the primary aim of the overall study and cross-sectional baseline data
are being used. Enough detail should be provided to ensure results are not
duplications of other published work.
[0] [0.5] [1]
SETTING: Describe the setting, locations, and relevant dates, including periods
of recruitment, exposure, follow-up, and data collection.
The dates of recruitment and testing should be provided. The delay between
cognitive testing and imaging should be specified and less than 6 months. Both
the above criteria are necessary for 1 point, either alone will be awarded 0.5.
A description of the clinical setting (e.g. tertiary referral centre, multiple
district general hospitals etc) is considered optimal, but is not necessary for full
credit.
[0] [0.5] [1]
PARTICIPANTS: Give the eligibility criteria, and the sources and methods of
selection of participants.
The authors should have clearly stipulated the criteria they used to include (and
if applicable, to exclude) subjects into the study. A positive statement of who
was sought for recruitment (whether any person with MS, or e.g. only people
with a particular clinical phenotype) with relevant exclusion criteria is necessary
for 1 mark.
Participants should not be excluded solely on the basis of higher levels of physical
or cognitive disability, and where recruited subjects were unable to tolerate MRI
this should be recorded.
[0] [0.5] [1]
The recruitment should be either a consecutive or random sample of eligible
participants. Where this is unclear, the study will be awarded 0.
[0] [1]
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VARIABLES: Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria, if applicable.
The cognitive tests performed should be specified. Whether results were
interpreted relative to a control population or published norms should be clearly
stated/described.
The definition of total lesion volume should be clearly defined, including
the brain regions covered (whether deep grey matter included or excluded,
whether posterior fossa included and how defined), the MRI sequence used for
measurement and whether the results were adjusted for total (estimated) brain
volume.
Clear definitions as above are required for both imaging and cognitive outcomes
for a score of 1. Where one of these is unclear, a maximum of 0.5 will be
awarded.
[0] [0.5] [1]
Potential confounding factors, including age, sex, education, drugs, pre-morbid
IQ, pre-morbid cognitive leisure activities & affective disorders, should be
measured. A score of 1 will be awarded where all these are identified, and 0.5 if
≥4 of them.
[0] [0.5] [1]
DATA SOURCES/MEASUREMENT: For each variable of interest, give sources
of data and details of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than one group.
The person(s) performing the cognitive testing should be identified, with their
level of training/experience.
Enough data should be provided to replicate the imaging sequences. This should
include at least the type of sequence performed (e.g. spin echo, gradient echo),
slice thickness and inter-slice interval, and preferably the pulse parameters (TE,
TR, flip angle, FOV, matrix size), number of slices and magnet strength.
The method for measuring/estimating lesion volume should be clearly described,
with details of the software package used if applicable. The person(s) performing
the analysis should be identified with their level of training/experience. Measures
of intra-/inter-observer variability should be provided.
All of the above criteria must be met for a score of 1; where ≥50%, but not all,
of the relevant information is presented, the study will be awarded 0.5.
[0] [0.5] [1]
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BIAS: Describe any efforts to address potential sources of bias.
Cognitive testing and image analysis should both be performed by individuals
blind to the results of the other and this should be clearly stated. Where there
is only a statement that the image analysis was performed blind to the cognitive
results, 0.5 will be awarded, otherwise the study will be scored 0.
Ideally the image analysis and cognitive testing should be carried out blind to
(as far as possible in the case of cognitive testing) all data on clinical status and
confounding factors.
[0] [0.5] [1]
STUDY SIZE: Explain how the study size was arrived at.
A calculation of study size should be provided.
[0] [1]
QUANTITATIVE VARIABLES: Explain how quantitative variables were handled
in the analyses. If applicable, describe which groupings were chosen and
why.
Ideally, the full range of cognitive scores and lesion volumes will be used for
the analysis, with or without transformation to Z-scores. This should be clearly
stated and correlations using the full range of values or correlations by rank will
be awarded 1 point.
If participants are categorised into groups by results of cognitive status (or, less
likely, lesion volumes) the justification of the group definitions should be provided
and boundaries pre-specified. A maximum of 0.5 will be awarded where outcomes
are dichotomised (or otherwise grouped) for analysis.
[0] [0.5] [1]
STATISTICAL METHODS: (a) Describe all statistical methods, including those
used to control for confounding. (b) Describe any methods used to examine
subgroups and interactions. (c) Explain how missing data were addressed. (d)
If applicable, describe analytical methods taking account of sampling strategy. (e)
Describe any sensitivity analyses.
Statistical methods should be clearly described, ideally correlations between
scores of cognition and lesion volume.
Unadjusted correlations should be calculated prior to controlling for potential
confounders. If either unadjusted correlations or controlling for confounders is




PARTICIPANTS: (a) Report numbers of individuals at each stage of study,
e.g. numbers potentially eligible, examined for eligibility, confirmed eligible,
included in the study, completing follow-up, and analysed. (b) Give reasons for
non-participation at each stage. (c) Consider use of a flow diagram.
Participants recruited but not completing either cognitive testing or imaging
should be specified. If this is unclear, a score of 0 is awarded.
[0] [1]
DESCRIPTIVE DATA: (a) Give characteristics of study participants (e.g.
demographic, clinical, social) and information on exposures and potential
confounders. (b) Indicate number of participants with missing data for each
variable of interest.
Summary statistics for basic demographic data (age, sex) and MS phenotype
should be provided. If this is not given, a score of 0 will be awarded.
Information on recent steroid use and disease-modifying therapy is considered
necessary for a score of 1, but not full results of all potential confounders. Ideally
these would be provided in supplementary material.
If results of multiple cognitive tests are used for analysis, the number of
participants with incomplete data for each test should be given. If this is unclear,
a maximum of 0.5 can be awarded.
[0] [0.5] [1]
OUTCOME DATA: Report numbers of outcome events or summary
measures.
Summary statistics should be presented for both cognitive outcomes and lesion
volumes. These should include measures of the dispersion as well as central
tendency. Where this is incomplete, e.g. only the numbers of participants
categorised as cognitively impaired versus not impaired are provided, a maximum
score of 0.5 can be awarded.
[0] [0.5] [1]
MAIN RESULTS: (a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision (e.g., 95% confidence interval).
Make clear which confounders were adjusted for and why they were included. (b)
Report category boundaries when continuous variables were categorised. (c) If
relevant, consider translating estimates of relative risk into absolute risk for a
meaningful time period.
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Unadjusted outcomes should be presented for cognitive data and, if applicable,





Table of cognitive tests and
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reference
data)





BRB-N 8 Both N Y (Italian
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BRB-N 8 Both N Y (Published
reference
data)
≥ 2 SD below
mean on 1 subtest
& ≥ 1.5 SD
on another; or
≥ 1.5SD below
mean on ≥ 3 tests.
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6 Both N Y (Italian
population)
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Unnamed 4 Both Y Y (Previously
published
control data)
≥ 2 SD below
mean on 1 test
and ≥ 1.5 SD on
another, or ≥ 1.5






























































SDMT 1 SDMT N N N/A
Zivadinov
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Unnamed 10+ N N N Unclear
Comi
1995
Unnamed 10+ N N Y (Italian
population)

















Ron 1991 Unnamed 10+ N Y Y (Controls) N/A
Pozzilli
1991
Unnamed N N Y Y (Controls) ≥ 2 SD below






























Unnamed 8 N Y N ≥ 1,2 or 3 SD
below control
mean
Summary of approaches to cognitive testing in all included
papers in systematic review (Chapter 3). Y: Yes; N: No; N/A:
Not applicable; BRB-N: Brief Repeatable Battery; MACFIMS:
Minimal Assessment of Cognitive Function in Multiple Sclerosis;
PASAT: Paced Auditory Serial Addition Test; SD: Standard





Data collection form used in
initial pilot study of visual rating
scale for MS imaging features
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 Scan ID:     Reader: 





T2/FLAIR white matter lesions  
        based on Fazekas scoring  
 
Lobar scores (images on left for guidance) 
0: None 
1: Discrete lesions 
2: Beginning of confluence or  >5 non-
confluent lesions 




1: Caps / pencil-thin lining around ventricles 
2: Smooth halo around ventricles 
3: Irregular periventricular hyperintensities 
extending into deep white matter 
 
Fazekas, F, et al. AJR 1987 149(2): 351-6. 
 
 
Juxtacortical and cortical lesions :  Number of lesions in each lobe which abut or involve cortex. 
 Scoring:  0: None  1: 1-2  2: 3-4  3: ≥5 
 
Cavitated lesions: Number of cavitated lesions. (Defined as lesions which are close to CSF signal on all sequences.) 








































       
   Frontal R       
L       
   Parietal R       
L       
   Temporal R       
L       
   Occipital R       
L       
   Insula R       
L       
        
Periventricular 
white matter 
R       
L       
Corpus callosum       
Basal ganglia R       
L       
Brainstem       
Cerebellar 
peduncles 
R       
L       
Cerebellar 
hemispheres 
R       
L       
! ! !
! ! !
2 1 3 
All ratings 0 – 3.  Basal ganglia score to include striatum, globus pallidus, thalamus and internal capsule. 
 
Lobes definitions: 
Frontal: anterior to 
central sulcus 
 
Parietal: anterior to 
parieto-occipital sulcus; 
superior to posterior 
extent of Sylvian fissure 
 





Temporal: lateral to 





 Scan ID:     Reader: 




























ENLARGED PERIVASCULAR SPACES 
Defined as small, sharply delineated structures of CSF intensity 
measuring up to 3mm and following the course of perforating vessels. 
All relevant slices for the anatomical area should be reviewed on T2 
weighted imaging and the highest number on a slice recorded.  
 
0: none    1: = <10    2: 11-20    3: 21-40    4: >40 
 
  as per Potter, G.M., et al. Int J Stroke, 2015. 10(3): 376-81 
 
Is there focal perivascular space enlargement related to any lesion? YES/NO 
If yes, where?             
 
 
ANY OTHER FINDINGS/COMMENTS  
 
Cerebral! Deep  
Superficial  
Corpus callosum  
Infratentorial  







0 1 2 3 
0 1 2 3 
Deep 
Superficial 
Atrophy scoring (0 – 3). This should 
be rated without reference to age. 





Data collection form used in
second pilot study and validation









3. Confluent white matter abnormality
Periventricular lesions
0. Absent
1. Caps/thin lining around ventricles
2. Intermediate appearances
3. Irregular hyperintensities extending into deep
white matter.
(Based on Fazekas, F et al. AJR (1987); 149(2):351-6.)
Please score all regions (other than periventricular white matter) with reference to the sample images and descriptions
provided for deep white matter, choosing the category which most closely matches scan appearances.
Lesion Cavitated Number/ (Juxta-)cortical Number/
Region Side score lesions?⇤ type lesions? type
[0 - 3] [Y/N] [F/P] [Y/N] [J/C/both]










































F: A lesion appears fully cavitated, with its
major part having signal characteristics
similar to CSF on all sequences.
P: A lesion appears partly cavitated. This
may include the internal structure appear-
ing lace-like, or only a small portion (<









The images on the left are provided for
guidance in rating cerebral atrophy.
The corpus callosum should be rated on the
mid-sagittal image.
Enlarged perivascular spaces
Defined as small, sharply delineated
structures of CSF intensity, up to 3mm
in diameter and following the course of
perforating vessels.
All relevant slices for the anatomical area
should be reviewed on T2w imaging and
the highest number on a slice recorded.





0: none 1: < 10 2: 11 - 20 3: 21 - 40 4: > 40.
(Rating as per Potter, G.M., et al. Int. J. Stroke, 2015. 10(3): 376-81)
Is there focal perivascular space enlargement related to any lesion [Y/N] ?







inter-rater agreement in second
pilot study of visual rating scale
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